Combined Tables for
CLNP023B1230 (Iptacopan C3G, APPEAR-C3G) - AMNOG initial full Dossier Submission

Table of Contents

Table 1-1.1: Demographic and Other Baseline Characteristics (Full Analysis Set)

Characteristic Category\Statistics	Treatment groups	
	Iptacopan (N=38)	Placebo (N=36)
Age (years)		
n	38	36
mean (SD)	26.1 (10.4)	29.8 (10.8)
median	21.5	25.5
range (Min - Max)	18-52	18-60
Age groups, n (%)		
< Median	21 (55.3)	9 (25.0)
>= Median	17 (44.7)	27 (75.0)
Sex, n (%)		
Male	27 (71.1)	20 (55.6)
Female	11 (28.9)	16 (44.4)
Race, n (%)		
White	27 (71.1)	24 (66.7)
Black or African American	1 (2.6)	1 (2.8)
Asian	9 (23.7)	9 (25.0)
American Indian or Alaska Native	0	1 (2.8)
Multiple	0	1 (2.8)
Unknown	1 (2.6)	0
Region, n (%)		
North America	7 (18.4)	8 (22.2)
Europe	22 (57.9)	19 (52.8)
Other	9 (23.7)	9 (25.0)
Ethnicity, n (%)		
Hispanic or Latino	1 (2.6)	6 (16.7)
Not Hispanic or Latino	34 (89.5)	29 (80.6)
Not Reported	2 (5.3)	0
Unknown	1 (2.6)	1 (2.8)
Height (cm)		
n	38	36
mean (SD)	173.0 (9.1)	169.5 (10.5)
median	173.5	169.3
range (Min - Max)	149-192	140-186
Weight (kg)		
n	38	36
mean (SD)	66.8 (15.4)	65.0 (15.2)
median	62.1	65.0
range (Min - Max)	42-108	36-110
Body Mass Index (BMI) (kg/m^2)		
n	38	36
mean (SD)	22.2 (4.1)	22.4 (4.0)
median	20.9	22.2
range (Min - Max)	17-36	16-37
Pulse rate (bpm)		
n	38	36
mean (SD)	75.3 (13.6)	76.6 (12.0)
median	76.0	75.5
range (Min - Max)	48-100	53-96

SBP (mmHg)		
n	38	36
mean (SD)	125.8 (13.3)	122.6 (11.4)
median	127.5	123.5
range (Min - Max)	89-153	100-148
DBP (mmHg)		
n	38	36
mean (SD)	77.7 (8.8)	77.7 (8.5)
median	79.5	78.5
range (Min - Max)	47-96	57-94
Baseline UPCR 24h (g/g)		
n	38	36
mean (SD)	3.8 (2.3)	2.9 (1.7)
median	3.4	2.6
range (Min - Max)	1-11	1-9
Baseline UPCR 24h, n (%)		
< 3 g/g	17 (44.7)	25 (69.4)
>= 3 g/g	21 (55.3)	11 (30.6)
Baseline UPCR 24h, n (%)		
< 3.5 g/g	21 (55.3)	29 (80.6)
>= 3.5 g/g	17 (44.7)	7 (19.4)
Baseline total urinary protein 24h, n (%)		
< 3 g/day	11 (28.9)	15 (41.7)
>= 3 g/day	27 (71.1)	21 (58.3)
Baseline eGFR (mL/min/1.73m^2)		
n	38	36
mean (SD)	89.3 (35.2)	99.2 (26.9)
median	91.0	106.0
range (Min - Max)	28-135	37-136
Baseline eGFR category, n (%)		
< 60 mL/min/1.73m2	10 (26.3)	4 (11.1)
>= 60 mL/min/1.73m2	28 (73.7)	32 (88.9)
Baseline eGFR category, n (%)		
< 90 mL/min/1.73m2	19 (50.0)	12 (33.3)
>= 90 mL/min/1.73m2	19 (50.0)	24 (66.7)
Baseline C3 (mg/dL)		
n	38	36
mean (SD)	316.8 (243.4)	339.3 (228.0)
median	284.0	295.5
range (Min - Max)	20-950	20-830
Baseline C3, n (%)		
< 45 mg/dL	28 (73.7)	26 (72.2)
>= 45 mg/dL	10 (26.3)	10 (27.8)
Corticosteroid and/or mycophenolic acid treatment at randomization, n (%)		
Yes	16 (42.1)	17 (47.2)
No	22 (57.9)	19 (52.8)

N: Number of subjects in analysis set.
n: Number of subjects.
SD: Standard deviation.
Min: Minimum
Max: Maximum
.....

Table 1-1.2: C3G Medical History (Full Analysis Set)

Characteristic Category\Statistics	Treatment groups	
	Iptacopan (N=38)	Placebo (N=36)
Age at C3G diagnosis (years)		
n	38	36
mean (SD)	22.0 (10.9)	25.3 (10.8)
median	19.0	21.0
range (Min - Max)	4-50	12-57
Age at C3G diagnosis, n (%)		
< 18 Years	15 (39.5)	6 (16.7)
>= 18 Years	23 (60.5)	30 (83.3)
Years since first C3G diagnosis (years)		
n	38	36
mean (SD)	4.7 (4.4)	4.8 (6.0)
median	3.9	2.6
range (Min - Max)	0-20	0-26
Years since first C3G diagnosis, n (%)		
< 2 Years	15 (39.5)	15 (41.7)
>= 2 Years	23 (60.5)	21 (58.3)
C3G subtype at diagnosis, n (%)		
C3GN	26 (68.4)	32 (88.9)
DDD	9 (23.7)	1 (2.8)
Mixed C3GN/DDD	2 (5.3)	2 (5.6)
Unknown	1 (2.6)	1 (2.8)
Hypertension at C3G diagnosis, n (%)		
Yes	23 (60.5)	18 (50.0)
No	15 (39.5)	18 (50.0)
Clinical presentation at C3G diagnosis, n (%)		
Nephrotic Syndrome	26 (68.4)	23 (63.9)
Nephritic Syndrome	5 (13.2)	5 (13.9)
Isolated Non-Nephrotic Proteinuria	5 (13.2)	7 (19.4)
Isolated Microscopic Hematuria	2 (5.3)	1 (2.8)
Serum creatinine (umol/L) at C3G diagnosis		
n	30	31
mean (SD)	90.2 (52.8)	76.8 (28.9)
median	76.4	69.0
range (Min - Max)	39-261	41-183
eGFR (mL/min/1.73m^2) at C3G diagnosis		
n	30	31
mean (SD)	111.0 (38.9)	110.3 (29.0)
median	123.2	116.1
range (Min - Max)	30-181	38-141
UPCR (g/g) at C3G diagnosis		
n	15	17
mean (SD)	3.5 (2.1)	4.4 (3.8)
median	3.2	3.4
range (Min - Max)	0-9	0-17
Complement C3 (mg/L) at C3G diagnosis		
n	24	25
mean (SD)	188.6 (142.8)	241.6 (249.9)

median	153.0	173.0
range (Min - Max)	20-510	40-934
Total Urine Protein (mg/day) at C3G diagnosis		
n	12	12
mean (SD)	3343.2 (2609.1)	3770.3 (2662.0)
median	2908.0	3385.5
range (Min - Max)	1175-11000	841-9910
Urine Albumin (mg/day) at C3G diagnosis		
n	1	3
mean (SD)	1852.3 ()	3220.6 (2602.1)
median	1852.3	3430.0
range (Min - Max)	1852-1852	520-5712
Complement auto-antibodies, n (%)		
C3Nef	9 (23.7)	8 (22.2)
Factor H Ab	0	1 (2.8)
Factor B Ab	1 (2.6)	0
Other	2 (5.3)	2 (5.6)
Negative	10 (26.3)	8 (22.2)
Missing	16 (42.1)	17 (47.2)
Complement factor gene variants, n (%)		
C3	6 (15.8)	11 (30.6)
CFH	5 (13.2)	1 (2.8)
CFHR5	0	1 (2.8)
Other	2 (5.3)	1 (2.8)
Negative	11 (28.9)	4 (11.1)
Missing	14 (36.8)	18 (50.0)

N: Number of subjects in analysis set.
n: Number of subjects.
SD: Standard deviation.
Min: Minimum
Max: Maximum
.....

Table 1-1.3: Further Baseline Characteristics (Full Analysis Set)

Characteristic Category/Statistics	Treatment groups Iptacopan (N=38)	Placebo (N=36)
FACIT - Fatigue Score (points)		
n	36	31
mean (SD)	42.4 (10.1)	41.9 (8.9)
median	45.0	44.0
range (Min - Max)	12-52	18-52
FACIT - Fatigue Score, n (%)		
< 7.8	0	0
7.8 - 44.2	17 (44.7)	16 (44.4)
> 44.2	19 (50.0)	15 (41.7)
Missing	2 (5.3)	5 (13.9)
EQ-5D VAS (points)		
n	36	31
mean (SD)	82.4 (14.9)	81.2 (13.0)
median	85.0	85.0
range (Min - Max)	50-100	48-100
EQ-5D VAS, n (%)		
< 15	0	0
15 - 85	19 (50.0)	16 (44.4)
> 85	17 (44.7)	15 (41.7)
Missing	2 (5.3)	5 (13.9)
SF-36 PCS (points)		
n	36	31
mean (SD)	51.8 (6.4)	54.4 (5.3)
median	52.9	55.4
range (Min - Max)	31-60	34-62
SF-36 PCS, n (%)		
< 16.7	0	0
16.7 - 60.8	36 (94.7)	30 (83.3)
> 60.8	0	1 (2.8)
Missing	2 (5.3)	5 (13.9)
SF-36 MCS (points)		
n	36	31
mean (SD)	50.0 (11.0)	48.9 (9.3)
median	52.8	50.6
range (Min - Max)	19-62	25-68
SF-36 MCS, n (%)		
< 15.4	0	0
15.4 - 60.3	32 (84.2)	29 (80.6)
> 60.3	4 (10.5)	2 (5.6)
Missing	2 (5.3)	5 (13.9)
PGIS (points)		
n	36	31
mean (SD)	0.7 (0.7)	1.0 (0.9)
median	1.0	1.0
range (Min - Max)	0-2	0-3
PGIS, n (%)		

0	15 (39.5)	10 (27.8)
1 - 3	21 (55.3)	21 (58.3)
4	0	0
Missing	2 (5.3)	5 (13.9)
Hematuria, n (%)		
With hematuria	25 (65.8)	16 (44.4)
Without hematuria	13 (34.2)	18 (50.0)
Missing	0	2 (5.6)

N: Number of subjects in analysis set.
n: Number of subjects.
SD: Standard deviation.
Min: Minimum
Max: Maximum
.....

Table 1-1.4: Adjustments of concomitant medications (Safety Analysis Set)

Analysis period Characteristic Category/Statistics	Treatment groups Iptacopan (N=38)	 Placebo (N=36)
Pre-Double-blind		
Adjusted concomitant medications, n (%)		
At least one	6 (15.8)	4 (11.1)
ACEI/ARB	3 (7.9)	2 (5.6)
Selective immunosuppressants	3 (7.9)	1 (2.8)
Glucocorticoids (systemic)	0	3 (8.3)
SGLT2 inhibitors	1 (2.6)	0
Other medication affecting proteinuria	5 (13.2)	2 (5.6)
Double-blind		
Adjusted concomitant medications, n (%)		
At least one	9 (23.7)	1 (2.8)
ACEI/ARB	5 (13.2)	1 (2.8)
Selective immunosuppressants	1 (2.6)	1 (2.8)
Glucocorticoids (systemic)	2 (5.3)	0
SGLT2 inhibitors	1 (2.6)	1 (2.8)
Other medication affecting proteinuria	6 (15.8)	1 (2.8)

N: Number of subjects in analysis set.
n: Number of subjects.
.....
Other medication affecting proteinuria" may contain other C3G relevant classes of concomitant medications.
Pre-Double-Blind" refers to the period between -90 days before the double blind-period and the day before the double-blind period.

Table 1-2.1: Follow-up times by endpoint and study treatment (Full Analysis Set)

Parameter	Iptacopan (N=38)	Placebo (N=36)
UPCR 24h (months)		
n	38	36
mean (SD)	5.8 (0.6)	5.9 (0.3)
median	5.9	5.9
range (Min - Max)	3 - 6	5 - 7
eGFR (months)		
n	38	36
mean (SD)	5.9 (0.3)	6.0 (0.2)
median	5.9	6.0
range (Min - Max)	5 - 6	5 - 7
FACIT - Fatigue Score (months)		
n	36	31
mean (SD)	5.9 (0.2)	5.9 (0.4)
median	5.9	6.0
range (Min - Max)	5 - 6	4 - 7
EQ-5D VAS Score (months)		
n	36	31
mean (SD)	5.9 (0.2)	5.9 (0.4)
median	5.9	6.0
range (Min - Max)	5 - 6	4 - 7
SF-36 Physical Component Score (months)		
n	36	31
mean (SD)	5.9 (0.2)	5.9 (0.4)
median	5.9	6.0
range (Min - Max)	5 - 6	4 - 7
SF-36 Mental Component Score (months)		
n	36	31
mean (SD)	5.9 (0.2)	5.9 (0.4)
median	5.9	6.0
range (Min - Max)	5 - 6	4 - 7
PGIS - Rate Overall Symptoms of Fatigue (months)		
n	36	31
mean (SD)	5.9 (0.2)	5.9 (0.4)
median	5.9	6.0
range (Min - Max)	5 - 6	4 - 7

N: Number of subjects in analysis set.
n: Number of subjects.
SD: Standard deviation.
.....

Table 1-2.2: Follow-up times by endpoint and study treatment (Safety Set)

Parameter	Iptacopan (N=38)	Placebo (N=36)
Adverse Event (months)		
n	38	36
mean (SD)	5.8 (0.6)	5.9 (0.3)
median	5.9	5.9
range (Min - Max)	3 - 6	5 - 7

N: Number of subjects in analysis set.
n: Number of subjects.
SD: Standard deviation.
.....

Table 1-3.1: FACIT fatigue: Return rates (Full Analysis Set)

Parameter Visit	Iptacopan (N=38)	Placebo (N=36)	Total (N=74)
FACIT - Fatigue Score, n (%)			
Baseline	36 (94.7)	31 (86.1)	67 (90.5)
Day 14	36 (94.7)	35 (97.2)	71 (95.9)
Day 30	36 (94.7)	35 (97.2)	71 (95.9)
Day 90	36 (94.7)	34 (94.4)	70 (94.6)
Day 180	38 (100.0)	36 (100.0)	74 (100.0)

N: Number of patients.
n (%): Number and percentage of patients with an event.
....
The return rate is the proportion of patients with valid data at the given visit based on the whole study population.

Table 1-3.2: EQ-5D-5L VAS: Return rates (Full Analysis Set)

Parameter Visit	Iptacopan (N=38)	Placebo (N=36)	Total (N=74)
EQ-5D VAS Score, n (%)			
Baseline	36 (94.7)	31 (86.1)	67 (90.5)
Day 14	36 (94.7)	35 (97.2)	71 (95.9)
Day 30	36 (94.7)	35 (97.2)	71 (95.9)
Day 90	36 (94.7)	34 (94.4)	70 (94.6)
Day 180	38 (100.0)	36 (100.0)	74 (100.0)

N: Number of patients.
n (%): Number and percentage of patients with an event.
....
The return rate is the proportion of patients with valid data at the given visit based on the whole study population.

Table 1-3.3: SF-36 PCS: Return rates (Full Analysis Set)

Parameter Visit	Iptacopan (N=38)	Placebo (N=36)	Total (N=74)
SF-36 Physical Component Score, n (%)			
Baseline	36 (94.7)	31 (86.1)	67 (90.5)
Day 14	36 (94.7)	35 (97.2)	71 (95.9)
Day 30	36 (94.7)	35 (97.2)	71 (95.9)
Day 90	36 (94.7)	34 (94.4)	70 (94.6)
Day 180	37 (97.4)	36 (100.0)	73 (98.6)

N: Number of patients.
n (%): Number and percentage of patients with an event.
....
The return rate is the proportion of patients with valid data at the given visit based on the whole study population.

Table 1-3.4: SF-36 MCS: Return rates (Full Analysis Set)

Parameter Visit	Iptacopan (N=38)	Placebo (N=36)	Total (N=74)
SF-36 Mental Component Score, n (%)			
Baseline	36 (94.7)	31 (86.1)	67 (90.5)
Day 14	36 (94.7)	35 (97.2)	71 (95.9)
Day 30	36 (94.7)	35 (97.2)	71 (95.9)
Day 90	36 (94.7)	34 (94.4)	70 (94.6)
Day 180	37 (97.4)	36 (100.0)	73 (98.6)

N: Number of patients.
n (%): Number and percentage of patients with an event.
....
The return rate is the proportion of patients with valid data at the given visit based on the whole study population.

Table 1-3.5: PGIS: Return rates (Full Analysis Set)

Parameter Visit	Iptacopan (N=38)	Placebo (N=36)	Total (N=74)
PGIS - Rate Overall Symptoms of Fatigue, n (%)			
Baseline	36 (94.7)	31 (86.1)	67 (90.5)
Day 14	36 (94.7)	35 (97.2)	71 (95.9)
Day 30	36 (94.7)	35 (97.2)	71 (95.9)
Day 90	36 (94.7)	34 (94.4)	70 (94.6)
Day 180	38 (100.0)	36 (100.0)	74 (100.0)

N: Number of patients.
n (%): Number and percentage of patients with an event.
....
The return rate is the proportion of patients with valid data at the given visit based on the whole study population.

Table 2-1.1: Proteinuria (UPCR): Analysis of change from baseline (Full Analysis Set)

	Treatment groups								
	Iptacopan (N=38)				Placebo (N=36)				Comparison
Visit	N[a]	Mean (SD)	N[b]	LS Mean (SE)	N[a]	Mean (SD)	N[b]	LS Mean (SE)	Difference [95% CI] p-value
Baseline	38	1.2 (0.5)			36	0.9 (0.5)			
Day 90	36	0.6 (0.9)	36	-0.5 (0.1)	35	0.9 (0.6)	35	-0.0 (0.1)	-0.5 [-0.79; -0.22] <.001
Day 180	37	0.8 (0.9)	37	-0.4 (0.1)	36	1.0 (0.5)	36	0.1 (0.1)	-0.4 [-0.72; -0.15] 0.003
Overall treatment effect			38	-0.4 (0.1)			36	0.0 (0.1)	-0.5 [-0.72; -0.22] <.001

CI: Confidence Interval
MMRM: Mixed Model for Repeated Measures
LS Mean: Least Square Mean
SE: Standard Error
SD: Standard Deviation
.....
[a] Number of patients with non-missing values at the timepoint
[b] Number of patients with non-missing values at baseline and at the timepoint after baseline
MMRM including treatment, time point, corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as fixed effects, treatment*time point as interaction term and baseline values as covariate.
Patients with an evaluable baseline score and at least one evaluable post-baseline score were included in the analysis.

Table 2-1.2: Proteinuria (UPCR) : Proportion of patients with a reduction of >= 1 g/g in UPCR (24h) at 6 months compared to the baseline visit (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup	Iptacopan (N=38) n / N* (%)	Placebo (N=36) n / N* (%)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Overall	20 / 38 (52.6)	4 / 36 (11.1)	9.42 [2.69; 32.98] <.001	4.57 [1.76; 11.89] 0.002	0.41 [0.22; 0.59] <.001

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm in a stratum one patient with 0.5 events was added to each treatment arm in the respective stratum for estimation of the OR/RR. In case of zero events in both treatment arms, no treatment comparison is performed.

Table 2-1.3: Proteinuria (UPCR) : Proportion of patients with a reduction of >= 1.5 g/g in UPCR (24h) at 6 months compared to the baseline visit (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup	Iptacopan (N=38) n / N* (%)	Placebo (N=36) n / N* (%)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Overall	13 / 38 (34.2)	4 / 36 (11.1)	4.22 [1.19; 14.99] 0.026	2.95 [1.08; 8.07] 0.035	0.22 [0.04; 0.40] 0.016

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm in a stratum one patient with 0.5 events was added to each treatment arm in the respective stratum for estimation of the OR/RR. In case of zero events in both treatment arms, no treatment comparison is performed.

Table 2-1.4: Proteinuria (UPCR) : Proportion of patients improving by at least one stage in UPCR (24h) at 6 months compared to the baseline visit (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup	Iptacopan (N=38) n / N* (%)	Placebo (N=36) n / N* (%)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Overall	16 / 38 (42.1)	6 / 36 (16.7)	3.96 [1.24; 12.65] 0.020	2.39 [1.10; 5.21] 0.029	0.24 [0.05; 0.43] 0.014

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm in a stratum one patient with 0.5 events was added to each treatment arm in the respective stratum for estimation of the OR/RR. In case of zero events in both treatment arms, no treatment comparison is performed.

Table 2-1.5: Proteinuria (UPCR) : Proportion of patients improving by at least one stage and a reduction of >= 1 g/g in UPCR (24h) at 6 months compared to the baseline visit (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup	Iptacopan (N=38) n / N* (%)	Placebo (N=36) n / N* (%)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Overall	14 / 38 (36.8)	3 / 36 (8.3)	5.99 [1.60; 22.44] 0.008	3.72 [1.31; 10.58] 0.014	0.27 [0.10; 0.45] 0.002

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm in a stratum one patient with 0.5 events was added to each treatment arm in the respective stratum for estimation of the OR/RR. In case of zero events in both treatment arms, no treatment comparison is performed.

Table 2-1.6: Proteinuria (UPCR) : Proportion of patients with a >= 50% reduction in UPCR (24h) at 6 months compared to the baseline visit (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup	Iptacopan (N=38) n / N* (%)	Placebo (N=36) n / N* (%)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Overall	11 / 38 (28.9)	2 / 36 (5.6)	5.76 [1.32; 25.07] 0.020	4.18 [1.17; 14.91] 0.027	0.23 [0.07; 0.39] 0.006

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm in a stratum one patient with 0.5 events was added to each treatment arm in the respective stratum for estimation of the OR/RR. In case of zero events in both treatment arms, no treatment comparison is performed.

Table 2-2.1: Combined renal endpoint : Proportion of patients with stable or improved eGFR compared to the baseline visit (<= 15% reduction in eGFR), and a >= 50% reduction in UPCR compared to the baseline visit (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup	Iptacopan (N=38) n / N* (%)	Placebo (N=36) n / N* (%)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Overall	11 / 38 (28.9)	2 / 36 (5.6)	5.76 [1.32; 25.07] 0.020	4.18 [1.17; 14.91] 0.027	0.23 [0.07; 0.39] 0.006

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm in a stratum one patient with 0.5 events was added to each treatment arm in the respective stratum for estimation of the OR/RR. In case of zero events in both treatment arms, no treatment comparison is performed.

Table 2-2.2: Combined renal endpoint : Proportion of patients with stable or improved eGFR compared to the baseline visit (<= 10% reduction in eGFR), and a >= 50% reduction in UPCR compared to the baseline visit (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup	Iptacopan (N=38) n / N* (%)	Placebo (N=36) n / N* (%)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Overall	10 / 38 (26.3)	2 / 36 (5.6)	5.03 [1.15; 21.99] 0.032	3.83 [1.06; 13.83] 0.040	0.20 [0.04; 0.36] 0.012

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm in a stratum one patient with 0.5 events was added to each treatment arm in the respective stratum for estimation of the OR/RR. In case of zero events in both treatment arms, no treatment comparison is performed.

Table 2-3.1: eGFR : Proportion of patients with stable or improved eGFR at month 6 compared to the baseline visit (<= 15% reduction in eGFR) (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup	Iptacopan (N=38) n / N* (%)	Placebo (N=36) n / N* (%)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Overall	34 / 38 (89.5)	32 / 36 (88.9)	1.05 [0.24; 4.57] 0.949	1.01 [0.85; 1.19] 0.951	0.00 [-0.14; 0.15] 0.950

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm in a stratum one patient with 0.5 events was added to each treatment arm in the respective stratum for estimation of the OR/RR. In case of zero events in both treatment arms, no treatment comparison is performed.

Table 2-3.2: eGFR : Proportion of patients with stable or improved eGFR at month 6 compared to the baseline visit (<= 10% reduction in eGFR) (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup	Iptacopan (N=38) n / N* (%)	Placebo (N=36) n / N* (%)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Overall	31 / 38 (81.6)	26 / 36 (72.2)	1.72 [0.57; 5.18] 0.332	1.13 [0.87; 1.47] 0.351	0.10 [-0.10; 0.29] 0.339

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm in a stratum one patient with 0.5 events was added to each treatment arm in the respective stratum for estimation of the OR/RR. In case of zero events in both treatment arms, no treatment comparison is performed.

Table 2-4.1: Histology total activity score: Analysis of change from baseline (Full Analysis Set)

	Treatment groups								Comparison
	Iptacopan (N=38)				Placebo (N=36)				
Visit	N[a]	Mean (SD)	N[b]	LS Mean (SE)	N[a]	Mean (SD)	N[b]	LS Mean (SE)	Difference [95% CI] p-value
Baseline	37	10.0 (2.5)			36	9.0 (2.6)			
Day 180	33	7.6 (1.8)	33	-2.0 (0.4)	34	8.1 (2.7)	34	-1.1 (0.4)	-0.9 [-1.90; 0.18] 0.104

CI: Confidence Interval
ANCOVA: Analysis of Covariance
LS Mean: Least Square Mean
SE: Standard Error
SD: Standard Deviation
.....
[a] Number of patients with non-missing values at Day 180
[b] Number of patients with non-missing values at baseline and at Day 180 after baseline
ANCOVA including treatment, corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as fixed effects and baseline values as covariate.
Patients with an evaluable baseline score and an evaluable post-baseline score were included in the analysis.

Table 2-5.1: Hematuria : Proportion of patients without hematuria (<= 5 rbc/HPF) at month 6 (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup	**Iptacopan (N=38) n / N* (%)**	**Placebo (N=36) n / N* (%)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Overall	22 / 36 (61.1)	18 / 32 (56.3)	1.24 [0.47; 3.29] 0.660	1.09 [0.73; 1.63] 0.660	0.05 [-0.18; 0.29] 0.660

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm in a stratum one patient with 0.5 events was added to each treatment arm in the respective stratum for estimation of the OR/RR. In case of zero events in both treatment arms, no treatment comparison is performed.

Table 3-1.1: FACIT - Fatigue: Analysis of change from baseline (Full Analysis Set)

	Treatment groups								Comparison
	Iptacopan (N=38)				Placebo (N=36)				
Visit	N[a]	Mean (SD)	N[b]	LS Mean (SE)	N[a]	Mean (SD)	N[b]	LS Mean (SE)	Difference [95% CI] p-value
Baseline	36	42.4 (10.1)			31	41.9 (8.9)			
Day 14	34	42.0 (9.5)	34	-0.2 (0.9)	30	43.6 (8.5)	30	1.6 (0.9)	-1.8 [-4.30; 0.72] 0.160
Day 30	34	41.6 (10.0)	34	-0.6 (1.0)	30	43.3 (7.5)	30	1.3 (1.0)	-1.9 [-4.70; 0.98] 0.195
Day 90	34	41.5 (11.8)	34	-0.9 (1.3)	31	44.1 (6.4)	31	1.9 (1.3)	-2.8 [-6.51; 0.83] 0.127
Day 180	36	42.3 (11.9)	36	-0.1 (1.2)	31	44.3 (5.9)	31	2.2 (1.3)	-2.3 [-5.69; 1.13] 0.186
Overall treatment effect			36	-0.5 (0.9)			31	1.7 (0.9)	-2.2 [-4.70; 0.32] 0.086

CI: Confidence Interval
MMRM: Mixed Model for Repeated Measures
LS Mean: Least Square Mean
SE: Standard Error
SD: Standard Deviation
.....
[a] Number of patients with non-missing values at the timepoint
[b] Number of patients with non-missing values at baseline and at the timepoint after baseline
MMRM including treatment, time point, corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as fixed effects, treatment*time point as interaction term and baseline values as covariate.
Patients with an evaluable baseline score and at least one evaluable post-baseline score were included in the analysis.

Table 3-1.2: FACIT - Fatigue: Improvement of FACIT fatigue - increase of >= 7.8 points at 6 months (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup	**Iptacopan (N=38) n / N* (%)**	**Placebo (N=36) n / N* (%)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Overall	3 / 36 (8.3)	6 / 31 (19.4)	0.39 [0.09; 1.74] 0.218	0.45 [0.12; 1.65] 0.227	-0.10 [-0.27; 0.06] 0.213

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm in a stratum one patient with 0.5 events was added to each treatment arm in the respective stratum for estimation of the OR/RR. In case of zero events in both treatment arms, no treatment comparison is performed.

Table 3-1.3: FACIT - Fatigue: Worsening of FACIT fatigue - decrease of >= 7.8 points at 6 months (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup	**Iptacopan (N=38) n / N* (%)**	**Placebo (N=36) n / N* (%)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Overall	1 / 36 (2.8)	1 / 31 (3.2)	0.85 [0.11; 6.39] 0.870	0.85 [0.12; 6.08] 0.871	-0.01 [-0.09; 0.08] 0.903

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm in a stratum one patient with 0.5 events was added to each treatment arm in the respective stratum for estimation of the OR/RR. In case of zero events in both treatment arms, no treatment comparison is performed.

Table 3-1.4: FACIT - Fatigue: No relevant worsening of FACIT fatigue - decrease of < 7.8 points at 6 months (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup	Iptacopan (N=38) n / N* (%)	Placebo (N=36) n / N* (%)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Overall	35 / 36 (97.2)	30 / 31 (96.8)	1.18 [0.16; 8.94] 0.870	1.01 [0.90; 1.13] 0.869	0.01 [-0.08; 0.09] 0.903

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm in a stratum one patient with 0.5 events was added to each treatment arm in the respective stratum for estimation of the OR/RR. In case of zero events in both treatment arms, no treatment comparison is performed.

Table 3-2.1: EQ-5D VAS: Analysis of change from baseline (Full Analysis Set)

	Treatment groups								Comparison
	Iptacopan (N=38)				Placebo (N=36)				
Visit	N[a]	Mean (SD)	N[b]	LS Mean (SE)	N[a]	Mean (SD)	N[b]	LS Mean (SE)	Difference [95% CI] p-value
Baseline	36	82.4 (14.9)			31	81.2 (13.0)			
Day 14	34	83.1 (14.3)	34	0.2 (1.5)	30	85.1 (11.3)	30	3.0 (1.6)	-2.8 [-7.08; 1.47] 0.195
Day 30	34	83.1 (14.2)	34	0.2 (1.5)	30	83.5 (12.7)	30	1.3 (1.7)	-1.1 [-5.64; 3.37] 0.617
Day 90	34	80.4 (17.4)	34	-1.5 (1.9)	31	84.2 (10.5)	31	2.5 (2.0)	-4.0 [-9.47; 1.46] 0.148
Day 180	36	83.9 (16.4)	36	1.5 (1.8)	31	82.3 (12.9)	31	0.6 (1.9)	0.9 [-4.37; 6.11] 0.741
Overall treatment effect			36	0.1 (1.4)			31	1.9 (1.5)	-1.8 [-5.93; 2.39] 0.399

CI: Confidence Interval
MMRM: Mixed Model for Repeated Measures
LS Mean: Least Square Mean
SE: Standard Error
SD: Standard Deviation
.....
[a] Number of patients with non-missing values at the timepoint
[b] Number of patients with non-missing values at baseline and at the timepoint after baseline
MMRM including treatment, time point, corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as fixed effects, treatment*time point as interaction term and baseline values as covariate.
Patients with an evaluable baseline score and at least one evaluable post-baseline score were included in the analysis.

Table 3-2.2: EQ-5D VAS: Improvement of EQ-5D-5L VAS - increase of >= 15 points at 6 months (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup	**Iptacopan (N=38) n / N* (%)**	**Placebo (N=36) n / N* (%)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Overall	6 / 36 (16.7)	3 / 31 (9.7)	1.89 [0.45; 7.88] 0.382	1.69 [0.51; 5.58] 0.386	0.08 [-0.08; 0.23] 0.312

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm in a stratum one patient with 0.5 events was added to each treatment arm in the respective stratum for estimation of the OR/RR. In case of zero events in both treatment arms, no treatment comparison is performed.

Table 3-2.3: EQ-5D VAS: Worsening of EQ-5D-5L VAS - decrease of >= 15 points at 6 months (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup	Iptacopan (N=38) n / N* (%)	Placebo (N=36) n / N* (%)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Overall	3 / 36 (8.3)	1 / 31 (3.2)	1.74 [0.29; 10.37] 0.542	1.67 [0.30; 9.23] 0.554	0.05 [-0.06; 0.16] 0.404

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm in a stratum one patient with 0.5 events was added to each treatment arm in the respective stratum for estimation of the OR/RR. In case of zero events in both treatment arms, no treatment comparison is performed.

Table 3-3.1: SF-36 PCS: Analysis of change from baseline (Full Analysis Set)

	Treatment groups								Comparison
	Iptacopan (N=38)				Placebo (N=36)				
Visit	N[a]	Mean (SD)	N[b]	LS Mean (SE)	N[a]	Mean (SD)	N[b]	LS Mean (SE)	Difference [95% CI] p-value
Baseline	36	51.8 (6.4)			31	54.4 (5.3)			
Day 14	34	51.5 (6.5)	34	-0.7 (0.7)	30	55.0 (5.1)	30	0.9 (0.7)	-1.6 [-3.53; 0.36] 0.107
Day 30	34	52.6 (6.9)	34	0.4 (0.8)	30	54.7 (4.9)	30	0.6 (0.8)	-0.1 [-2.37; 2.10] 0.904
Day 90	34	51.8 (8.7)	34	-0.6 (1.0)	31	54.4 (4.7)	31	0.3 (1.0)	-0.9 [-3.80; 1.96] 0.526
Day 180	35	52.1 (7.1)	35	-0.1 (0.8)	31	53.9 (5.3)	31	-0.2 (0.9)	0.1 [-2.19; 2.48] 0.900
Overall treatment effect			36	-0.2 (0.6)			31	0.4 (0.6)	-0.6 [-2.40; 1.15] 0.485

CI: Confidence Interval
MMRM: Mixed Model for Repeated Measures
LS Mean: Least Square Mean
SE: Standard Error
SD: Standard Deviation
.....
[a] Number of patients with non-missing values at the timepoint
[b] Number of patients with non-missing values at baseline and at the timepoint after baseline
MMRM including treatment, time point, corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as fixed effects, treatment*time point as interaction term and baseline values as covariate.
Patients with an evaluable baseline score and at least one evaluable post-baseline score were included in the analysis.

Table 3-3.2: PCS: Improvement of SF-36 Physical Component Score - increase of >= 9.4 points at 6 months (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup	**Iptacopan (N=38) n / N* (%)**	**Placebo (N=36) n / N* (%)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Overall	0 / 36	1 / 31 (3.2)	0.39 [0.03; 4.60] 0.455	0.42 [0.04; 4.21] 0.458	-0.03 [-0.10; 0.03] 0.293

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm in a stratum one patient with 0.5 events was added to each treatment arm in the respective stratum for estimation of the OR/RR. In case of zero events in both treatment arms, no treatment comparison is performed.

Table 3-3.3: PCS: Worsening of SF-36 Physical Component Score - decrease of >= 9.4 points at 6 months (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup	Iptacopan (N=38) n / N* (%)	Placebo (N=36) n / N* (%)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Overall	0 / 36	1 / 31 (3.2)	0.43 [0.04; 4.94] 0.495	0.44 [0.04; 4.77] 0.498	-0.03 [-0.09; 0.03] 0.321

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm in a stratum one patient with 0.5 events was added to each treatment arm in the respective stratum for estimation of the OR/RR. In case of zero events in both treatment arms, no treatment comparison is performed.

Table 3-4.1: SF-36 MCS: Analysis of change from baseline (Full Analysis Set)

	Treatment groups								Comparison
	Iptacopan (N=38)				Placebo (N=36)				
Visit	N[a]	Mean (SD)	N[b]	LS Mean (SE)	N[a]	Mean (SD)	N[b]	LS Mean (SE)	Difference [95% CI] p-value
Baseline	36	50.0 (11.0)			31	48.9 (9.3)			
Day 14	34	50.1 (10.0)	34	0.2 (0.9)	30	49.5 (9.8)	30	0.4 (0.9)	-0.2 [-2.72; 2.30] 0.869
Day 30	34	47.9 (11.1)	34	-2.0 (1.2)	30	50.1 (11.5)	30	0.9 (1.3)	-3.0 [-6.58; 0.68] 0.109
Day 90	34	49.3 (10.7)	34	-0.7 (1.2)	31	50.6 (9.7)	31	1.3 (1.3)	-2.1 [-5.62; 1.49] 0.250
Day 180	35	48.5 (12.1)	35	-1.4 (1.5)	31	50.0 (8.5)	31	0.8 (1.6)	-2.2 [-6.58; 2.27] 0.333
Overall treatment effect			36	-1.0 (0.9)			31	0.9 (1.0)	-1.8 [-4.60; 0.91] 0.185

CI: Confidence Interval
MMRM: Mixed Model for Repeated Measures
LS Mean: Least Square Mean
SE: Standard Error
SD: Standard Deviation
.....
[a] Number of patients with non-missing values at the timepoint
[b] Number of patients with non-missing values at baseline and at the timepoint after baseline
MMRM including treatment, time point, corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as fixed effects, treatment*time point as interaction term and baseline values as covariate.
Patients with an evaluable baseline score and at least one evaluable post-baseline score were included in the analysis.

Table 3-4.2: MCS: Improvement of SF-36 Mental Component Score - increase of >= 9.6 points at 6 months (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup	**Iptacopan (N=38) n / N* (%)**	**Placebo (N=36) n / N* (%)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Overall	3 / 36 (8.3)	4 / 31 (12.9)	0.61 [0.13; 2.98] 0.542	0.65 [0.16; 2.63] 0.543	-0.05 [-0.20; 0.10] 0.547

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm in a stratum one patient with 0.5 events was added to each treatment arm in the respective stratum for estimation of the OR/RR. In case of zero events in both treatment arms, no treatment comparison is performed.

Table 3-4.3: MCS: Worsening of SF-36 Mental Component Score - decrease of >= 9.6 points at 6 months (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup	**Iptacopan (N=38) n / N* (%)**	**Placebo (N=36) n / N* (%)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Overall	4 / 36 (11.1)	3 / 31 (9.7)	1.08 [0.22; 5.45] 0.923	1.07 [0.27; 4.32] 0.923	0.01 [-0.14; 0.15] 0.923

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm in a stratum one patient with 0.5 events was added to each treatment arm in the respective stratum for estimation of the OR/RR. In case of zero events in both treatment arms, no treatment comparison is performed.

Table 3-5.1: PGIS: Analysis of change from baseline (Full Analysis Set)

	Treatment groups								Comparison
	Iptacopan (N=38)				Placebo (N=36)				
Visit	N[a]	Mean (SD)	N[b]	LS Mean (SE)	N[a]	Mean (SD)	N[b]	LS Mean (SE)	Difference [95% CI] p-value
Baseline	36	0.7 (0.7)			31	1.0 (0.9)			
Day 14	34	0.8 (0.8)	34	0.0 (0.1)	30	0.8 (0.8)	30	-0.1 (0.1)	0.2 [-0.16; 0.46] 0.336
Day 30	34	0.8 (0.8)	34	0.0 (0.1)	30	0.9 (0.9)	30	-0.0 (0.1)	0.0 [-0.31; 0.41] 0.795
Day 90	34	0.9 (1.0)	34	0.2 (0.1)	31	0.7 (0.7)	31	-0.2 (0.1)	0.4 [0.06; 0.72] 0.021
Day 180	36	0.8 (0.9)	36	0.0 (0.1)	31	0.7 (0.7)	31	-0.2 (0.1)	0.2 [-0.06; 0.54] 0.120
Overall treatment effect			36	0.1 (0.1)			31	-0.1 (0.1)	0.2 [-0.03; 0.44] 0.084

CI: Confidence Interval
MMRM: Mixed Model for Repeated Measures
LS Mean: Least Square Mean
SE: Standard Error
SD: Standard Deviation
.....
[a] Number of patients with non-missing values at the timepoint
[b] Number of patients with non-missing values at baseline and at the timepoint after baseline
MMRM including treatment, time point, corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as fixed effects, treatment*time point as interaction term and baseline values as covariate.
Patients with an evaluable baseline score and at least one evaluable post-baseline score were included in the analysis.

Table 3-5.2: PGIS: Worsening of PGIS - increase of >= 1 point at 6 months (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup	**Iptacopan (N=38) n / N* (%)**	**Placebo (N=36) n / N* (%)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Overall	5 / 36 (13.9)	4 / 31 (12.9)	1.08 [0.26; 4.45] 0.914	1.07 [0.30; 3.77] 0.915	0.01 [-0.15; 0.17] 0.914

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm in a stratum one patient with 0.5 events was added to each treatment arm in the respective stratum for estimation of the OR/RR. In case of zero events in both treatment arms, no treatment comparison is performed.

Table 3-5.3: PGIS: No worsening of PGIS - increase of < 1 point at 6 months (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup	**Iptacopan (N=38) n / N* (%)**	**Placebo (N=36) n / N* (%)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Overall	31 / 36 (86.1)	27 / 31 (87.1)	0.92 [0.22; 3.81] 0.914	0.99 [0.82; 1.19] 0.913	-0.01 [-0.17; 0.15] 0.914

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm in a stratum one patient with 0.5 events was added to each treatment arm in the respective stratum for estimation of the OR/RR. In case of zero events in both treatment arms, no treatment comparison is performed.

Table 3-5.4: PGIS: Improvement of PGIS - decrease of >= 1 point at 6 months (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup	**Iptacopan (N=38) n / N* (%)**	**Placebo (N=36) n / N* (%)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Overall	4 / 36 (11.1)	12 / 31 (38.7)	0.20 [0.06; 0.71] 0.013	0.28 [0.09; 0.83] 0.021	-0.27 [-0.48; -0.07] 0.008

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm in a stratum one patient with 0.5 events was added to each treatment arm in the respective stratum for estimation of the OR/RR. In case of zero events in both treatment arms, no treatment comparison is performed.

Table 4-1: Adverse events: Binary analysis (Safety Set)

	Treatment groups		Comparison		
Parameter	**Iptacopan (N=38) n / N* (%)**	**Placebo (N=36) n / N* (%)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Any adverse events	29 / 38 (76.3)	24 / 36 (66.7)	1.61 [0.58; 4.47] 0.359	1.14 [0.86; 1.53] 0.363	0.10 [-0.11; 0.30] 0.356
Serious adverse events	3 / 38 (7.9)	1 / 36 (2.8)	3.00 [0.30; 30.26] 0.352	2.84 [0.31; 26.08] 0.356	0.05 [-0.05; 0.15] 0.321
Grade >= 3 adverse events	2 / 38 (5.3)	1 / 36 (2.8)	1.94 [0.17; 22.42] 0.594	1.89 [0.18; 20.00] 0.595	0.02 [-0.06; 0.11] 0.584
Adverse events leading to treatment discontinuation	0 / 38	0 / 36	- [-; -] -	- [-; -] -	- [-; -] -

N: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment as factor.
The RR and RD (with Wald CIs and p-values) were calculated from a 2x2 table.
In case of zero events in only one treatment arm one patient with 0.5 events was added to each treatment arm for estimation of the OR/RR.
In case of zero events in both treatment arms, no treatment comparison is performed.

Table 4-2: Any adverse events by SOC and PT: Binary analysis (Safety Set)

	Treatment groups		Comparison		
System Organ Class Preferred Term	Iptacopan (N=38) n / N* (%)	Placebo (N=36) n / N* (%)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Blood and lymphatic system disorders					
At least one	4 / 38 (10.5)	1 / 36 (2.8)	4.12 [0.44; 38.74] 0.216	3.79 [0.44; 32.32] 0.223	0.08 [-0.03; 0.19] 0.173
Gastrointestinal disorders					
At least one	5 / 38 (13.2)	7 / 36 (19.4)	0.63 [0.18; 2.19] 0.466	0.68 [0.24; 1.94] 0.467	-0.06 [-0.23; 0.11] 0.464
Infections and infestations					
At least one	18 / 38 (47.4)	13 / 36 (36.1)	1.59 [0.63; 4.04] 0.328	1.31 [0.76; 2.27] 0.332	0.11 [-0.11; 0.34] 0.323
COVID-19	8 / 38 (21.1)	6 / 36 (16.7)	1.33 [0.41; 4.31] 0.631	1.26 [0.49; 3.28] 0.632	0.04 [-0.13; 0.22] 0.629
Nasopharyngitis	4 / 38 (10.5)	1 / 36 (2.8)	4.12 [0.44; 38.74] 0.216	3.79 [0.44; 32.32] 0.223	0.08 [-0.03; 0.19] 0.173
Investigations					
At least one	10 / 38 (26.3)	4 / 36 (11.1)	2.86 [0.81; 10.13] 0.104	2.37 [0.82; 6.88] 0.113	0.15 [-0.02; 0.33] 0.086
Blood creatine phosphokinase increased	5 / 38 (13.2)	1 / 36 (2.8)	5.30 [0.59; 47.82] 0.137	4.74 [0.58; 38.61] 0.146	0.10 [-0.02; 0.22] 0.090
Nervous system disorders					
At least one	3 / 38 (7.9)	5 / 36 (13.9)	0.53 [0.12; 2.41] 0.412	0.57 [0.15; 2.21] 0.415	-0.06 [-0.20; 0.08] 0.407

N: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
SOC: System organ class
PT: Preferred term
.....
MedDRA version: 26.1
The OR and the respective 95% CI was estimated using a logistic regression model with treatment as factor.
The RR and RD (with Wald CIs and p-values) were calculated from a 2x2 table.
In case of zero events in only one treatment arm one patient with 0.5 events was added to each treatment arm for estimation of the OR/RR.
In case of zero events in both treatment arms, no treatment comparison is performed.

Table 4-3: Serious adverse events by SOC and PT: Binary analysis (Safety Set)

	Treatment groups		Comparison		
System Organ Class Preferred Term	Iptacopan (N=38) n / N* (%)	Placebo (N=36) n / N* (%)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Selection criteria not fullfilled.					

N: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
SOC: System organ class
PT: Preferred term
.....
MedDRA version: 26.1
The OR and the respective 95% CI was estimated using a logistic regression model with treatment as factor.
The RR and RD (with Wald CIs and p-values) were calculated from a 2x2 table.
In case of zero events in only one treatment arm one patient with 0.5 events was added to each treatment arm for estimation of the OR/RR.
In case of zero events in both treatment arms, no treatment comparison is performed.

Table 4-4: Grade >= 3 adverse events by SOC and PT: Binary analysis (Safety Set)

	Treatment groups		Comparison		
System Organ Class Preferred Term	Iptacopan (N=38) n / N* (%)	Placebo (N=36) n / N* (%)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Selection criteria not fullfilled.					

N: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
SOC: System organ class
PT: Preferred term
.....
MedDRA version: 26.1
The OR and the respective 95% CI was estimated using a logistic regression model with treatment as factor.
The RR and RD (with Wald CIs and p-values) were calculated from a 2x2 table.
In case of zero events in only one treatment arm one patient with 0.5 events was added to each treatment arm for estimation of the OR/RR.
In case of zero events in both treatment arms, no treatment comparison is performed.

Table 4-5: Adverse events leading to treatment discontinuation by SOC and PT: number and percentage of patients with event (Safety Set)

	Treatment groups		Comparison		
System Organ Class Preferred Term	Iptacopan (N=38) n / N* (%)	Placebo (N=36) n / N* (%)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Selection criteria not fullfilled.					

N: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
SOC: System organ class
PT: Preferred term
.....
MedDRA version: 26.1
The OR and the respective 95% CI was estimated using a logistic regression model with treatment as factor.
The RR and RD (with Wald CIs and p-values) were calculated from a 2x2 table.
In case of zero events in only one treatment arm one patient with 0.5 events was added to each treatment arm for estimation of the OR/RR.
In case of zero events in both treatment arms, no treatment comparison is performed.

Table 4-6: Adverse events of special interest: Binary analysis (Safety Set)

	Treatment groups		Comparison		
Adverse Event of Special Interest	**Iptacopan (N=38) n / N* (%)**	**Placebo (N=36) n / N* (%)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Treatment Emergent Adverse Events of Special Interest					
Decreased platelets					
	0 / 38	0 / 36	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Hypersensitivity					
	0 / 38	0 / 36	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Infections caused by encapsulated bacteria					
	2 / 38 (5.3)	1 / 36 (2.8)	1.94	1.89	0.02
			[0.17; 22.42]	[0.18; 20.00]	[-0.06; 0.11]
			0.594	0.595	0.584
Malignancy					
	0 / 38	0 / 36	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Serious or severe infections					
	2 / 38 (5.3)	0 / 36	5.00	4.74	0.05
			[0.23; 107.80]	[0.24; 95.55]	[-0.02; 0.12]
			0.304	0.310	0.146
Testicular effects					
	0 / 38	0 / 36	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Thyroid changes					
	0 / 38	1 / 36 (2.8)	0.31	0.32	-0.03
			[0.01; 7.79]	[0.01; 7.52]	[-0.08; 0.03]
			0.474	0.476	0.310
Serious Treatment Emergent Adverse Events of Special Interest					
Decreased platelets					
	0 / 38	0 / 36	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Hypersensitivity					
	0 / 38	0 / 36	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Infections caused by encapsulated bacteria					
	0 / 38	0 / 36	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Malignancy					
	0 / 38	0 / 36	-	-	-
			[-; -]	[-; -]	[-; -]

			-	-	-
Serious or severe infections					
	2 / 38 (5.3)	0 / 36	5.00	4.74	0.05
			[0.23; 107.80]	[0.24; 95.55]	[-0.02; 0.12]
			0.304	0.310	0.146
Testicular effects					
	0 / 38	0 / 36	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Thyroid changes					
	0 / 38	0 / 36	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Severe Treatment Emergent Adverse Events of Special Interest (grade >=3)					
Decreased platelets					
	0 / 38	0 / 36	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Hypersensitivity					
	0 / 38	0 / 36	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Infections caused by encapsulated bacteria					
	0 / 38	0 / 36	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Malignancy					
	0 / 38	0 / 36	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Serious or severe infections					
	1 / 38 (2.6)	0 / 36	2.92	2.85	0.03
			[0.12; 74.03]	[0.12; 67.68]	[-0.02; 0.08]
			0.516	0.518	0.311
Testicular effects					
	0 / 38	0 / 36	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Thyroid changes					
	0 / 38	0 / 36	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment as factor.
The RR and RD (with Wald CIs and p-values) were calculated from a 2x2 table.
In case of zero events in only one treatment arm one patient with 0.5 events was added to each treatment arm for estimation of the OR/RR.
In case of zero events in both treatment arms, no treatment comparison is performed.

Table 5-2.1.1: Proteinuria (UPCR): Analysis of change from baseline - subgroup analysis (Full Analysis Set)

	Treatment groups						
	Iptacopan (N=38)		Placebo (N=36)		Comparison		
Subgroup Level	N[a]	LS Mean (SE)	N[a]	LS Mean (SE)	Overall treatment effect	[95% CI]	p-value
Age groups (Interaction test: p = 0.473)							
< Median	21	-0.3 (0.1)	9	0.0 (0.2)	-0.4	[-0.81; 0.03]	0.068
>= Median	17	-0.6 (0.1)	27	0.0 (0.1)	-0.6	[-0.93; -0.25]	<.001
Sex (Interaction test: p = 0.387)							
Male	27	-0.5 (0.1)	20	0.0 (0.1)	-0.5	[-0.86; -0.22]	0.001
Female	11	-0.3 (0.2)	16	0.0 (0.1)	-0.3	[-0.73; 0.11]	0.145
Race (Interaction test: p = 0.648)							
White	27	-0.5 (0.1)	24	-0.0 (0.1)	-0.4	[-0.73; -0.13]	0.006
Other	11	-0.4 (0.2)	12	0.1 (0.2)	-0.6	[-1.00; -0.11]	0.016
Region (Interaction test: p = 0.591)							
North America	7	-0.7 (0.2)	8	-0.0 (0.2)	-0.7	[-1.28; -0.16]	0.013
Europe	22	-0.4 (0.1)	19	-0.0 (0.1)	-0.4	[-0.72; -0.05]	0.024
Other	9	-0.3 (0.2)	9	0.2 (0.2)	-0.5	[-0.99; 0.01]	0.053
Corticosteroid and/or mycophenolic acid treatment at randomization (Interaction test: p = 0.366)							
Yes	16	-0.2 (0.1)	17	0.2 (0.1)	-0.3	[-0.71; 0.03]	0.070
No	22	-0.7 (0.1)	19	-0.1 (0.1)	-0.6	[-0.90; -0.24]	0.001
C3G subtype at diagnosis (Interaction test: p = 0.481)							
C3GN	26	-0.5 (0.1)	32	0.0 (0.1)	-0.5	[-0.81; -0.24]	<.001
DDD	9	-0.3 (0.2)	1	-0.2 (0.5)	-0.1	[-1.26; 1.04]	0.847
Mixed C3GN/DDD	2	- (-)	2	- (-)	-	[-; -]	-
Unknown	1	- (-)	1	- (-)	-	[-; -]	-
Baseline UPCR 24h (Interaction test: p = 0.046)							
< 3 g/g	17	-0.6 (0.1)	25	0.1 (0.1)	-0.7	[-1.02; -0.37]	<.001
>= 3 g/g	21	-0.3 (0.1)	11	-0.1 (0.2)	-0.2	[-0.56; 0.21]	0.367
Baseline total urinary protein 24h (Interaction test: p = 0.845)							

< 3 g/day	11	-0.4 (0.2)	15	0.1 (0.2)	-0.5	[-0.92; -0.08]	0.019
>= 3 g/day	27	-0.5 (0.1)	21	-0.0 (0.1)	-0.5	[-0.77; -0.14]	0.005
Baseline eGFR category (Interaction test: p = 0.720)							
< 60 mL/min/1.73m2	10	-0.4 (0.2)	4	0.2 (0.3)	-0.6	[-1.23; 0.05]	0.069
>= 60 mL/min/1.73m2	28	-0.5 (0.1)	32	0.0 (0.1)	-0.5	[-0.74; -0.19]	0.001
Baseline eGFR category (Interaction test: p = 0.786)							
< 90 mL/min/1.73m2	19	-0.5 (0.1)	12	-0.0 (0.2)	-0.5	[-0.89; -0.10]	0.016
>= 90 mL/min/1.73m2	19	-0.4 (0.1)	24	0.1 (0.1)	-0.4	[-0.75; -0.10]	0.011
Baseline C3 (Interaction test: p = 0.868)							
< 45 mg/dL	28	-0.4 (0.1)	26	0.1 (0.1)	-0.5	[-0.75; -0.16]	0.003
>= 45 mg/dL	10	-0.5 (0.2)	10	-0.0 (0.2)	-0.5	[-0.99; -0.02]	0.040
Years since first C3G diagnosis (Interaction test: p = 0.370)							
< 2 Years	15	-0.3 (0.1)	15	0.1 (0.1)	-0.3	[-0.72; 0.05]	0.089
>= 2 Years	23	-0.5 (0.1)	21	0.0 (0.1)	-0.6	[-0.89; -0.23]	0.001
Age at C3G diagnosis (Interaction test: p = 0.103)							
< 18 Years	15	-0.3 (0.1)	6	-0.2 (0.2)	-0.1	[-0.62; 0.39]	0.649
>= 18 Years	23	-0.5 (0.1)	30	0.1 (0.1)	-0.6	[-0.90; -0.31]	<.001
Hypertension at C3G diagnosis (Interaction test: p = 0.826)							
Yes	23	-0.4 (0.1)	18	0.0 (0.1)	-0.4	[-0.79; -0.11]	0.010
No	15	-0.5 (0.1)	18	0.0 (0.1)	-0.5	[-0.88; -0.13]	0.009

CI: Confidence Interval
MMRM: Mixed Model for Repeated Measures
LS Mean: Least Square Mean
SE: Standard Error
.....
[a] Number of patients included in the analysis
MMRM including treatment, time point, subgroup, corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as fixed effects, treatment*time point and treatment*subgroup as interaction terms and baseline values as covariate.
Patients with an evaluable baseline score and at least one evaluable post-baseline score were included in the analysis.

Table 5-2.1.2: Proteinuria (UPCR) : Proportion of patients with a reduction of >= 1 g/g in UPCR (24h) at 6 months compared to the baseline visit - subgroup analysis (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup Level	Iptacopan (N=38) n / N* (%)	Placebo (N=36) n / N* (%)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Age groups (Interaction test: p = 0.083)					
< Median	10 / 21 (47.6)	2 / 9 (22.2)	2.36 [0.43; 13.06] 0.324	1.58 [0.55; 4.47] 0.393	0.18 [-0.14; 0.50] 0.265
>= Median	10 / 17 (58.8)	2 / 27 (7.4)	21.12 [3.52; 126.59] <.001	7.94 [1.98; 31.80] 0.003	0.52 [0.26; 0.77] <.001
Sex (Interaction test: p = 0.137)					
Male	15 / 27 (55.6)	1 / 20 (5.0)	18.41 [2.88; 117.76] 0.002	7.82 [1.61; 37.97] 0.011	0.51 [0.30; 0.72] <.001
Female	5 / 11 (45.5)	3 / 16 (18.8)	2.92 [0.55; 15.57] 0.209	1.89 [0.61; 5.89] 0.273	0.19 [-0.15; 0.53] 0.270
Race (Interaction test: p = 0.752)					
White	15 / 27 (55.6)	3 / 24 (12.5)	9.46 [2.19; 40.78] 0.003	4.43 [1.47; 13.36] 0.008	0.43 [0.20; 0.66] <.001
Other	5 / 11 (45.5)	1 / 12 (8.3)	6.26 [0.78; 50.12] 0.084	3.68 [0.76; 17.70] 0.105	0.35 [0.01; 0.69] 0.042
Region (Interaction test: p = 0.856)					
North America	5 / 7 (71.4)	2 / 8 (25.0)	5.26 [0.62; 44.33] 0.127	2.09 [0.75; 5.84] 0.159	0.38 [-0.08; 0.83] 0.110
Europe	10 / 22 (45.5)	1 / 19 (5.3)	11.41 [1.74; 75.04] 0.011	6.18 [1.25; 30.42] 0.025	0.41 [0.18; 0.63] <.001
Other	5 / 9 (55.6)	1 / 9 (11.1)	6.84 [0.78; 60.01] 0.083	3.77 [0.73; 19.36] 0.112	0.45 [0.06; 0.84] 0.022
Corticosteroid and/or mycophenolic acid treatment at randomization (Interaction test: p = 0.984)					
Yes	6 / 16 (37.5)	1 / 17 (5.9)	9.60 [1.00; 91.96] 0.050	6.38 [0.86; 47.29] 0.070	0.32 [0.05; 0.58] 0.018
No	14 / 22 (63.6)	3 / 19 (15.8)	9.33 [2.07; 42.18] 0.004	4.03 [1.36; 11.93] 0.012	0.48 [0.22; 0.74] <.001
C3G subtype at diagnosis (Interaction test: p = 0.652)					
C3GN	13 / 26 (50.0)	4 / 32 (12.5)	6.87 [1.81; 26.05] 0.005	3.69 [1.41; 9.70] 0.008	0.36 [0.13; 0.58] 0.002
DDD	6 / 9 (66.7)	0 / 1	3.33	1.74	0.40

			[0.20; 54.36]	[0.35; 8.61]	[-0.03; 0.83]
			0.398	0.499	0.068
Mixed C3GN/DDD	0 / 2	0 / 2	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Unknown	1 / 1 (100.0)	0 / 1	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline UPCR 24h (Interaction test: p = 0.149)					
< 3 g/g	7 / 17 (41.2)	0 / 25	19.53	11.21	0.41
			[2.13; 178.65]	[1.50; 83.82]	[0.17; 0.64]
			0.009	0.019	<.001
>= 3 g/g	13 / 21 (61.9)	4 / 11 (36.4)	3.02	1.71	0.26
			[0.64; 14.22]	[0.74; 3.97]	[-0.09; 0.60]
			0.161	0.209	0.142
Baseline total urinary protein 24h (Interaction test: p = 0.977)					
< 3 g/day	3 / 11 (27.3)	0 / 15	7.20	5.18	0.27
			[0.69; 75.45]	[0.66; 40.46]	[0.01; 0.54]
			0.100	0.117	0.042
>= 3 g/day	17 / 27 (63.0)	4 / 21 (19.0)	7.50	3.31	0.44
			[1.93; 29.07]	[1.31; 8.36]	[0.19; 0.69]
			0.004	0.011	<.001
Baseline eGFR category (Interaction test: p = 0.927)					
< 60 mL/min/1.73m2	8 / 10 (80.0)	1 / 4 (25.0)	7.67	2.67	0.56
			[0.69; 85.75]	[0.61; 11.72]	[0.05; 1.00]
			0.098	0.193	0.033
>= 60 mL/min/1.73m2	12 / 28 (42.9)	3 / 32 (9.4)	6.74	4.06	0.33
			[1.74; 26.09]	[1.41; 11.65]	[0.13; 0.54]
			0.006	0.009	0.001
Baseline eGFR category (Interaction test: p = 0.430)					
< 90 mL/min/1.73m2	12 / 19 (63.2)	1 / 12 (8.3)	12.89	5.58	0.55
			[1.83; 90.63]	[1.11; 27.99]	[0.27; 0.82]
			0.010	0.037	<.001
>= 90 mL/min/1.73m2	8 / 19 (42.1)	3 / 24 (12.5)	4.93	3.14	0.30
			[1.13; 21.43]	[1.07; 9.19]	[0.06; 0.55]
			0.033	0.037	0.016
Baseline C3 (Interaction test: p = 0.362)					
< 45 mg/dL	12 / 28 (42.9)	3 / 26 (11.5)	6.06	3.71	0.31
			[1.43; 25.58]	[1.19; 11.61]	[0.09; 0.53]
			0.014	0.024	0.005
>= 45 mg/dL	8 / 10 (80.0)	1 / 10 (10.0)	20.40	5.19	0.65
			[2.15; 193.69]	[1.12; 24.09]	[0.31; 0.99]
			0.009	0.036	<.001
Years since first C3G diagnosis (Interaction test: p = 0.511)					
< 2 Years	7 / 15 (46.7)	2 / 15 (13.3)	5.38	3.21	0.36
			[0.97; 29.79]	[0.97; 10.58]	[0.09; 0.63]
			0.054	0.055	0.009
>= 2 Years	13 / 23 (56.5)	2 / 21 (9.5)	12.02	5.89	0.47
			[2.20; 65.62]	[1.49; 23.26]	[0.23; 0.71]
			0.004	0.011	<.001
Age at C3G diagnosis (Interaction test: p = 0.028)					

< 18 Years	6 / 15 (40.0)	2 / 6 (33.3)	0.98 [0.12; 7.90] 0.987	1.08 [0.30; 3.81] 0.908	0.03 [-0.43; 0.49] 0.909
>= 18 Years	14 / 23 (60.9)	2 / 30 (6.7)	20.71 [4.21; 101.97] <.001	7.53 [2.23; 25.41] 0.001	0.54 [0.33; 0.75] <.001
Hypertension at C3G diagnosis (Interaction test: p = 0.858)					
Yes	11 / 23 (47.8)	2 / 18 (11.1)	7.76 [1.40; 43.04] 0.019	4.26 [1.07; 16.97] 0.040	0.36 [0.11; 0.61] 0.005
No	9 / 15 (60.0)	2 / 18 (11.1)	9.66 [1.78; 52.52] 0.009	4.25 [1.30; 13.92] 0.017	0.48 [0.18; 0.77] 0.002

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm one patient with 0.5 events was added to each treatment arm for estimation of the OR/RR.
In case of zero events in both treatment arms, no treatment comparison is performed.

Table 5-2.1.3: Proteinuria (UPCR) : Proportion of patients with a reduction of >= 1.5 g/g in UPCR (24h) at 6 months compared to the baseline visit - subgroup analysis (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup Level	Iptacopan (N=38) n / N* (%)	Placebo (N=36) n / N* (%)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Age groups (Interaction test: p = 0.317)					
< Median	8 / 21 (38.1)	2 / 9 (22.2)	1.58 [0.28; 8.90] 0.604	1.23 [0.42; 3.58] 0.707	0.08 [-0.22; 0.39] 0.599
>= Median	5 / 17 (29.4)	2 / 27 (7.4)	5.68 [0.93; 34.82] 0.060	3.97 [0.87; 18.13] 0.075	0.22 [-0.02; 0.46] 0.070
Sex (Interaction test: p = 0.310)					
Male	9 / 27 (33.3)	1 / 20 (5.0)	7.28 [1.13; 46.72] 0.036	4.82 [0.95; 24.42] 0.058	0.29 [0.09; 0.49] 0.004
Female	4 / 11 (36.4)	3 / 16 (18.8)	2.03 [0.37; 11.11] 0.412	1.56 [0.47; 5.19] 0.472	0.11 [-0.22; 0.44] 0.509
Race (Interaction test: p = 0.890)					
White	9 / 27 (33.3)	3 / 24 (12.5)	3.64 [0.83; 15.94] 0.086	2.65 [0.82; 8.62] 0.105	0.21 [-0.01; 0.43] 0.065
Other	4 / 11 (36.4)	1 / 12 (8.3)	4.36 [0.53; 35.83] 0.171	2.92 [0.58; 14.80] 0.195	0.25 [-0.07; 0.57] 0.126
Region (Interaction test: p = N.E.)					
North America	3 / 7 (42.9)	2 / 8 (25.0)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Europe	6 / 22 (27.3)	1 / 19 (5.3)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Other	4 / 9 (44.4)	1 / 9 (11.1)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Corticosteroid and/or mycophenolic acid treatment at randomization (Interaction test: p = 0.898)					
Yes	3 / 16 (18.8)	1 / 17 (5.9)	3.69 [0.34; 39.84] 0.282	3.19 [0.37; 27.58] 0.292	0.13 [-0.09; 0.35] 0.255
No	10 / 22 (45.5)	3 / 19 (15.8)	4.44 [1.00; 19.75] 0.050	2.88 [0.93; 8.95] 0.068	0.30 [0.03; 0.56] 0.028
C3G subtype at diagnosis (Interaction test: p = 0.598)					
C3GN	9 / 26 (34.6)	4 / 32 (12.5)	3.48 [0.89; 13.56] 0.073	2.51 [0.89; 7.05] 0.081	0.20 [-0.01; 0.42] 0.066
DDD	4 / 9 (44.4)	0 / 1	1.47	1.21	0.20

			[0.09; 24.66]	[0.23; 6.38]	[-0.15; 0.55]
			0.787	0.822	0.264
Mixed C3GN/DDD	0 / 2	0 / 2	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Unknown	0 / 1	0 / 1	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline UPCR 24h (Interaction test: p = 0.292)					
< 3 g/g	3 / 17 (17.6)	0 / 25	6.90	5.53	0.17
			[0.69; 68.76]	[0.64; 47.43]	[-0.01; 0.35]
			0.099	0.119	0.063
>= 3 g/g	10 / 21 (47.6)	4 / 11 (36.4)	1.66	1.32	0.12
			[0.36; 7.71]	[0.54; 3.21]	[-0.23; 0.47]
			0.519	0.543	0.518
Baseline total urinary protein 24h (Interaction test: p = 0.900)					
< 3 g/day	1 / 11 (9.1)	0 / 15	2.91	2.56	0.09
			[0.23; 36.69]	[0.27; 24.31]	[-0.08; 0.26]
			0.408	0.412	0.297
>= 3 g/day	12 / 27 (44.4)	4 / 21 (19.0)	3.50	2.34	0.25
			[0.92; 13.40]	[0.88; 6.21]	[0.00; 0.51]
			0.067	0.088	0.047
Baseline eGFR category (Interaction test: p = 0.436)					
< 60 mL/min/1.73m2	4 / 10 (40.0)	1 / 4 (25.0)	1.45	1.54	0.23
			[0.14; 14.73]	[0.35; 6.68]	[-0.20; 0.67]
			0.751	0.566	0.295
>= 60 mL/min/1.73m2	9 / 28 (32.1)	3 / 32 (9.4)	4.33	3.08	0.23
			[1.09; 17.24]	[1.06; 8.97]	[0.04; 0.41]
			0.037	0.039	0.018
Baseline eGFR category (Interaction test: p = N.E.)					
< 90 mL/min/1.73m2	7 / 19 (36.8)	1 / 12 (8.3)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 90 mL/min/1.73m2	6 / 19 (31.6)	3 / 24 (12.5)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline C3 (Interaction test: p = 0.671)					
< 45 mg/dL	10 / 28 (35.7)	3 / 26 (11.5)	4.56	3.10	0.24
			[1.05; 19.74]	[0.97; 9.86]	[0.03; 0.45]
			0.042	0.056	0.026
>= 45 mg/dL	3 / 10 (30.0)	1 / 10 (10.0)	2.57	2.11	0.15
			[0.29; 22.62]	[0.37; 12.13]	[-0.19; 0.49]
			0.396	0.405	0.385
Years since first C3G diagnosis (Interaction test: p = 0.747)					
< 2 Years	5 / 15 (33.3)	2 / 15 (13.3)	3.15	2.33	0.22
			[0.55; 18.00]	[0.64; 8.47]	[-0.06; 0.49]
			0.196	0.198	0.117
>= 2 Years	8 / 23 (34.8)	2 / 21 (9.5)	4.71	3.48	0.24
			[0.85; 26.20]	[0.80; 15.16]	[0.00; 0.47]
			0.077	0.096	0.046
Age at C3G diagnosis (Interaction test: p = 0.100)					

< 18 Years	5 / 15 (33.3)	2 / 6 (33.3)	0.72 [0.09; 5.95] 0.759	0.79 [0.21; 3.07] 0.739	-0.07 [-0.51; 0.37] 0.747
>= 18 Years	8 / 23 (34.8)	2 / 30 (6.7)	6.85 [1.42; 33.17] 0.017	4.42 [1.22; 16.02] 0.024	0.28 [0.07; 0.49] 0.008
Hypertension at C3G diagnosis (Interaction test: p = 0.811)					
Yes	8 / 23 (34.8)	2 / 18 (11.1)	4.43 [0.78; 25.08] 0.092	3.11 [0.75; 12.95] 0.118	0.23 [-0.01; 0.48] 0.058
No	5 / 15 (33.3)	2 / 18 (11.1)	3.29 [0.59; 18.27] 0.173	2.33 [0.64; 8.54] 0.201	0.19 [-0.08; 0.45] 0.167

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm one patient with 0.5 events was added to each treatment arm for estimation of the OR/RR.
In case of zero events in both treatment arms, no treatment comparison is performed.

Table 5-2.1.4: Proteinuria (UPCR) : Proportion of patients improving by at least one stage in UPCR (24h) at 6 months compared to the baseline visit - subgroup analysis (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup Level	Iptacopan (N=38) n / N* (%)	Placebo (N=36) n / N* (%)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Age groups (Interaction test: p = 0.220)					
< Median	8 / 21 (38.1)	2 / 9 (22.2)	1.47 [0.25; 8.82] 0.673	1.23 [0.42; 3.58] 0.707	0.08 [-0.22; 0.39] 0.599
>= Median	8 / 17 (47.1)	4 / 27 (14.8)	6.58 [1.41; 30.63] 0.016	3.25 [1.19; 8.86] 0.021	0.33 [0.07; 0.59] 0.014
Sex (Interaction test: p = 0.321)					
Male	11 / 27 (40.7)	2 / 20 (10.0)	6.29 [1.29; 30.74] 0.023	3.55 [1.04; 12.13] 0.044	0.32 [0.10; 0.53] 0.004
Female	5 / 11 (45.5)	4 / 16 (25.0)	1.99 [0.38; 10.52] 0.420	1.42 [0.55; 3.65] 0.471	0.11 [-0.22; 0.44] 0.509
Race (Interaction test: p = 0.576)					
White	12 / 27 (44.4)	4 / 24 (16.7)	4.58 [1.14; 18.34] 0.031	2.65 [1.00; 7.01] 0.049	0.28 [0.04; 0.51] 0.021
Other	4 / 11 (36.4)	2 / 12 (16.7)	2.33 [0.34; 15.88] 0.389	1.61 [0.50; 5.22] 0.426	0.13 [-0.16; 0.42] 0.389
Region (Interaction test: p = 0.678)					
North America	3 / 7 (42.9)	2 / 8 (25.0)	1.66 [0.20; 14.08] 0.640	1.27 [0.39; 4.11] 0.693	0.06 [-0.35; 0.48] 0.767
Europe	10 / 22 (45.5)	3 / 19 (15.8)	5.38 [1.12; 25.78] 0.035	2.93 [0.95; 9.00] 0.061	0.30 [0.04; 0.56] 0.023
Other	3 / 9 (33.3)	1 / 9 (11.1)	2.91 [0.30; 28.01] 0.355	2.05 [0.40; 10.57] 0.390	0.18 [-0.16; 0.51] 0.299
Corticosteroid and/or mycophenolic acid treatment at randomization (Interaction test: p = 0.948)					
Yes	3 / 16 (18.8)	1 / 17 (5.9)	3.69 [0.34; 39.84] 0.282	3.19 [0.37; 27.58] 0.292	0.13 [-0.09; 0.35] 0.255
No	13 / 22 (59.1)	5 / 19 (26.3)	4.04 [1.07; 15.27] 0.039	2.25 [0.98; 5.14] 0.056	0.33 [0.04; 0.61] 0.024
C3G subtype at diagnosis (Interaction test: p = 0.414)					
C3GN	12 / 26 (46.2)	6 / 32 (18.8)	3.63 [1.04; 12.65] 0.043	2.16 [0.99; 4.70] 0.052	0.24 [0.01; 0.46] 0.040
DDD	3 / 9 (33.3)	0 / 1	0.92	1.00	0.20

			[0.05; 17.14]	[0.18; 5.65]	[-0.15; 0.55]
			0.958	1.000	0.264
Mixed C3GN/DDD	0 / 2	0 / 2	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Unknown	1 / 1 (100.0)	0 / 1	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline UPCR 24h (Interaction test: p = 0.659)					
< 3 g/g	3 / 17 (17.6)	1 / 25 (4.0)	4.01	3.29	0.13
			[0.51; 31.78]	[0.54; 19.94]	[-0.06; 0.33]
			0.189	0.194	0.185
>= 3 g/g	13 / 21 (61.9)	5 / 11 (45.5)	2.24	1.38	0.17
			[0.45; 11.08]	[0.71; 2.70]	[-0.15; 0.50]
			0.324	0.342	0.295
Baseline total urinary protein 24h (Interaction test: p = 0.377)					
< 3 g/day	2 / 11 (18.2)	2 / 15 (13.3)	1.47	1.35	0.05
			[0.16; 13.43]	[0.23; 7.81]	[-0.23; 0.33]
			0.734	0.735	0.739
>= 3 g/day	14 / 27 (51.9)	4 / 21 (19.0)	4.70	2.54	0.33
			[1.25; 17.76]	[1.06; 6.08]	[0.09; 0.57]
			0.022	0.037	0.006
Baseline eGFR category (Interaction test: p = 0.905)					
< 60 mL/min/1.73m2	4 / 10 (40.0)	0 / 4	3.14	2.22	0.32
			[0.25; 39.86]	[0.29; 16.77]	[0.00; 0.64]
			0.377	0.440	0.048
>= 60 mL/min/1.73m2	12 / 28 (42.9)	6 / 32 (18.8)	3.74	2.28	0.24
			[1.08; 12.94]	[1.03; 5.05]	[0.02; 0.46]
			0.037	0.043	0.029
Baseline eGFR category (Interaction test: p = 0.213)					
< 90 mL/min/1.73m2	10 / 19 (52.6)	1 / 12 (8.3)	8.79	4.18	0.41
			[1.21; 63.86]	[0.87; 20.08]	[0.14; 0.67]
			0.032	0.074	0.003
>= 90 mL/min/1.73m2	6 / 19 (31.6)	5 / 24 (20.8)	1.95	1.56	0.11
			[0.45; 8.39]	[0.58; 4.17]	[-0.14; 0.37]
			0.371	0.378	0.378
Baseline C3 (Interaction test: p = 0.147)					
< 45 mg/dL	9 / 28 (32.1)	5 / 26 (19.2)	2.13	1.67	0.13
			[0.57; 7.99]	[0.68; 4.12]	[-0.09; 0.35]
			0.261	0.265	0.243
>= 45 mg/dL	7 / 10 (70.0)	1 / 10 (10.0)	13.39	4.62	0.56
			[1.45; 123.92]	[0.98; 21.74]	[0.20; 0.92]
			0.022	0.053	0.003
Years since first C3G diagnosis (Interaction test: p = 0.347)					
< 2 Years	6 / 15 (40.0)	4 / 15 (26.7)	2.03	1.54	0.16
			[0.43; 9.70]	[0.62; 3.84]	[-0.14; 0.47]
			0.373	0.352	0.297
>= 2 Years	10 / 23 (43.5)	2 / 21 (9.5)	5.87	3.46	0.32
			[1.19; 28.95]	[1.04; 11.48]	[0.07; 0.56]
			0.030	0.042	0.010
Age at C3G diagnosis (Interaction test: p = 0.150)					

< 18 Years	4 / 15 (26.7)	1 / 6 (16.7)	0.89 [0.09; 8.64] 0.917	1.05 [0.24; 4.66] 0.944	0.03 [-0.34; 0.41] 0.869
>= 18 Years	12 / 23 (52.2)	5 / 30 (16.7)	6.94 [1.76; 27.47] 0.006	3.14 [1.34; 7.32] 0.008	0.36 [0.13; 0.59] 0.002
Hypertension at C3G diagnosis (Interaction test: p = 0.602)					
Yes	8 / 23 (34.8)	3 / 18 (16.7)	2.86 [0.59; 13.89] 0.193	2.04 [0.65; 6.38] 0.222	0.17 [-0.08; 0.42] 0.172
No	8 / 15 (53.3)	3 / 18 (16.7)	5.20 [1.04; 25.95] 0.044	2.65 [0.97; 7.19] 0.056	0.34 [0.03; 0.64] 0.030

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm one patient with 0.5 events was added to each treatment arm for estimation of the OR/RR.
In case of zero events in both treatment arms, no treatment comparison is performed.

Table 5-2.1.5: Proteinuria (UPCR) : Proportion of patients improving by at least one stage and a reduction of >= 1 g/g in UPCR (24h) at 6 months compared to the baseline visit - subgroup analysis (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup Level	Iptacopan (N=38) n / N* (%)	Placebo (N=36) n / N* (%)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Age groups (Interaction test: p = N.E.)					
< Median	7 / 21 (33.3)	2 / 9 (22.2)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
>= Median	7 / 17 (41.2)	1 / 27 (3.7)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Sex (Interaction test: p = 0.408)					
Male	10 / 27 (37.0)	1 / 20 (5.0)	9.08 [1.40; 58.98] 0.021	5.34 [1.07; 26.66] 0.041	0.33 [0.13; 0.53] 0.001
Female	4 / 11 (36.4)	2 / 16 (12.5)	3.04 [0.48; 19.16] 0.237	2.00 [0.56; 7.09] 0.283	0.16 [-0.14; 0.46] 0.301
Race (Interaction test: p = 0.532)					
White	11 / 27 (40.7)	2 / 24 (8.3)	6.87 [1.46; 32.33] 0.015	4.07 [1.18; 14.09] 0.027	0.32 [0.11; 0.53] 0.003
Other	3 / 11 (27.3)	1 / 12 (8.3)	2.91 [0.33; 25.36] 0.333	2.17 [0.40; 11.92] 0.372	0.14 [-0.14; 0.43] 0.311
Region (Interaction test: p = 0.262)					
North America	2 / 7 (28.6)	2 / 8 (25.0)	0.96 [0.11; 8.40] 0.972	0.93 [0.24; 3.59] 0.910	-0.06 [-0.47; 0.34] 0.761
Europe	9 / 22 (40.9)	1 / 19 (5.3)	10.01 [1.49; 67.14] 0.018	5.58 [1.12; 27.90] 0.036	0.36 [0.14; 0.59] 0.002
Other	3 / 9 (33.3)	0 / 9	5.62 [0.49; 64.82] 0.166	3.73 [0.46; 30.08] 0.217	0.30 [-0.01; 0.61] 0.057
Corticosteroid and/or mycophenolic acid treatment at randomization (Interaction test: p = 0.750)					
Yes	3 / 16 (18.8)	0 / 17	9.07 [0.43; 191.04] 0.156	7.41 [0.41; 133.11] 0.174	0.19 [-0.00; 0.38] 0.055
No	11 / 22 (50.0)	3 / 19 (15.8)	5.33 [1.20; 23.66] 0.028	3.17 [1.03; 9.70] 0.044	0.34 [0.08; 0.61] 0.012
C3G subtype at diagnosis (Interaction test: p = 0.316)					
C3GN	10 / 26 (38.5)	3 / 32 (9.4)	5.21 [1.30; 20.95] 0.020	3.25 [1.14; 9.27] 0.027	0.26 [0.05; 0.47] 0.013
DDD	3 / 9 (33.3)	0 / 1	0.97	1.00	0.20

			[0.06; 16.54]	[0.18; 5.65]	[-0.15; 0.55]
			0.982	1.000	0.264
Mixed C3GN/DDD	0 / 2	0 / 2	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Unknown	1 / 1 (100.0)	0 / 1	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline UPCR 24h (Interaction test: p = 0.523)					
< 3 g/g	3 / 17 (17.6)	0 / 25	6.99	5.63	0.17
			[0.69; 70.33]	[0.67; 47.03]	[-0.01; 0.36]
			0.099	0.110	0.058
>= 3 g/g	11 / 21 (52.4)	3 / 11 (27.3)	2.88	1.78	0.26
			[0.60; 13.84]	[0.72; 4.42]	[-0.04; 0.56]
			0.186	0.214	0.092
Baseline total urinary protein 24h (Interaction test: p = 0.949)					
< 3 g/day	2 / 11 (18.2)	0 / 15	4.98	3.87	0.18
			[0.44; 56.65]	[0.46; 32.31]	[-0.05; 0.41]
			0.196	0.211	0.119
>= 3 g/day	12 / 27 (44.4)	3 / 21 (14.3)	4.54	2.81	0.30
			[1.13; 18.29]	[1.00; 7.89]	[0.07; 0.54]
			0.033	0.049	0.010
Baseline eGFR category (Interaction test: p = 0.734)					
< 60 mL/min/1.73m2	4 / 10 (40.0)	0 / 4	3.17	2.22	0.32
			[0.26; 38.72]	[0.29; 16.77]	[0.00; 0.64]
			0.367	0.440	0.048
>= 60 mL/min/1.73m2	10 / 28 (35.7)	3 / 32 (9.4)	5.25	3.41	0.26
			[1.31; 20.99]	[1.16; 10.01]	[0.06; 0.46]
			0.019	0.026	0.009
Baseline eGFR category (Interaction test: p = N.E.)					
< 90 mL/min/1.73m2	8 / 19 (42.1)	0 / 12	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 90 mL/min/1.73m2	6 / 19 (31.6)	3 / 24 (12.5)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline C3 (Interaction test: p = 0.617)					
< 45 mg/dL	8 / 28 (28.6)	2 / 26 (7.7)	4.31	3.16	0.21
			[0.91; 20.49]	[0.88; 11.36]	[0.02; 0.40]
			0.066	0.078	0.030
>= 45 mg/dL	6 / 10 (60.0)	1 / 10 (10.0)	8.43	4.06	0.47
			[0.99; 71.96]	[0.85; 19.38]	[0.09; 0.85]
			0.051	0.079	0.014
Years since first C3G diagnosis (Interaction test: p = 0.454)					
< 2 Years	5 / 15 (33.3)	2 / 15 (13.3)	3.25	2.38	0.23
			[0.56; 18.80]	[0.69; 8.22]	[-0.03; 0.49]
			0.188	0.169	0.086
>= 2 Years	9 / 23 (39.1)	1 / 21 (4.8)	8.57	5.44	0.33
			[1.31; 56.21]	[1.10; 26.78]	[0.11; 0.55]
			0.025	0.037	0.004
Age at C3G diagnosis (Interaction test: p = 0.106)					

< 18 Years	4 / 15 (26.7)	1 / 6 (16.7)	0.98 [0.11; 9.05] 0.984	1.05 [0.24; 4.66] 0.944	0.03 [-0.34; 0.41] 0.869
>= 18 Years	10 / 23 (43.5)	2 / 30 (6.7)	10.42 [2.14; 50.75] 0.004	5.46 [1.57; 19.01] 0.008	0.37 [0.16; 0.58] <.001
Hypertension at C3G diagnosis (Interaction test: p = N.E.)					
Yes	7 / 23 (30.4)	1 / 18 (5.6)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
No	7 / 15 (46.7)	2 / 18 (11.1)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm one patient with 0.5 events was added to each treatment arm for estimation of the OR/RR.
In case of zero events in both treatment arms, no treatment comparison is performed.

Table 5-2.1.6: Proteinuria (UPCR) : Proportion of patients with a >= 50% reduction in UPCR (24h) at 6 months compared to the baseline visit - subgroup analysis (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup Level	Iptacopan (N=38) n / N* (%)	Placebo (N=36) n / N* (%)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Age groups (Interaction test: p = N.E.)					
< Median	7 / 21 (33.3)	1 / 9 (11.1)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
>= Median	4 / 17 (23.5)	1 / 27 (3.7)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Sex (Interaction test: p = 0.467)					
Male	9 / 27 (33.3)	1 / 20 (5.0)	7.09 [1.11; 45.25] 0.038	4.82 [0.95; 24.42] 0.058	0.29 [0.09; 0.49] 0.004
Female	2 / 11 (18.2)	1 / 16 (6.3)	2.43 [0.27; 21.98] 0.429	2.00 [0.31; 13.03] 0.469	0.08 [-0.17; 0.33] 0.529
Race (Interaction test: p = 0.824)					
White	8 / 27 (29.6)	2 / 24 (8.3)	4.00 [0.85; 18.81] 0.080	3.01 [0.83; 10.90] 0.093	0.21 [0.01; 0.41] 0.038
Other	3 / 11 (27.3)	0 / 12	5.49 [0.51; 58.65] 0.159	4.16 [0.52; 32.99] 0.177	0.26 [0.00; 0.53] 0.050
Region (Interaction test: p = N.E.)					
North America	2 / 7 (28.6)	1 / 8 (12.5)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Europe	6 / 22 (27.3)	1 / 19 (5.3)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Other	3 / 9 (33.3)	0 / 9	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Corticosteroid and/or mycophenolic acid treatment at randomization (Interaction test: p = 0.716)					
Yes	3 / 16 (18.8)	0 / 17	9.07 [0.43; 191.04] 0.156	7.41 [0.41; 133.11] 0.174	0.19 [-0.00; 0.38] 0.055
No	8 / 22 (36.4)	2 / 19 (10.5)	4.86 [0.88; 26.68] 0.069	3.45 [0.83; 14.33] 0.088	0.26 [0.01; 0.50] 0.038
C3G subtype at diagnosis (Interaction test: p = N.E.)					
C3GN	7 / 26 (26.9)	2 / 32 (6.3)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
DDD	4 / 9 (44.4)	0 / 1	N.E.	N.E.	N.E.

			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Mixed C3GN/DDD	0 / 2	0 / 2	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Unknown	0 / 1	0 / 1	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline UPCR 24h (Interaction test: p = N.E.)					
< 3 g/g	5 / 17 (29.4)	0 / 25	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 3 g/g	6 / 21 (28.6)	2 / 11 (18.2)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline total urinary protein 24h (Interaction test: p = 0.599)					
< 3 g/day	3 / 11 (27.3)	0 / 15	7.33	5.18	0.27
			[0.69; 77.60]	[0.66; 40.46]	[0.01; 0.54]
			0.098	0.117	0.042
>= 3 g/day	8 / 27 (29.6)	2 / 21 (9.5)	3.49	2.68	0.20
			[0.73; 16.54]	[0.74; 9.68]	[-0.00; 0.41]
			0.116	0.133	0.055
Baseline eGFR category (Interaction test: p = 0.366)					
< 60 mL/min/1.73m2	2 / 10 (20.0)	0 / 4	1.48	1.38	0.16
			[0.12; 18.87]	[0.16; 11.67]	[-0.08; 0.40]
			0.764	0.767	0.194
>= 60 mL/min/1.73m2	9 / 28 (32.1)	2 / 32 (6.3)	6.18	4.32	0.26
			[1.35; 28.35]	[1.19; 15.65]	[0.07; 0.45]
			0.019	0.026	0.007
Baseline eGFR category (Interaction test: p = N.E.)					
< 90 mL/min/1.73m2	5 / 19 (26.3)	0 / 12	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 90 mL/min/1.73m2	6 / 19 (31.6)	2 / 24 (8.3)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline C3 (Interaction test: p = N.E.)					
< 45 mg/dL	8 / 28 (28.6)	1 / 26 (3.8)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 45 mg/dL	3 / 10 (30.0)	1 / 10 (10.0)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Years since first C3G diagnosis (Interaction test: p = 0.302)					
< 2 Years	2 / 15 (13.3)	1 / 15 (6.7)	1.88	1.75	0.08
			[0.21; 16.41]	[0.27; 11.31]	[-0.13; 0.29]
			0.570	0.555	0.455
>= 2 Years	9 / 23 (39.1)	1 / 21 (4.8)	8.52	5.44	0.33
			[1.33; 54.62]	[1.10; 26.78]	[0.11; 0.55]
			0.024	0.037	0.004
Age at C3G diagnosis (Interaction test: p = N.E.)					

< 18 Years	5 / 15 (33.3)	1 / 6 (16.7)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
>= 18 Years	6 / 23 (26.1)	1 / 30 (3.3)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Hypertension at C3G diagnosis (Interaction test: p = N.E.)					
Yes	5 / 23 (21.7)	1 / 18 (5.6)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
No	6 / 15 (40.0)	1 / 18 (5.6)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm one patient with 0.5 events was added to each treatment arm for estimation of the OR/RR.
In case of zero events in both treatment arms, no treatment comparison is performed.

Table 5-2.2.1: Combined renal endpoint : Proportion of patients with stable or improved eGFR compared to the baseline visit (<= 15% reduction in eGFR), and a >= 50% reduction in UPCR compared to the baseline visit - subgroup analysis (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup Level	Iptacopan (N=38) n / N* (%)	Placebo (N=36) n / N* (%)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Age groups (Interaction test: p = N.E.)					
< Median	7 / 21 (33.3)	1 / 9 (11.1)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
>= Median	4 / 17 (23.5)	1 / 27 (3.7)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Sex (Interaction test: p = 0.467)					
Male	9 / 27 (33.3)	1 / 20 (5.0)	7.09 [1.11; 45.25] 0.038	4.82 [0.95; 24.42] 0.058	0.29 [0.09; 0.49] 0.004
Female	2 / 11 (18.2)	1 / 16 (6.3)	2.43 [0.27; 21.98] 0.429	2.00 [0.31; 13.03] 0.469	0.08 [-0.17; 0.33] 0.529
Race (Interaction test: p = 0.824)					
White	8 / 27 (29.6)	2 / 24 (8.3)	4.00 [0.85; 18.81] 0.080	3.01 [0.83; 10.90] 0.093	0.21 [0.01; 0.41] 0.038
Other	3 / 11 (27.3)	0 / 12	5.49 [0.51; 58.65] 0.159	4.16 [0.52; 32.99] 0.177	0.26 [0.00; 0.53] 0.050
Region (Interaction test: p = N.E.)					
North America	2 / 7 (28.6)	1 / 8 (12.5)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Europe	6 / 22 (27.3)	1 / 19 (5.3)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Other	3 / 9 (33.3)	0 / 9	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Corticosteroid and/or mycophenolic acid treatment at randomization (Interaction test: p = 0.716)					
Yes	3 / 16 (18.8)	0 / 17	9.07 [0.43; 191.04] 0.156	7.41 [0.41; 133.11] 0.174	0.19 [-0.00; 0.38] 0.055
No	8 / 22 (36.4)	2 / 19 (10.5)	4.86 [0.88; 26.68] 0.069	3.45 [0.83; 14.33] 0.088	0.26 [0.01; 0.50] 0.038
C3G subtype at diagnosis (Interaction test: p = N.E.)					
C3GN	7 / 26 (26.9)	2 / 32 (6.3)	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]

			N.E.	N.E.	N.E.
DDD	4 / 9 (44.4)	0 / 1	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Mixed C3GN/DDD	0 / 2	0 / 2	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Unknown	0 / 1	0 / 1	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline UPCR 24h (Interaction test: p = N.E.)					
< 3 g/g	5 / 17 (29.4)	0 / 25	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 3 g/g	6 / 21 (28.6)	2 / 11 (18.2)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline total urinary protein 24h (Interaction test: p = 0.599)					
< 3 g/day	3 / 11 (27.3)	0 / 15	7.33	5.18	0.27
			[0.69; 77.60]	[0.66; 40.46]	[0.01; 0.54]
			0.098	0.117	0.042
>= 3 g/day	8 / 27 (29.6)	2 / 21 (9.5)	3.49	2.68	0.20
			[0.73; 16.54]	[0.74; 9.68]	[-0.00; 0.41]
			0.116	0.133	0.055
Baseline eGFR category (Interaction test: p = 0.366)					
< 60 mL/min/1.73m2	2 / 10 (20.0)	0 / 4	1.48	1.38	0.16
			[0.12; 18.87]	[0.16; 11.67]	[-0.08; 0.40]
			0.764	0.767	0.194
>= 60 mL/min/1.73m2	9 / 28 (32.1)	2 / 32 (6.3)	6.18	4.32	0.26
			[1.35; 28.35]	[1.19; 15.65]	[0.07; 0.45]
			0.019	0.026	0.007
Baseline eGFR category (Interaction test: p = N.E.)					
< 90 mL/min/1.73m2	5 / 19 (26.3)	0 / 12	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 90 mL/min/1.73m2	6 / 19 (31.6)	2 / 24 (8.3)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline C3 (Interaction test: p = N.E.)					
< 45 mg/dL	8 / 28 (28.6)	1 / 26 (3.8)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 45 mg/dL	3 / 10 (30.0)	1 / 10 (10.0)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Years since first C3G diagnosis (Interaction test: p = 0.302)					
< 2 Years	2 / 15 (13.3)	1 / 15 (6.7)	1.88	1.75	0.08
			[0.21; 16.41]	[0.27; 11.31]	[-0.13; 0.29]
			0.570	0.555	0.455
>= 2 Years	9 / 23 (39.1)	1 / 21 (4.8)	8.52	5.44	0.33
			[1.33; 54.62]	[1.10; 26.78]	[0.11; 0.55]

			0.024	0.037	0.004
Age at C3G diagnosis (Interaction test: p = N.E.)					
< 18 Years	5 / 15 (33.3)	1 / 6 (16.7)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 18 Years	6 / 23 (26.1)	1 / 30 (3.3)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Hypertension at C3G diagnosis (Interaction test: p = N.E.)					
Yes	5 / 23 (21.7)	1 / 18 (5.6)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
No	6 / 15 (40.0)	1 / 18 (5.6)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm one patient with 0.5 events was added to each treatment arm for estimation of the OR/RR.
In case of zero events in both treatment arms, no treatment comparison is performed.

Table 5-2.2.2: Combined renal endpoint : Proportion of patients with stable or improved eGFR compared to the baseline visit (<= 10% reduction in eGFR), and a >= 50% reduction in UPCR compared to the baseline visit - subgroup analysis (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup Level	Iptacopan (N=38) n / N* (%)	Placebo (N=36) n / N* (%)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Age groups (Interaction test: p = N.E.)					
< Median	6 / 21 (28.6)	1 / 9 (11.1)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
>= Median	4 / 17 (23.5)	1 / 27 (3.7)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Sex (Interaction test: p = N.E.)					
Male	8 / 27 (29.6)	1 / 20 (5.0)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Female	2 / 11 (18.2)	1 / 16 (6.3)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Race (Interaction test: p = N.E.)					
White	7 / 27 (25.9)	2 / 24 (8.3)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Other	3 / 11 (27.3)	0 / 12	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Region (Interaction test: p = N.E.)					
North America	1 / 7 (14.3)	1 / 8 (12.5)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Europe	6 / 22 (27.3)	1 / 19 (5.3)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Other	3 / 9 (33.3)	0 / 9	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Corticosteroid and/or mycophenolic acid treatment at randomization (Interaction test: p = N.E.)					
Yes	3 / 16 (18.8)	0 / 17	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
No	7 / 22 (31.8)	2 / 19 (10.5)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
C3G subtype at diagnosis (Interaction test: p = N.E.)					
C3GN	6 / 26 (23.1)	2 / 32 (6.3)	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]

			N.E.	N.E.	N.E.
DDD	4 / 9 (44.4)	0 / 1	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Mixed C3GN/DDD	0 / 2	0 / 2	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Unknown	0 / 1	0 / 1	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline UPCR 24h (Interaction test: p = N.E.)					
< 3 g/g	5 / 17 (29.4)	0 / 25	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 3 g/g	5 / 21 (23.8)	2 / 11 (18.2)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline total urinary protein 24h (Interaction test: p = N.E.)					
< 3 g/day	3 / 11 (27.3)	0 / 15	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 3 g/day	7 / 27 (25.9)	2 / 21 (9.5)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline eGFR category (Interaction test: p = 0.432)					
< 60 mL/min/1.73m2	2 / 10 (20.0)	0 / 4	1.51	1.38	0.16
			[0.12; 19.08]	[0.16; 11.67]	[-0.08; 0.40]
			0.751	0.767	0.194
>= 60 mL/min/1.73m2	8 / 28 (28.6)	2 / 32 (6.3)	5.17	3.86	0.22
			[1.12; 23.84]	[1.04; 14.33]	[0.04; 0.41]
			0.035	0.043	0.018
Baseline eGFR category (Interaction test: p = N.E.)					
< 90 mL/min/1.73m2	4 / 19 (21.1)	0 / 12	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 90 mL/min/1.73m2	6 / 19 (31.6)	2 / 24 (8.3)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline C3 (Interaction test: p = N.E.)					
< 45 mg/dL	7 / 28 (25.0)	1 / 26 (3.8)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 45 mg/dL	3 / 10 (30.0)	1 / 10 (10.0)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Years since first C3G diagnosis (Interaction test: p = N.E.)					
< 2 Years	2 / 15 (13.3)	1 / 15 (6.7)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 2 Years	8 / 23 (34.8)	1 / 21 (4.8)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]

			N.E.	N.E.	N.E.
Age at C3G diagnosis (Interaction test: p = N.E.)					
< 18 Years	5 / 15 (33.3)	1 / 6 (16.7)	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 18 Years	5 / 23 (21.7)	1 / 30 (3.3)	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]
			N.E.	N.E.	N.E.
Hypertension at C3G diagnosis (Interaction test: p = N.E.)					
Yes	4 / 23 (17.4)	1 / 18 (5.6)	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]
			N.E.	N.E.	N.E.
No	6 / 15 (40.0)	1 / 18 (5.6)	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]
			N.E.	N.E.	N.E.

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm one patient with 0.5 events was added to each treatment arm for estimation of the OR/RR.
In case of zero events in both treatment arms, no treatment comparison is performed.

Table 5-2.3.1: eGFR : Proportion of patients with stable or improved eGFR at month 6 compared to the baseline visit (<= 15% reduction in eGFR) - subgroup analysis (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup Level	Iptacopan (N=38) n / N* (%)	Placebo (N=36) n / N* (%)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Age groups (Interaction test: p = 0.697)					
< Median	18 / 21 (85.7)	8 / 9 (88.9)	0.89 [0.11; 7.25] 0.914	0.97 [0.67; 1.40] 0.869	-0.04 [-0.32; 0.24] 0.787
>= Median	16 / 17 (94.1)	24 / 27 (88.9)	1.58 [0.21; 11.82] 0.657	1.05 [0.86; 1.28] 0.647	0.05 [-0.11; 0.22] 0.528
Sex (Interaction test: p = 0.851)					
Male	23 / 27 (85.2)	17 / 20 (85.0)	1.06 [0.23; 4.91] 0.941	1.01 [0.78; 1.30] 0.947	0.00 [-0.21; 0.21] 0.986
Female	11 / 11 (100.0)	15 / 16 (93.8)	1.40 [0.11; 17.57] 0.793	1.03 [0.82; 1.28] 0.826	0.05 [-0.06; 0.16] 0.380
Race (Interaction test: p = 0.389)					
White	25 / 27 (92.6)	21 / 24 (87.5)	1.78 [0.27; 11.71] 0.547	1.06 [0.88; 1.27] 0.550	0.05 [-0.11; 0.22] 0.546
Other	9 / 11 (81.8)	11 / 12 (91.7)	0.54 [0.07; 3.95] 0.547	0.89 [0.58; 1.35] 0.577	-0.11 [-0.43; 0.21] 0.495
Region (Interaction test: p = 0.588)					
North America	6 / 7 (85.7)	8 / 8 (100.0)	0.37 [0.03; 5.01] 0.453	0.83 [0.52; 1.32] 0.429	-0.19 [-0.47; 0.10] 0.198
Europe	21 / 22 (95.5)	17 / 19 (89.5)	2.07 [0.25; 17.28] 0.502	1.07 [0.88; 1.30] 0.523	0.06 [-0.10; 0.21] 0.492
Other	7 / 9 (77.8)	7 / 9 (77.8)	0.97 [0.13; 7.40] 0.976	0.98 [0.56; 1.71] 0.942	-0.03 [-0.43; 0.38] 0.903
Corticosteroid and/or mycophenolic acid treatment at randomization (Interaction test: p = 0.093)					
Yes	13 / 16 (81.3)	16 / 17 (94.1)	0.27 [0.03; 2.92] 0.282	0.86 [0.66; 1.12] 0.274	-0.13 [-0.35; 0.09] 0.255
No	21 / 22 (95.5)	16 / 19 (84.2)	3.94 [0.37; 41.48] 0.254	1.13 [0.91; 1.41] 0.253	0.11 [-0.07; 0.30] 0.235
C3G subtype at diagnosis (Interaction test: p = 0.543)					
C3GN	23 / 26 (88.5)	29 / 32 (90.6)	0.76 [0.14; 4.19] 0.757	0.97 [0.80; 1.18] 0.779	-0.02 [-0.19; 0.14] 0.772
DDD	8 / 9 (88.9)	1 / 1 (100.0)	2.17	1.22	-0.20

			[0.12; 37.87]	[0.50; 2.97]	[-0.55; 0.15]
			0.594	0.668	0.264
Mixed C3GN/DDD	2 / 2 (100.0)	1 / 2 (50.0)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Unknown	1 / 1 (100.0)	1 / 1 (100.0)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline UPCR 24h (Interaction test: p = 0.383)					
< 3 g/g	16 / 17 (94.1)	24 / 25 (96.0)	0.67	0.97	-0.02
			[0.09; 5.23]	[0.80; 1.17]	[-0.16; 0.12]
			0.701	0.729	0.795
>= 3 g/g	18 / 21 (85.7)	8 / 11 (72.7)	2.28	1.18	0.13
			[0.37; 13.91]	[0.79; 1.76]	[-0.17; 0.44]
			0.373	0.417	0.395
Baseline total urinary protein 24h (Interaction test: p = 0.249)					
< 3 g/day	10 / 11 (90.9)	15 / 15 (100.0)	0.34	0.90	-0.09
			[0.03; 4.25]	[0.69; 1.17]	[-0.26; 0.08]
			0.403	0.427	0.293
>= 3 g/day	24 / 27 (88.9)	17 / 21 (81.0)	1.90	1.10	0.08
			[0.37; 9.67]	[0.86; 1.41]	[-0.13; 0.29]
			0.439	0.452	0.445
Baseline eGFR category (Interaction test: p = 0.610)					
< 60 mL/min/1.73m2	7 / 10 (70.0)	3 / 4 (75.0)	0.88	0.90	-0.15
			[0.09; 8.87]	[0.47; 1.73]	[-0.56; 0.25]
			0.916	0.749	0.459
>= 60 mL/min/1.73m2	27 / 28 (96.4)	29 / 32 (90.6)	1.87	1.06	0.06
			[0.32; 11.02]	[0.90; 1.24]	[-0.07; 0.18]
			0.491	0.487	0.364
Baseline eGFR category (Interaction test: p = 0.142)					
< 90 mL/min/1.73m2	15 / 19 (78.9)	11 / 12 (91.7)	0.44	0.85	-0.16
			[0.06; 3.26]	[0.62; 1.16]	[-0.38; 0.06]
			0.421	0.299	0.149
>= 90 mL/min/1.73m2	19 / 19 (100.0)	21 / 24 (87.5)	3.66	1.12	0.12
			[0.38; 35.65]	[0.93; 1.35]	[-0.01; 0.25]
			0.263	0.228	0.069
Baseline C3 (Interaction test: p = 0.185)					
< 45 mg/dL	24 / 28 (85.7)	24 / 26 (92.3)	0.50	0.93	-0.07
			[0.08; 2.99]	[0.77; 1.12]	[-0.23; 0.10]
			0.447	0.439	0.434
>= 45 mg/dL	10 / 10 (100.0)	8 / 10 (80.0)	3.52	1.25	0.24
			[0.31; 40.43]	[0.82; 1.91]	[-0.03; 0.51]
			0.312	0.299	0.078
Years since first C3G diagnosis (Interaction test: p = 0.965)					
< 2 Years	14 / 15 (93.3)	14 / 15 (93.3)	1.01	1.00	0.00
			[0.13; 8.19]	[0.79; 1.28]	[-0.18; 0.18]
			0.990	0.988	0.989
>= 2 Years	20 / 23 (87.0)	18 / 21 (85.7)	1.08	1.01	0.01
			[0.19; 6.10]	[0.78; 1.31]	[-0.20; 0.22]
			0.932	0.934	0.932
Age at C3G diagnosis (Interaction test: p = 0.704)					

< 18 Years	12 / 15 (80.0)	5 / 6 (83.3)	0.96 [0.11; 8.43] 0.969	0.96 [0.59; 1.55] 0.857	-0.09 [-0.44; 0.26] 0.596
>= 18 Years	22 / 23 (95.7)	27 / 30 (90.0)	1.64 [0.28; 9.79] 0.585	1.05 [0.88; 1.26] 0.582	0.06 [-0.08; 0.20] 0.431
Hypertension at C3G diagnosis (Interaction test: p = 0.290)					
Yes	19 / 23 (82.6)	16 / 18 (88.9)	0.59 [0.10; 3.66] 0.572	0.93 [0.72; 1.19] 0.552	-0.07 [-0.28; 0.15] 0.549
No	15 / 15 (100.0)	16 / 18 (88.9)	2.78 [0.26; 29.63] 0.398	1.12 [0.88; 1.41] 0.353	0.12 [-0.03; 0.28] 0.111

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm one patient with 0.5 events was added to each treatment arm for estimation of the OR/RR.
In case of zero events in both treatment arms, no treatment comparison is performed.

Table 5-2.3.2: eGFR : Proportion of patients with stable or improved eGFR at month 6 compared to the baseline visit (<= 10% reduction in eGFR) - subgroup analysis (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup Level	Iptacopan (N=38) n / N* (%)	Placebo (N=36) n / N* (%)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Age groups (Interaction test: p = 0.719)					
< Median	17 / 21 (81.0)	7 / 9 (77.8)	1.26 [0.18; 8.60] 0.816	1.03 [0.67; 1.58] 0.894	0.02 [-0.30; 0.35] 0.891
>= Median	14 / 17 (82.4)	19 / 27 (70.4)	1.96 [0.44; 8.74] 0.379	1.17 [0.84; 1.63] 0.365	0.12 [-0.14; 0.37] 0.367
Sex (Interaction test: p = 0.630)					
Male	21 / 27 (77.8)	14 / 20 (70.0)	1.48 [0.40; 5.56] 0.559	1.10 [0.78; 1.56] 0.575	0.07 [-0.18; 0.33] 0.574
Female	10 / 11 (90.9)	12 / 16 (75.0)	2.67 [0.35; 20.52] 0.344	1.19 [0.80; 1.77] 0.397	0.15 [-0.15; 0.44] 0.328
Race (Interaction test: p = 0.146)					
White	24 / 27 (88.9)	17 / 24 (70.8)	3.31 [0.75; 14.68] 0.115	1.26 [0.94; 1.68] 0.121	0.18 [-0.03; 0.40] 0.100
Other	7 / 11 (63.6)	9 / 12 (75.0)	0.60 [0.10; 3.64] 0.579	0.83 [0.43; 1.59] 0.578	-0.12 [-0.53; 0.28] 0.553
Region (Interaction test: p = 0.237)					
North America	5 / 7 (71.4)	7 / 8 (87.5)	0.46 [0.05; 4.65] 0.510	0.79 [0.45; 1.38] 0.402	-0.22 [-0.59; 0.16] 0.252
Europe	20 / 22 (90.9)	13 / 19 (68.4)	4.59 [0.80; 26.37] 0.087	1.32 [0.95; 1.83] 0.098	0.22 [-0.02; 0.46] 0.074
Other	6 / 9 (66.7)	6 / 9 (66.7)	1.03 [0.14; 7.34] 0.979	1.00 [0.48; 2.09] 1.000	0.00 [-0.46; 0.46] 1.000
Corticosteroid and/or mycophenolic acid treatment at randomization (Interaction test: p = 0.127)					
Yes	12 / 16 (75.0)	14 / 17 (82.4)	0.64 [0.12; 3.46] 0.607	0.91 [0.64; 1.30] 0.609	-0.07 [-0.35; 0.21] 0.606
No	19 / 22 (86.4)	12 / 19 (63.2)	3.69 [0.80; 17.12] 0.095	1.37 [0.93; 2.00] 0.108	0.23 [-0.03; 0.49] 0.080
C3G subtype at diagnosis (Interaction test: p = 0.844)					
C3GN	21 / 26 (80.8)	23 / 32 (71.9)	1.65 [0.47; 5.77] 0.430	1.13 [0.83; 1.54] 0.440	0.09 [-0.13; 0.32] 0.425
DDD	8 / 9 (88.9)	1 / 1 (100.0)	2.27	1.22	-0.20

			[0.13; 39.23]	[0.50; 2.97]	[-0.55; 0.15]
			0.574	0.668	0.264
Mixed C3GN/DDD	1 / 2 (50.0)	1 / 2 (50.0)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Unknown	1 / 1 (100.0)	1 / 1 (100.0)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline UPCR 24h (Interaction test: p = 0.904)					
< 3 g/g	15 / 17 (88.2)	19 / 25 (76.0)	2.10	1.15	0.12
			[0.42; 10.45]	[0.85; 1.57]	[-0.12; 0.36]
			0.367	0.370	0.315
>= 3 g/g	16 / 21 (76.2)	7 / 11 (63.6)	1.82	1.20	0.12
			[0.37; 8.93]	[0.72; 1.98]	[-0.21; 0.46]
			0.458	0.489	0.470
Baseline total urinary protein 24h (Interaction test: p = 0.534)					
< 3 g/day	9 / 11 (81.8)	12 / 15 (80.0)	1.07	1.02	0.02
			[0.17; 6.67]	[0.68; 1.53]	[-0.31; 0.34]
			0.943	0.931	0.909
>= 3 g/day	22 / 27 (81.5)	14 / 21 (66.7)	2.20	1.22	0.15
			[0.58; 8.31]	[0.86; 1.74]	[-0.10; 0.40]
			0.246	0.262	0.242
Baseline eGFR category (Interaction test: p = 0.893)					
< 60 mL/min/1.73m2	7 / 10 (70.0)	2 / 4 (50.0)	2.42	1.26	0.13
			[0.22; 26.51]	[0.40; 3.98]	[-0.46; 0.72]
			0.470	0.696	0.667
>= 60 mL/min/1.73m2	24 / 28 (85.7)	24 / 32 (75.0)	2.00	1.14	0.11
			[0.53; 7.56]	[0.89; 1.47]	[-0.09; 0.31]
			0.305	0.297	0.289
Baseline eGFR category (Interaction test: p = 0.679)					
< 90 mL/min/1.73m2	14 / 19 (73.7)	6 / 12 (50.0)	2.81	1.45	0.22
			[0.61; 12.98]	[0.74; 2.85]	[-0.14; 0.58]
			0.185	0.276	0.224
>= 90 mL/min/1.73m2	17 / 19 (89.5)	20 / 24 (83.3)	1.70	1.07	0.06
			[0.28; 10.44]	[0.85; 1.35]	[-0.14; 0.26]
			0.568	0.568	0.569
Baseline C3 (Interaction test: p = 0.079)					
< 45 mg/dL	21 / 28 (75.0)	20 / 26 (76.9)	0.90	0.98	-0.02
			[0.26; 3.15]	[0.72; 1.32]	[-0.25; 0.21]
			0.869	0.869	0.869
>= 45 mg/dL	10 / 10 (100.0)	6 / 10 (60.0)	8.22	1.71	0.48
			[0.78; 86.87]	[0.92; 3.16]	[0.18; 0.78]
			0.080	0.089	0.002
Years since first C3G diagnosis (Interaction test: p = 0.335)					
< 2 Years	14 / 15 (93.3)	11 / 15 (73.3)	3.73	1.25	0.20
			[0.50; 27.74]	[0.89; 1.76]	[-0.06; 0.46]
			0.198	0.190	0.133
>= 2 Years	17 / 23 (73.9)	15 / 21 (71.4)	1.17	1.04	0.03
			[0.31; 4.47]	[0.70; 1.55]	[-0.24; 0.30]
			0.815	0.829	0.825
Age at C3G diagnosis (Interaction test: p = 0.100)					

< 18 Years	10 / 15 (66.7)	5 / 6 (83.3)	0.54 [0.07; 4.40] 0.567	0.79 [0.45; 1.37] 0.398	-0.24 [-0.60; 0.12] 0.196
>= 18 Years	21 / 23 (91.3)	21 / 30 (70.0)	4.51 [0.87; 23.45] 0.073	1.30 [1.00; 1.70] 0.051	0.21 [0.01; 0.41] 0.038
Hypertension at C3G diagnosis (Interaction test: p = 0.526)					
Yes	17 / 23 (73.9)	12 / 18 (66.7)	1.42 [0.37; 5.50] 0.609	1.11 [0.73; 1.69] 0.632	0.07 [-0.22; 0.36] 0.626
No	14 / 15 (93.3)	14 / 18 (77.8)	3.05 [0.42; 22.35] 0.272	1.20 [0.89; 1.63] 0.240	0.17 [-0.05; 0.40] 0.138

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm one patient with 0.5 events was added to each treatment arm for estimation of the OR/RR.
In case of zero events in both treatment arms, no treatment comparison is performed.

Table 5-2.4.1: Histology total activity score: Analysis of change from baseline - subgroup analysis (Full Analysis Set)

	Treatment groups						
	Iptacopan (N=38)		Placebo (N=36)		Comparison		
Subgroup Level	N[a]	LS Mean (SE)	N[a]	LS Mean (SE)	Overall treatment effect	[95% CI]	p-value
Age groups (Interaction test: p = 0.451)							
< Median	19	-2.4 (0.5)	8	-1.3 (0.7)	-1.1	[-2.91; 0.62]	0.199
>= Median	14	-1.4 (0.6)	26	-1.1 (0.4)	-0.3	[-1.70; 1.11]	0.679
Sex (Interaction test: p = 0.493)							
Male	25	-1.8 (0.4)	19	-1.1 (0.5)	-0.7	[-1.99; 0.62]	0.301
Female	8	-2.6 (0.7)	15	-1.2 (0.5)	-1.5	[-3.32; 0.39]	0.120
Race (Interaction test: p = 0.338)							
White	25	-1.9 (0.4)	24	-1.4 (0.4)	-0.5	[-1.77; 0.67]	0.374
Other	8	-2.2 (0.7)	10	-0.5 (0.7)	-1.7	[-3.67; 0.32]	0.099
Region (Interaction test: p = 0.285)							
North America	7	-2.1 (0.8)	8	-1.3 (0.7)	-0.8	[-3.03; 1.39]	0.458
Europe	19	-1.9 (0.5)	19	-1.5 (0.5)	-0.3	[-1.70; 1.03]	0.625
Other	7	-2.2 (0.8)	7	0.2 (0.8)	-2.4	[-4.68; -0.18]	0.035
Corticosteroid and/or mycophenolic acid treatment at randomization (Interaction test: p = 0.079)							
Yes	15	-1.3 (0.5)	15	-1.5 (0.5)	0.2	[-1.37; 1.71]	0.826
No	18	-2.5 (0.5)	19	-0.9 (0.5)	-1.6	[-3.00; -0.30]	0.018
C3G subtype at diagnosis (Interaction test: p = 0.494)							
C3GN	22	-2.2 (0.5)	30	-1.2 (0.4)	-1.0	[-2.17; 0.21]	0.104
DDD	9	-1.8 (0.7)	1	-2.4 (2.1)	0.6	[-3.84; 5.02]	0.791
Mixed C3GN/DDD	1	- (-)	2	- (-)	-	[-; -]	-
Unknown	1	- (-)	1	- (-)	-	[-; -]	-
Baseline UPCR 24h (Interaction test: p = 0.707)							
< 3 g/g	14	-2.2 (0.6)	24	-1.1 (0.4)	-1.1	[-2.51; 0.35]	0.136
>= 3 g/g	19	-1.8 (0.5)	10	-1.1 (0.7)	-0.7	[-2.33; 1.00]	0.426
Baseline total urinary protein 24h (Interaction test: p = 0.531)							

< 3 g/day	9	-2.3 (0.7)	14	-1.0 (0.6)	-1.3	[-3.19; 0.51]	0.151
>= 3 g/day	24	-1.9 (0.4)	20	-1.2 (0.5)	-0.6	[-1.92; 0.65]	0.325
Baseline eGFR category (Interaction test: p = 0.773)							
< 60 mL/min/1.73m2	10	-2.0 (0.7)	4	-0.8 (1.1)	-1.2	[-3.77; 1.36]	0.351
>= 60 mL/min/1.73m2	23	-1.9 (0.4)	30	-1.2 (0.4)	-0.8	[-1.98; 0.39]	0.183
Baseline eGFR category (Interaction test: p = 0.518)							
< 90 mL/min/1.73m2	18	-1.9 (0.5)	12	-0.5 (0.6)	-1.3	[-2.91; 0.24]	0.096
>= 90 mL/min/1.73m2	15	-2.1 (0.5)	22	-1.4 (0.5)	-0.6	[-2.07; 0.78]	0.368
Baseline C3 (Interaction test: p = 0.528)							
< 45 mg/dL	23	-1.7 (0.4)	24	-1.1 (0.4)	-0.6	[-1.86; 0.61]	0.315
>= 45 mg/dL	10	-2.6 (0.7)	10	-1.3 (0.7)	-1.4	[-3.31; 0.60]	0.171
Years since first C3G diagnosis (Interaction test: p = 0.382)							
< 2 Years	14	-2.4 (0.5)	14	-2.1 (0.5)	-0.3	[-1.88; 1.20]	0.659
>= 2 Years	19	-1.7 (0.5)	20	-0.4 (0.5)	-1.2	[-2.54; 0.08]	0.066
Age at C3G diagnosis (Interaction test: p = 0.810)							
< 18 Years	11	-1.9 (0.6)	6	-0.8 (0.9)	-1.1	[-3.28; 1.05]	0.308
>= 18 Years	22	-2.0 (0.5)	28	-1.2 (0.4)	-0.8	[-2.05; 0.43]	0.197
Hypertension at C3G diagnosis (Interaction test: p = 0.842)							
Yes	21	-2.0 (0.5)	17	-1.3 (0.5)	-0.7	[-2.13; 0.69]	0.313
No	12	-1.8 (0.6)	17	-0.9 (0.5)	-0.9	[-2.53; 0.67]	0.250

CI: Confidence Interval
ANCOVA: Analysis of Covariance
LS Mean: Least Square Mean
SE: Standard Error
.....
[a] Number of patients included in the analysis
ANCOVA including treatment, subgroup, corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as fixed effects and treatment*subgroup as interaction term and baseline values as covariate.
Patients with an evaluable baseline score and an evaluable post-baseline score were included in the analysis.

Table 5-2.5.1: Hematuria : Proportion of patients without hematuria (<= 5 rbc/HPF) at month 6 - subgroup analysis (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup Level	Iptacopan (N=38) n / N* (%)	Placebo (N=36) n / N* (%)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Age groups (Interaction test: p = 0.725)					
< Median	10 / 19 (52.6)	4 / 8 (50.0)	1.17 [0.22; 6.23] 0.856	1.04 [0.47; 2.27] 0.929	0.02 [-0.41; 0.45] 0.931
>= Median	12 / 17 (70.6)	14 / 24 (58.3)	1.71 [0.46; 6.43] 0.426	1.21 [0.77; 1.90] 0.415	0.12 [-0.17; 0.41] 0.415
Sex (Interaction test: p = 0.890)					
Male	16 / 25 (64.0)	11 / 18 (61.1)	1.12 [0.32; 3.92] 0.863	1.03 [0.65; 1.65] 0.889	0.02 [-0.27; 0.31] 0.889
Female	6 / 11 (54.5)	7 / 14 (50.0)	1.29 [0.26; 6.47] 0.756	1.02 [0.48; 2.19] 0.952	0.01 [-0.40; 0.42] 0.952
Race (Interaction test: p = 0.835)					
White	17 / 25 (68.0)	13 / 21 (61.9)	1.32 [0.39; 4.48] 0.655	1.10 [0.72; 1.69] 0.660	0.06 [-0.21; 0.34] 0.657
Other	5 / 11 (45.5)	5 / 11 (45.5)	1.06 [0.19; 5.75] 0.948	1.04 [0.43; 2.52] 0.929	0.02 [-0.41; 0.45] 0.931
Region (Interaction test: p = 0.730)					
North America	3 / 6 (50.0)	3 / 7 (42.9)	1.31 [0.17; 10.10] 0.795	1.08 [0.39; 3.04] 0.879	0.03 [-0.52; 0.58] 0.911
Europe	14 / 21 (66.7)	12 / 17 (70.6)	0.84 [0.21; 3.36] 0.808	0.95 [0.61; 1.48] 0.828	-0.03 [-0.33; 0.26] 0.827
Other	5 / 9 (55.6)	3 / 8 (37.5)	2.19 [0.31; 15.50] 0.433	1.60 [0.57; 4.50] 0.376	0.22 [-0.24; 0.68] 0.350
Corticosteroid and/or mycophenolic acid treatment at randomization (Interaction test: p = 0.685)					
Yes	10 / 15 (66.7)	9 / 16 (56.3)	1.56 [0.36; 6.69] 0.553	1.19 [0.68; 2.08] 0.553	0.10 [-0.24; 0.44] 0.549
No	12 / 21 (57.1)	9 / 16 (56.3)	1.04 [0.28; 3.85] 0.957	1.02 [0.57; 1.79] 0.957	0.01 [-0.31; 0.33] 0.957
C3G subtype at diagnosis (Interaction test: p = 0.232)					
C3GN	10 / 24 (41.7)	15 / 28 (53.6)	0.63 [0.21; 1.92] 0.417	0.78 [0.43; 1.41] 0.415	-0.12 [-0.39; 0.16] 0.406
DDD	9 / 9 (100.0)	1 / 1 (100.0)	5.08 [0.21; 120.28]	1.38 [0.60; 3.19]	N.E. [N.E.; N.E.]

			0.314	0.454	N.E.
Mixed C3GN/DDD	2 / 2 (100.0)	1 / 2 (50.0)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Unknown	1 / 1 (100.0)	1 / 1 (100.0)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline UPCR 24h (Interaction test: p = 0.121)					
< 3 g/g	9 / 16 (56.3)	14 / 21 (66.7)	0.65	0.87	-0.09
			[0.17; 2.51]	[0.52; 1.45]	[-0.41; 0.23]
			0.534	0.585	0.586
>= 3 g/g	13 / 20 (65.0)	4 / 11 (36.4)	3.24	1.80	0.29
			[0.70; 15.03]	[0.77; 4.21]	[-0.06; 0.64]
			0.133	0.174	0.106
Baseline total urinary protein 24h (Interaction test: p = 0.670)					
< 3 g/day	5 / 10 (50.0)	7 / 13 (53.8)	0.89	0.96	-0.02
			[0.18; 4.38]	[0.46; 2.04]	[-0.45; 0.41]
			0.890	0.925	0.924
>= 3 g/day	17 / 26 (65.4)	11 / 19 (57.9)	1.38	1.13	0.08
			[0.41; 4.69]	[0.70; 1.82]	[-0.21; 0.36]
			0.604	0.615	0.610
Baseline eGFR category (Interaction test: p = 0.844)					
< 60 mL/min/1.73m2	5 / 10 (50.0)	1 / 3 (33.3)	1.74	1.30	0.14
			[0.16; 18.34]	[0.27; 6.37]	[-0.53; 0.82]
			0.647	0.746	0.673
>= 60 mL/min/1.73m2	17 / 26 (65.4)	17 / 29 (58.6)	1.34	1.12	0.07
			[0.45; 4.01]	[0.74; 1.69]	[-0.19; 0.33]
			0.602	0.598	0.598
Baseline eGFR category (Interaction test: p = 0.521)					
< 90 mL/min/1.73m2	10 / 18 (55.6)	6 / 10 (60.0)	0.86	1.00	-0.00
			[0.18; 4.16]	[0.51; 1.94]	[-0.38; 0.37]
			0.848	0.993	0.993
>= 90 mL/min/1.73m2	12 / 18 (66.7)	12 / 22 (54.5)	1.67	1.22	0.12
			[0.46; 6.07]	[0.74; 2.02]	[-0.18; 0.42]
			0.437	0.434	0.430
Baseline C3 (Interaction test: p = 0.566)					
< 45 mg/dL	15 / 27 (55.6)	13 / 24 (54.2)	1.07	1.03	0.01
			[0.35; 3.23]	[0.62; 1.70]	[-0.26; 0.29]
			0.910	0.920	0.920
>= 45 mg/dL	7 / 9 (77.8)	5 / 8 (62.5)	2.06	1.38	0.28
			[0.28; 14.95]	[0.64; 2.96]	[-0.13; 0.70]
			0.473	0.409	0.184
Years since first C3G diagnosis (Interaction test: p = 0.849)					
< 2 Years	9 / 15 (60.0)	8 / 14 (57.1)	1.12	1.06	0.03
			[0.25; 4.91]	[0.57; 1.95]	[-0.33; 0.39]
			0.884	0.862	0.861
>= 2 Years	13 / 21 (61.9)	10 / 18 (55.6)	1.35	1.17	0.09
			[0.37; 4.93]	[0.69; 1.97]	[-0.22; 0.40]
			0.649	0.566	0.563
Age at C3G diagnosis (Interaction test: p = 0.447)					
< 18 Years	6 / 14 (42.9)	2 / 4 (50.0)	0.80	0.90	-0.04

			[0.10; 6.18]	[0.27; 3.00]	[-0.63; 0.56]
			0.829	0.864	0.905
>= 18 Years	16 / 22 (72.7)	16 / 28 (57.1)	2.01	1.27	0.16
			[0.60; 6.67]	[0.84; 1.92]	[-0.11; 0.42]
			0.256	0.250	0.244
Hypertension at C3G diagnosis (Interaction test: p = 0.322)					
Yes	13 / 22 (59.1)	6 / 15 (40.0)	2.20	1.49	0.20
			[0.57; 8.41]	[0.73; 3.03]	[-0.13; 0.52]
			0.251	0.272	0.237
No	9 / 14 (64.3)	12 / 17 (70.6)	0.79	0.90	-0.07
			[0.17; 3.63]	[0.53; 1.54]	[-0.41; 0.27]
			0.762	0.705	0.695

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm one patient with 0.5 events was added to each treatment arm for estimation of the OR/RR.
In case of zero events in both treatment arms, no treatment comparison is performed.

Table 5-3.1.1: FACIT - Fatigue: Analysis of change from baseline - subgroup analysis (Full Analysis Set)

	Treatment groups						
	Iptacopan (N=38)		Placebo (N=36)		Comparison		
Subgroup Level	N[a]	LS Mean (SE)	N[a]	LS Mean (SE)	Overall treatment effect	[95% CI]	p-value
Age groups (Interaction test: p = 0.153)							
< Median	19	-1.3 (1.2)	8	3.3 (1.8)	-4.5	[-8.78; -0.31]	0.036
>= Median	17	0.4 (1.2)	23	1.2 (1.1)	-0.7	[-4.05; 2.56]	0.656
Sex (Interaction test: p = 0.286)							
Male	25	0.8 (1.0)	18	2.3 (1.2)	-1.5	[-4.52; 1.56]	0.335
Female	11	-3.3 (1.5)	13	0.9 (1.3)	-4.2	[-8.18; -0.20]	0.040
Race (Interaction test: p = 0.116)							
White	26	0.3 (1.0)	21	1.3 (1.1)	-1.0	[-3.91; 1.97]	0.512
Other	10	-2.5 (1.6)	10	2.7 (1.5)	-5.2	[-9.61; -0.74]	0.023
Region (Interaction test: p = 0.672)							
North America	7	0.7 (1.9)	7	1.7 (1.9)	-1.0	[-6.45; 4.39]	0.705
Europe	21	-0.7 (1.1)	17	1.1 (1.3)	-1.8	[-5.16; 1.58]	0.292
Other	8	-1.0 (1.8)	7	3.2 (1.9)	-4.2	[-9.46; 1.13]	0.121
Corticosteroid and/or mycophenolic acid treatment at randomization (Interaction test: p = 0.283)							
Yes	16	-1.9 (1.3)	12	1.9 (1.4)	-3.8	[-7.61; 0.06]	0.054
No	20	0.8 (1.1)	19	1.9 (1.2)	-1.1	[-4.29; 2.19]	0.519
Baseline UPCR 24h (Interaction test: p = 0.581)							
< 3 g/g	15	-2.0 (1.3)	21	1.3 (1.1)	-3.4	[-6.77; 0.02]	0.052
>= 3 g/g	21	0.7 (1.1)	10	2.7 (1.6)	-2.0	[-5.82; 1.86]	0.308
Baseline total urinary protein 24h (Interaction test: p = 0.107)							
< 3 g/day	10	-2.9 (1.6)	12	2.3 (1.4)	-5.2	[-9.41; -0.93]	0.018
>= 3 g/day	26	0.5 (1.0)	19	1.5 (1.2)	-1.0	[-3.99; 2.04]	0.520
Baseline eGFR category (Interaction test: p = 0.400)							
< 60 mL/min/1.73m2	10	0.2 (1.6)	2	-0.7 (3.6)	0.9	[-6.93; 8.68]	0.824
>= 60 mL/min/1.73m2	26	-0.7	29	1.9	-2.6	[-5.39; 0.17]	0.065

		(1.0)		(1.0)			
Baseline eGFR category (Interaction test: p = 0.101)							
< 90 mL/min/1.73m2	18	0.8 (1.2)	9	0.5 (1.7)	0.3	[-3.77; 4.34]	0.889
>= 90 mL/min/1.73m2	18	-1.7 (1.2)	22	2.3 (1.1)	-3.9	[-7.12; -0.73]	0.017
Baseline C3 (Interaction test: p = 0.652)							
< 45 mg/dL	26	-0.4 (1.0)	22	2.1 (1.1)	-2.5	[-5.53; 0.43]	0.093
>= 45 mg/dL	10	-0.5 (1.7)	9	0.8 (1.7)	-1.3	[-6.00; 3.41]	0.585
Years since first C3G diagnosis (Interaction test: p = 0.245)							
< 2 Years	14	-0.4 (1.4)	12	3.8 (1.5)	-4.1	[-8.22; -0.01]	0.049
>= 2 Years	22	-0.5 (1.1)	19	0.6 (1.2)	-1.1	[-4.24; 2.11]	0.505
Age at C3G diagnosis (Interaction test: p = 0.615)							
< 18 Years	14	-2.7 (1.3)	5	-0.2 (2.1)	-2.5	[-7.50; 2.46]	0.316
>= 18 Years	22	1.1 (1.1)	26	2.1 (1.0)	-1.1	[-3.94; 1.77]	0.452
Hypertension at C3G diagnosis (Interaction test: p = 0.937)							
Yes	22	-0.8 (1.1)	16	1.2 (1.3)	-2.0	[-5.34; 1.31]	0.231
No	14	0.1 (1.4)	15	2.3 (1.3)	-2.2	[-5.98; 1.56]	0.246

CI: Confidence Interval
MMRM: Mixed Model for Repeated Measures
LS Mean: Least Square Mean
SE: Standard Error
.....
[a] Number of patients included in the analysis
MMRM including treatment, time point, subgroup, corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as fixed effects, treatment*time point and treatment*subgroup as interaction terms and baseline values as covariate.
Patients with an evaluable baseline score and at least one evaluable post-baseline score were included in the analysis.

Table 5-3.1.2: FACIT - Fatigue: Improvement of FACIT fatigue - increase of >= 7.8 points at 6 months - subgroup analysis (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup Level	Iptacopan (N=38) n / N* (%)	Placebo (N=36) n / N* (%)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Age groups (Interaction test: p = N.E.)					
< Median	1 / 19 (5.3)	2 / 8 (25.0)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
>= Median	2 / 17 (11.8)	4 / 23 (17.4)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Sex (Interaction test: p = N.E.)					
Male	2 / 25 (8.0)	3 / 18 (16.7)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Female	1 / 11 (9.1)	3 / 13 (23.1)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Race (Interaction test: p = N.E.)					
White	3 / 26 (11.5)	4 / 21 (19.0)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Other	0 / 10	2 / 10 (20.0)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Region (Interaction test: p = N.E.)					
North America	1 / 7 (14.3)	1 / 7 (14.3)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Europe	2 / 21 (9.5)	3 / 17 (17.6)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Other	0 / 8	2 / 7 (28.6)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Corticosteroid and/or mycophenolic acid treatment at randomization (Interaction test: p = N.E.)					
Yes	1 / 16 (6.3)	1 / 12 (8.3)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
No	2 / 20 (10.0)	5 / 19 (26.3)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
C3G subtype at diagnosis (Interaction test: p = N.E.)					
C3GN	2 / 25 (8.0)	6 / 27 (22.2)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
DDD	1 / 8 (12.5)	0 / 1	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]

			N.E.	N.E.	N.E.
Mixed C3GN/DDD	0 / 2	0 / 2	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Unknown	0 / 1	0 / 1	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline UPCR 24h (Interaction test: p = N.E.)					
< 3 g/g	0 / 15	3 / 21 (14.3)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 3 g/g	3 / 21 (14.3)	3 / 10 (30.0)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline total urinary protein 24h (Interaction test: p = N.E.)					
< 3 g/day	0 / 10	3 / 12 (25.0)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 3 g/day	3 / 26 (11.5)	3 / 19 (15.8)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline eGFR category (Interaction test: p = N.E.)					
< 60 mL/min/1.73m2	0 / 10	0 / 2	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 60 mL/min/1.73m2	3 / 26 (11.5)	6 / 29 (20.7)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline eGFR category (Interaction test: p = N.E.)					
< 90 mL/min/1.73m2	2 / 18 (11.1)	1 / 9 (11.1)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 90 mL/min/1.73m2	1 / 18 (5.6)	5 / 22 (22.7)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline C3 (Interaction test: p = N.E.)					
< 45 mg/dL	3 / 26 (11.5)	5 / 22 (22.7)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 45 mg/dL	0 / 10	1 / 9 (11.1)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Years since first C3G diagnosis (Interaction test: p = N.E.)					
< 2 Years	0 / 14	6 / 12 (50.0)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 2 Years	3 / 22 (13.6)	0 / 19	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Age at C3G diagnosis (Interaction test: p = N.E.)					
< 18 Years	0 / 14	0 / 5	N.E.	N.E.	N.E.

			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 18 Years	3 / 22 (13.6)	6 / 26 (23.1)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Hypertension at C3G diagnosis (Interaction test: p = N.E.)					
Yes	2 / 22 (9.1)	4 / 16 (25.0)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
No	1 / 14 (7.1)	2 / 15 (13.3)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm one patient with 0.5 events was added to each treatment arm for estimation of the OR/RR.
In case of zero events in both treatment arms, no treatment comparison is performed.

Table 5-3.1.3: FACIT - Fatigue: Worsening of FACIT fatigue - decrease of >= 7.8 points at 6 months - subgroup analysis (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup Level	Iptacopan (N=38) n / N* (%)	Placebo (N=36) n / N* (%)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Age groups (Interaction test: p = N.E.)					
< Median	0 / 19	0 / 8	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
>= Median	1 / 17 (5.9)	1 / 23 (4.3)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Sex (Interaction test: p = N.E.)					
Male	0 / 25	0 / 18	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Female	1 / 11 (9.1)	1 / 13 (7.7)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Race (Interaction test: p = N.E.)					
White	0 / 26	0 / 21	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Other	1 / 10 (10.0)	1 / 10 (10.0)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Region (Interaction test: p = N.E.)					
North America	0 / 7	0 / 7	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Europe	1 / 21 (4.8)	0 / 17	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Other	0 / 8	1 / 7 (14.3)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Corticosteroid and/or mycophenolic acid treatment at randomization (Interaction test: p = N.E.)					
Yes	1 / 16 (6.3)	0 / 12	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
No	0 / 20	1 / 19 (5.3)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
C3G subtype at diagnosis (Interaction test: p = N.E.)					
C3GN	1 / 25 (4.0)	1 / 27 (3.7)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
DDD	0 / 8	0 / 1	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]

			N.E.	N.E.	N.E.
Mixed C3GN/DDD	0 / 2	0 / 2	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Unknown	0 / 1	0 / 1	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline UPCR 24h (Interaction test: p = N.E.)					
< 3 g/g	1 / 15 (6.7)	1 / 21 (4.8)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 3 g/g	0 / 21	0 / 10	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline total urinary protein 24h (Interaction test: p = N.E.)					
< 3 g/day	1 / 10 (10.0)	1 / 12 (8.3)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 3 g/day	0 / 26	0 / 19	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline eGFR category (Interaction test: p = N.E.)					
< 60 mL/min/1.73m2	0 / 10	0 / 2	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 60 mL/min/1.73m2	1 / 26 (3.8)	1 / 29 (3.4)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline eGFR category (Interaction test: p = N.E.)					
< 90 mL/min/1.73m2	0 / 18	1 / 9 (11.1)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 90 mL/min/1.73m2	1 / 18 (5.6)	0 / 22	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline C3 (Interaction test: p = N.E.)					
< 45 mg/dL	1 / 26 (3.8)	1 / 22 (4.5)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 45 mg/dL	0 / 10	0 / 9	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Years since first C3G diagnosis (Interaction test: p = N.E.)					
< 2 Years	0 / 14	1 / 12 (8.3)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 2 Years	1 / 22 (4.5)	0 / 19	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Age at C3G diagnosis (Interaction test: p = N.E.)					
< 18 Years	1 / 14 (7.1)	0 / 5	N.E.	N.E.	N.E.

			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 18 Years	0 / 22	1 / 26 (3.8)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Hypertension at C3G diagnosis (Interaction test: p = N.E.)					
Yes	1 / 22 (4.5)	1 / 16 (6.3)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
No	0 / 14	0 / 15	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm one patient with 0.5 events was added to each treatment arm for estimation of the OR/RR.
In case of zero events in both treatment arms, no treatment comparison is performed.

Table 5-3.1.4: FACIT - Fatigue: No relevant worsening of FACIT fatigue - decrease of < 7.8 points at 6 months - subgroup analysis (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup Level	Iptacopan (N=38) n / N* (%)	Placebo (N=36) n / N* (%)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Age groups (Interaction test: p = 0.566)					
< Median	19 / 19 (100.0)	8 / 8 (100.0)	2.18 [0.12; 39.00] 0.597	1.06 [0.84; 1.33] 0.632	N.E. [N.E.; N.E.] N.E.
>= Median	16 / 17 (94.1)	22 / 23 (95.7)	0.76 [0.10; 6.05] 0.799	0.98 [0.81; 1.18] 0.801	-0.01 [-0.15; 0.12] 0.851
Sex (Interaction test: p = 0.759)					
Male	25 / 25 (100.0)	18 / 18 (100.0)	1.44 [0.08; 24.72] 0.803	1.02 [0.89; 1.16] 0.812	N.E. [N.E.; N.E.] N.E.
Female	10 / 11 (90.9)	12 / 13 (92.3)	0.82 [0.10; 6.89] 0.856	0.97 [0.70; 1.35] 0.867	-0.02 [-0.26; 0.23] 0.893
Race (Interaction test: p = 0.904)					
White	26 / 26 (100.0)	21 / 21 (100.0)	1.24 [0.07; 21.15] 0.880	1.01 [0.90; 1.13] 0.868	N.E. [N.E.; N.E.] N.E.
Other	9 / 10 (90.0)	9 / 10 (90.0)	1.00 [0.12; 8.57] 1.000	1.00 [0.69; 1.44] 1.000	0.00 [-0.28; 0.28] 1.000
Region (Interaction test: p = 0.707)					
North America	7 / 7 (100.0)	7 / 7 (100.0)	0.97 [0.05; 18.44] 0.982	0.99 [0.71; 1.39] 0.969	N.E. [N.E.; N.E.] N.E.
Europe	20 / 21 (95.2)	17 / 17 (100.0)	0.60 [0.05; 7.26] 0.690	0.97 [0.83; 1.14] 0.722	-0.04 [-0.13; 0.04] 0.353
Other	8 / 8 (100.0)	6 / 7 (85.7)	2.62 [0.19; 35.34] 0.468	1.15 [0.77; 1.71] 0.491	0.13 [-0.12; 0.39] 0.300
Corticosteroid and/or mycophenolic acid treatment at randomization (Interaction test: p = 0.347)					
Yes	15 / 16 (93.8)	12 / 12 (100.0)	0.41 [0.02; 11.05] 0.598	0.95 [0.79; 1.14] 0.570	-0.06 [-0.18; 0.06] 0.302
No	20 / 20 (100.0)	18 / 19 (94.7)	3.32 [0.13; 86.75] 0.470	1.06 [0.92; 1.22] 0.456	0.05 [-0.05; 0.15] 0.304
C3G subtype at diagnosis (Interaction test: p = 0.414)					
C3GN	24 / 25 (96.0)	26 / 27 (96.3)	0.93 [0.12; 7.08] 0.941	0.99 [0.86; 1.15] 0.940	-0.00 [-0.11; 0.10] 0.955
DDD	8 / 8 (100.0)	1 / 1 (100.0)	4.48 [0.19; 106.55]	1.36 [0.59; 3.13]	N.E. [N.E.; N.E.]

			0.354	0.469	N.E.
Mixed C3GN/DDD	2 / 2 (100.0)	2 / 2 (100.0)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Unknown	1 / 1 (100.0)	1 / 1 (100.0)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline UPCR 24h (Interaction test: p = 0.573)					
< 3 g/g	14 / 15 (93.3)	20 / 21 (95.2)	0.73	0.97	-0.02
			[0.09; 5.84]	[0.79; 1.19]	[-0.17; 0.13]
			0.768	0.754	0.812
>= 3 g/g	21 / 21 (100.0)	10 / 10 (100.0)	2.03	1.05	N.E.
			[0.12; 35.79]	[0.86; 1.27]	[N.E.; N.E.]
			0.628	0.650	N.E.
Baseline total urinary protein 24h (Interaction test: p = 0.785)					
< 3 g/day	9 / 10 (90.0)	11 / 12 (91.7)	0.80	0.96	-0.03
			[0.09; 6.88]	[0.70; 1.31]	[-0.27; 0.21]
			0.842	0.776	0.797
>= 3 g/day	26 / 26 (100.0)	19 / 19 (100.0)	1.32	1.02	N.E.
			[0.08; 22.45]	[0.90; 1.15]	[N.E.; N.E.]
			0.849	0.792	N.E.
Baseline eGFR category (Interaction test: p = 0.452)					
< 60 mL/min/1.73m2	10 / 10 (100.0)	2 / 2 (100.0)	3.85	1.24	N.E.
			[0.18; 82.75]	[0.68; 2.25]	[N.E.; N.E.]
			0.390	0.485	N.E.
>= 60 mL/min/1.73m2	25 / 26 (96.2)	28 / 29 (96.6)	0.93	0.99	-0.00
			[0.12; 7.13]	[0.87; 1.14]	[-0.10; 0.09]
			0.944	0.925	0.945
Baseline eGFR category (Interaction test: p = 0.173)					
< 90 mL/min/1.73m2	18 / 18 (100.0)	8 / 9 (88.9)	4.40	1.16	0.11
			[0.35; 55.89]	[0.87; 1.56]	[-0.10; 0.31]
			0.253	0.317	0.303
>= 90 mL/min/1.73m2	17 / 18 (94.4)	22 / 22 (100.0)	0.41	0.94	-0.05
			[0.03; 4.88]	[0.80; 1.11]	[-0.15; 0.05]
			0.477	0.484	0.328
Baseline C3 (Interaction test: p = 0.930)					
< 45 mg/dL	25 / 26 (96.2)	21 / 22 (95.5)	1.24	1.01	0.01
			[0.16; 9.63]	[0.87; 1.18]	[-0.10; 0.12]
			0.840	0.859	0.893
>= 45 mg/dL	10 / 10 (100.0)	9 / 9 (100.0)	1.05	1.00	N.E.
			[0.06; 19.37]	[0.77; 1.29]	[N.E.; N.E.]
			0.972	0.989	N.E.
Years since first C3G diagnosis (Interaction test: p = 0.351)					
< 2 Years	14 / 14 (100.0)	11 / 12 (91.7)	2.79	1.09	0.07
			[0.22; 36.05]	[0.85; 1.40]	[-0.08; 0.22]
			0.432	0.496	0.348
>= 2 Years	21 / 22 (95.5)	19 / 19 (100.0)	0.53	0.96	-0.05
			[0.04; 6.38]	[0.82; 1.12]	[-0.14; 0.04]
			0.620	0.601	0.286
Age at C3G diagnosis (Interaction test: p = 0.790)					
< 18 Years	13 / 14 (92.9)	5 / 5 (100.0)	1.12	1.01	-0.09

			[0.08; 15.07]	[0.69; 1.47]	[-0.25; 0.06]
			0.930	0.977	0.242
>= 18 Years	22 / 22 (100.0)	25 / 26 (96.2)	1.82	1.03	0.04
			[0.15; 21.63]	[0.90; 1.17]	[-0.04; 0.11]
			0.634	0.652	0.335
Hypertension at C3G diagnosis (Interaction test: p = 0.827)					
Yes	21 / 22 (95.5)	15 / 16 (93.8)	1.40	1.03	0.02
			[0.18; 11.05]	[0.84; 1.26]	[-0.13; 0.16]
			0.751	0.759	0.816
No	14 / 14 (100.0)	15 / 15 (100.0)	0.94	1.00	N.E.
			[0.05; 16.50]	[0.84; 1.19]	[N.E.; N.E.]
			0.968	0.972	N.E.

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm one patient with 0.5 events was added to each treatment arm for estimation of the OR/RR.
In case of zero events in both treatment arms, no treatment comparison is performed.

Table 5-3.2.1: EQ-5D VAS: Analysis of change from baseline - subgroup analysis (Full Analysis Set)

	Treatment groups						
	Iptacopan (N=38)		Placebo (N=36)		Comparison		
Subgroup Level	N[a]	LS Mean (SE)	N[a]	LS Mean (SE)	Overall treatment effect	[95% CI]	p-value
Age groups (Interaction test: p = 0.760)							
< Median	19	-0.3 (2.0)	8	0.2 (3.1)	-0.5	[-7.85; 6.89]	0.897
>= Median	17	0.5 (2.1)	23	2.4 (1.8)	-1.9	[-7.59; 3.72]	0.496
Sex (Interaction test: p = 0.730)							
Male	25	0.2 (1.8)	18	2.7 (2.1)	-2.5	[-7.91; 2.96]	0.366
Female	11	-0.1 (2.8)	13	0.8 (2.4)	-0.9	[-8.12; 6.39]	0.812
Race (Interaction test: p = 0.885)							
White	26	-0.1 (1.7)	21	1.4 (1.9)	-1.5	[-6.58; 3.58]	0.558
Other	10	0.6 (2.8)	10	2.8 (2.7)	-2.2	[-9.93; 5.58]	0.577
Region (Interaction test: p = 0.869)							
North America	7	1.2 (3.3)	7	0.7 (3.4)	0.5	[-8.97; 9.99]	0.915
Europe	21	-0.6 (1.9)	17	1.7 (2.2)	-2.3	[-8.10; 3.48]	0.428
Other	8	0.9 (3.1)	7	3.3 (3.3)	-2.5	[-11.59; 6.67]	0.592
Corticosteroid and/or mycophenolic acid treatment at randomization (Interaction test: p = 0.186)							
Yes	16	-2.5 (2.1)	12	2.6 (2.5)	-5.1	[-11.61; 1.38]	0.120
No	20	2.4 (1.9)	19	1.7 (2.0)	0.6	[-4.82; 6.09]	0.816
Baseline UPCR 24h (Interaction test: p = 0.376)							
< 3 g/g	15	-0.3 (2.2)	21	2.9 (1.9)	-3.2	[-9.06; 2.63]	0.276
>= 3 g/g	21	0.4 (1.9)	10	-0.4 (2.8)	0.7	[-5.89; 7.38]	0.822
Baseline total urinary protein 24h (Interaction test: p = 0.898)							
< 3 g/day	10	1.6 (2.9)	12	3.4 (2.5)	-1.8	[-9.26; 5.60]	0.624
>= 3 g/day	26	-0.6 (1.8)	19	0.7 (2.1)	-1.2	[-6.46; 3.98]	0.636
Baseline eGFR category (Interaction test: p = 0.930)							
< 60 mL/min/1.73m2	10	-2.1 (2.8)	2	-0.3 (6.2)	-1.7	[-15.16; 11.70]	0.797
>= 60 mL/min/1.73m2	26	0.9	29	2.0	-1.1	[-5.72; 3.52]	0.636

		(1.7)		(1.6)			
Baseline eGFR category (Interaction test: p = 0.994)							
< 90 mL/min/1.73m2	18	-0.5 (2.1)	9	1.1 (3.0)	-1.6	[-8.64; 5.51]	0.661
>= 90 mL/min/1.73m2	18	0.6 (2.0)	22	2.1 (1.8)	-1.5	[-7.03; 3.97]	0.581
Baseline C3 (Interaction test: p = 0.882)							
< 45 mg/dL	26	0.5 (1.7)	22	2.0 (1.8)	-1.6	[-6.58; 3.44]	0.532
>= 45 mg/dL	10	-1.0 (2.9)	9	1.3 (3.0)	-2.3	[-10.34; 5.76]	0.572
Years since first C3G diagnosis (Interaction test: p = 0.744)							
< 2 Years	14	0.8 (2.3)	12	3.5 (2.6)	-2.7	[-9.64; 4.26]	0.442
>= 2 Years	22	-0.3 (1.8)	19	0.9 (2.0)	-1.2	[-6.60; 4.14]	0.649
Age at C3G diagnosis (Interaction test: p = 0.884)							
< 18 Years	14	-1.0 (2.3)	5	-0.3 (3.9)	-0.7	[-9.71; 8.29]	0.875
>= 18 Years	22	0.8 (1.9)	26	2.3 (1.7)	-1.5	[-6.49; 3.56]	0.562
Hypertension at C3G diagnosis (Interaction test: p = 0.948)							
Yes	22	1.7 (1.8)	16	4.0 (2.1)	-2.3	[-7.83; 3.27]	0.415
No	14	-2.6 (2.3)	15	-0.6 (2.2)	-2.0	[-8.30; 4.29]	0.527

CI: Confidence Interval
MMRM: Mixed Model for Repeated Measures
LS Mean: Least Square Mean
SE: Standard Error
.....
[a] Number of patients included in the analysis
MMRM including treatment, time point, subgroup, corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as fixed effects, treatment*time point and treatment*subgroup as interaction terms and baseline values as covariate.
Patients with an evaluable baseline score and at least one evaluable post-baseline score were included in the analysis.

Table 5-3.2.2: EQ-5D VAS: Improvement of EQ-5D-5L VAS - increase of >= 15 points at 6 months - subgroup analysis (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup Level	Iptacopan (N=38) n / N* (%)	Placebo (N=36) n / N* (%)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Age groups (Interaction test: p = N.E.)					
< Median	4 / 19 (21.1)	0 / 8	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
>= Median	2 / 17 (11.8)	3 / 23 (13.0)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Sex (Interaction test: p = N.E.)					
Male	2 / 25 (8.0)	1 / 18 (5.6)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Female	4 / 11 (36.4)	2 / 13 (15.4)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Race (Interaction test: p = N.E.)					
White	5 / 26 (19.2)	2 / 21 (9.5)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Other	1 / 10 (10.0)	1 / 10 (10.0)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Region (Interaction test: p = N.E.)					
North America	1 / 7 (14.3)	0 / 7	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Europe	4 / 21 (19.0)	2 / 17 (11.8)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Other	1 / 8 (12.5)	1 / 7 (14.3)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Corticosteroid and/or mycophenolic acid treatment at randomization (Interaction test: p = N.E.)					
Yes	1 / 16 (6.3)	0 / 12	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
No	5 / 20 (25.0)	3 / 19 (15.8)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
C3G subtype at diagnosis (Interaction test: p = N.E.)					
C3GN	4 / 25 (16.0)	3 / 27 (11.1)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
DDD	2 / 8 (25.0)	0 / 1	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]

			N.E.	N.E.	N.E.
Mixed C3GN/DDD	0 / 2	0 / 2	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Unknown	0 / 1	0 / 1	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline UPCR 24h (Interaction test: p = N.E.)					
< 3 g/g	1 / 15 (6.7)	2 / 21 (9.5)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 3 g/g	5 / 21 (23.8)	1 / 10 (10.0)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline total urinary protein 24h (Interaction test: p = N.E.)					
< 3 g/day	1 / 10 (10.0)	1 / 12 (8.3)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 3 g/day	5 / 26 (19.2)	2 / 19 (10.5)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline eGFR category (Interaction test: p = N.E.)					
< 60 mL/min/1.73m2	0 / 10	0 / 2	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 60 mL/min/1.73m2	6 / 26 (23.1)	3 / 29 (10.3)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline eGFR category (Interaction test: p = N.E.)					
< 90 mL/min/1.73m2	2 / 18 (11.1)	0 / 9	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 90 mL/min/1.73m2	4 / 18 (22.2)	3 / 22 (13.6)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline C3 (Interaction test: p = N.E.)					
< 45 mg/dL	6 / 26 (23.1)	3 / 22 (13.6)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 45 mg/dL	0 / 10	0 / 9	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Years since first C3G diagnosis (Interaction test: p = N.E.)					
< 2 Years	3 / 14 (21.4)	3 / 12 (25.0)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 2 Years	3 / 22 (13.6)	0 / 19	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Age at C3G diagnosis (Interaction test: p = N.E.)					
< 18 Years	1 / 14 (7.1)	0 / 5	N.E.	N.E.	N.E.

			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 18 Years	5 / 22 (22.7)	3 / 26 (11.5)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Hypertension at C3G diagnosis (Interaction test: p = N.E.)					
Yes	4 / 22 (18.2)	2 / 16 (12.5)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
No	2 / 14 (14.3)	1 / 15 (6.7)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm one patient with 0.5 events was added to each treatment arm for estimation of the OR/RR.
In case of zero events in both treatment arms, no treatment comparison is performed.

Table 5-3.2.3: EQ-5D VAS: Worsening of EQ-5D-5L VAS - decrease of >= 15 points at 6 months - subgroup analysis (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup Level	Iptacopan (N=38) n / N* (%)	Placebo (N=36) n / N* (%)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Age groups (Interaction test: p = N.E.)					
< Median	1 / 19 (5.3)	1 / 8 (12.5)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
>= Median	2 / 17 (11.8)	0 / 23	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Sex (Interaction test: p = N.E.)					
Male	1 / 25 (4.0)	0 / 18	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Female	2 / 11 (18.2)	1 / 13 (7.7)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Race (Interaction test: p = N.E.)					
White	2 / 26 (7.7)	1 / 21 (4.8)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Other	1 / 10 (10.0)	0 / 10	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Region (Interaction test: p = N.E.)					
North America	0 / 7	0 / 7	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Europe	3 / 21 (14.3)	1 / 17 (5.9)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Other	0 / 8	0 / 7	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Corticosteroid and/or mycophenolic acid treatment at randomization (Interaction test: p = N.E.)					
Yes	3 / 16 (18.8)	0 / 12	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
No	0 / 20	1 / 19 (5.3)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
C3G subtype at diagnosis (Interaction test: p = N.E.)					
C3GN	3 / 25 (12.0)	1 / 27 (3.7)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
DDD	0 / 8	0 / 1	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]

			N.E.	N.E.	N.E.
Mixed C3GN/DDD	0 / 2	0 / 2	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Unknown	0 / 1	0 / 1	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline UPCR 24h (Interaction test: p = N.E.)					
< 3 g/g	1 / 15 (6.7)	1 / 21 (4.8)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 3 g/g	2 / 21 (9.5)	0 / 10	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline total urinary protein 24h (Interaction test: p = N.E.)					
< 3 g/day	1 / 10 (10.0)	0 / 12	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 3 g/day	2 / 26 (7.7)	1 / 19 (5.3)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline eGFR category (Interaction test: p = N.E.)					
< 60 mL/min/1.73m2	0 / 10	0 / 2	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 60 mL/min/1.73m2	3 / 26 (11.5)	1 / 29 (3.4)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline eGFR category (Interaction test: p = N.E.)					
< 90 mL/min/1.73m2	1 / 18 (5.6)	0 / 9	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 90 mL/min/1.73m2	2 / 18 (11.1)	1 / 22 (4.5)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline C3 (Interaction test: p = N.E.)					
< 45 mg/dL	3 / 26 (11.5)	1 / 22 (4.5)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 45 mg/dL	0 / 10	0 / 9	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Years since first C3G diagnosis (Interaction test: p = N.E.)					
< 2 Years	0 / 14	0 / 12	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 2 Years	3 / 22 (13.6)	1 / 19 (5.3)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Age at C3G diagnosis (Interaction test: p = N.E.)					
< 18 Years	2 / 14 (14.3)	1 / 5 (20.0)	N.E.	N.E.	N.E.

			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 18 Years	1 / 22 (4.5)	0 / 26	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Hypertension at C3G diagnosis (Interaction test: p = N.E.)					
Yes	1 / 22 (4.5)	0 / 16	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
No	2 / 14 (14.3)	1 / 15 (6.7)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm one patient with 0.5 events was added to each treatment arm for estimation of the OR/RR.
In case of zero events in both treatment arms, no treatment comparison is performed.

Table 5-3.3.1: SF-36 PCS: Analysis of change from baseline - subgroup analysis (Full Analysis Set)

	Treatment groups						
	Iptacopan (N=38)		Placebo (N=36)		Comparison		
Subgroup Level	N[a]	LS Mean (SE)	N[a]	LS Mean (SE)	Overall treatment effect	[95% CI]	p-value
Age groups (Interaction test: p = 0.266)							
< Median	19	-0.0 (0.8)	8	-0.8 (1.2)	0.8	[-2.15; 3.72]	0.596
>= Median	17	-0.4 (0.9)	23	0.8 (0.7)	-1.3	[-3.53; 1.03]	0.277
Sex (Interaction test: p = 0.115)							
Male	25	0.7 (0.7)	18	0.7 (0.8)	0.0	[-2.11; 2.13]	0.992
Female	11	-2.6 (1.1)	13	0.2 (0.9)	-2.8	[-5.68; 0.12]	0.060
Race (Interaction test: p = 0.511)							
White	26	0.1 (0.7)	21	0.4 (0.8)	-0.3	[-2.42; 1.81]	0.777
Other	10	-1.2 (1.1)	10	0.3 (1.1)	-1.5	[-4.63; 1.58]	0.329
Region (Interaction test: p = 0.636)							
North America	7	-0.7 (1.3)	7	-0.7 (1.3)	-0.0	[-3.85; 3.79]	0.988
Europe	21	0.3 (0.8)	17	0.5 (0.9)	-0.2	[-2.61; 2.14]	0.844
Other	8	-1.2 (1.3)	7	1.0 (1.3)	-2.2	[-5.86; 1.46]	0.235
Corticosteroid and/or mycophenolic acid treatment at randomization (Interaction test: p = 0.680)							
Yes	16	-0.7 (0.9)	12	0.4 (1.0)	-1.0	[-3.71; 1.64]	0.441
No	20	0.2 (0.8)	19	0.5 (0.8)	-0.3	[-2.60; 1.94]	0.773
Baseline UPCR 24h (Interaction test: p = 0.576)							
< 3 g/g	15	-0.4 (0.9)	21	0.6 (0.8)	-1.0	[-3.53; 1.46]	0.412
>= 3 g/g	21	-0.1 (0.8)	10	-0.1 (1.1)	-0.0	[-2.72; 2.67]	0.986
Baseline total urinary protein 24h (Interaction test: p = 0.406)							
< 3 g/day	10	-0.2 (1.1)	12	-0.5 (1.0)	0.3	[-2.73; 3.32]	0.846
>= 3 g/day	26	-0.2 (0.7)	19	1.0 (0.8)	-1.2	[-3.35; 0.93]	0.262
Baseline eGFR category (Interaction test: p = 0.659)							
< 60 mL/min/1.73m2	10	-0.5 (1.1)	2	1.3 (2.5)	-1.7	[-7.18; 3.68]	0.522
>= 60 mL/min/1.73m2	26	-0.2	29	0.3	-0.5	[-2.45; 1.47]	0.620

		(0.7)		(0.7)			
Baseline eGFR category (Interaction test: p = 0.577)							
< 90 mL/min/1.73m2	18	0.0 (0.9)	9	0.0 (1.2)	-0.0	[-2.94; 2.93]	0.998
>= 90 mL/min/1.73m2	18	-0.5 (0.8)	22	0.5 (0.8)	-1.0	[-3.28; 1.25]	0.375
Baseline C3 (Interaction test: p = 0.188)							
< 45 mg/dL	26	0.1 (0.7)	22	0.0 (0.7)	0.1	[-1.98; 2.12]	0.943
>= 45 mg/dL	10	-1.1 (1.1)	9	1.3 (1.2)	-2.4	[-5.66; 0.80]	0.138
Years since first C3G diagnosis (Interaction test: p = 0.497)							
< 2 Years	14	-0.3 (1.0)	12	-0.4 (1.0)	0.1	[-2.69; 2.92]	0.936
>= 2 Years	22	-0.3 (0.8)	19	0.8 (0.8)	-1.1	[-3.36; 1.16]	0.334
Age at C3G diagnosis (Interaction test: p = 0.932)							
< 18 Years	14	-0.7 (0.9)	5	-0.1 (1.6)	-0.6	[-4.27; 3.09]	0.750
>= 18 Years	22	0.0 (0.8)	26	0.5 (0.7)	-0.4	[-2.50; 1.67]	0.695
Hypertension at C3G diagnosis (Interaction test: p = 0.773)							
Yes	22	0.2 (0.8)	16	0.6 (0.9)	-0.4	[-2.76; 1.87]	0.703
No	14	-0.8 (0.9)	15	0.1 (0.9)	-0.9	[-3.59; 1.71]	0.481

CI: Confidence Interval
MMRM: Mixed Model for Repeated Measures
LS Mean: Least Square Mean
SE: Standard Error
.....
[a] Number of patients included in the analysis
MMRM including treatment, time point, subgroup, corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as fixed effects, treatment*time point and treatment*subgroup as interaction terms and baseline values as covariate.
Patients with an evaluable baseline score and at least one evaluable post-baseline score were included in the analysis.

Table 5-3.3.2: PCS: Improvement of SF-36 Physical Component Score - increase of >= 9.4 points at 6 months - subgroup analysis (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup Level	Iptacopan (N=38) n / N* (%)	Placebo (N=36) n / N* (%)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Age groups (Interaction test: p = N.E.)					
< Median	0 / 19	0 / 8	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
>= Median	0 / 17	1 / 23 (4.3)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Sex (Interaction test: p = N.E.)					
Male	0 / 25	1 / 18 (5.6)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Female	0 / 11	0 / 13	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Race (Interaction test: p = N.E.)					
White	0 / 26	0 / 21	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Other	0 / 10	1 / 10 (10.0)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Region (Interaction test: p = N.E.)					
North America	0 / 7	0 / 7	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Europe	0 / 21	0 / 17	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Other	0 / 8	1 / 7 (14.3)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Corticosteroid and/or mycophenolic acid treatment at randomization (Interaction test: p = N.E.)					
Yes	0 / 16	1 / 12 (8.3)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
No	0 / 20	0 / 19	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
C3G subtype at diagnosis (Interaction test: p = N.E.)					
C3GN	0 / 25	1 / 27 (3.7)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
DDD	0 / 8	0 / 1	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]

			N.E.	N.E.	N.E.
Mixed C3GN/DDD	0 / 2	0 / 2	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Unknown	0 / 1	0 / 1	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline UPCR 24h (Interaction test: p = N.E.)					
< 3 g/g	0 / 15	1 / 21 (4.8)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 3 g/g	0 / 21	0 / 10	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline total urinary protein 24h (Interaction test: p = N.E.)					
< 3 g/day	0 / 10	0 / 12	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 3 g/day	0 / 26	1 / 19 (5.3)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline eGFR category (Interaction test: p = N.E.)					
< 60 mL/min/1.73m2	0 / 10	0 / 2	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 60 mL/min/1.73m2	0 / 26	1 / 29 (3.4)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline eGFR category (Interaction test: p = N.E.)					
< 90 mL/min/1.73m2	0 / 18	0 / 9	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 90 mL/min/1.73m2	0 / 18	1 / 22 (4.5)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline C3 (Interaction test: p = N.E.)					
< 45 mg/dL	0 / 26	1 / 22 (4.5)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 45 mg/dL	0 / 10	0 / 9	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Years since first C3G diagnosis (Interaction test: p = N.E.)					
< 2 Years	0 / 14	0 / 12	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 2 Years	0 / 22	1 / 19 (5.3)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Age at C3G diagnosis (Interaction test: p = N.E.)					
< 18 Years	0 / 14	0 / 5	N.E.	N.E.	N.E.

			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 18 Years	0 / 22	1 / 26 (3.8)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Hypertension at C3G diagnosis (Interaction test: p = N.E.)					
Yes	0 / 22	1 / 16 (6.3)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
No	0 / 14	0 / 15	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm one patient with 0.5 events was added to each treatment arm for estimation of the OR/RR.
In case of zero events in both treatment arms, no treatment comparison is performed.

Table 5-3.3.3: PCS: Worsening of SF-36 Physical Component Score - decrease of >= 9.4 points at 6 months - subgroup analysis (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup Level	Iptacopan (N=38) n / N* (%)	Placebo (N=36) n / N* (%)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Age groups (Interaction test: p = N.E.)					
< Median	0 / 19	0 / 8	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
>= Median	0 / 17	1 / 23 (4.3)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Sex (Interaction test: p = N.E.)					
Male	0 / 25	0 / 18	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Female	0 / 11	1 / 13 (7.7)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Race (Interaction test: p = N.E.)					
White	0 / 26	0 / 21	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Other	0 / 10	1 / 10 (10.0)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Region (Interaction test: p = N.E.)					
North America	0 / 7	0 / 7	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Europe	0 / 21	0 / 17	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Other	0 / 8	1 / 7 (14.3)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Corticosteroid and/or mycophenolic acid treatment at randomization (Interaction test: p = N.E.)					
Yes	0 / 16	0 / 12	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
No	0 / 20	1 / 19 (5.3)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
C3G subtype at diagnosis (Interaction test: p = N.E.)					
C3GN	0 / 25	1 / 27 (3.7)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
DDD	0 / 8	0 / 1	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]

			N.E.	N.E.	N.E.
Mixed C3GN/DDD	0 / 2	0 / 2	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Unknown	0 / 1	0 / 1	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline UPCR 24h (Interaction test: p = N.E.)					
< 3 g/g	0 / 15	1 / 21 (4.8)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 3 g/g	0 / 21	0 / 10	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline total urinary protein 24h (Interaction test: p = N.E.)					
< 3 g/day	0 / 10	1 / 12 (8.3)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 3 g/day	0 / 26	0 / 19	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline eGFR category (Interaction test: p = N.E.)					
< 60 mL/min/1.73m2	0 / 10	0 / 2	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 60 mL/min/1.73m2	0 / 26	1 / 29 (3.4)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline eGFR category (Interaction test: p = N.E.)					
< 90 mL/min/1.73m2	0 / 18	1 / 9 (11.1)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 90 mL/min/1.73m2	0 / 18	0 / 22	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline C3 (Interaction test: p = N.E.)					
< 45 mg/dL	0 / 26	1 / 22 (4.5)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 45 mg/dL	0 / 10	0 / 9	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Years since first C3G diagnosis (Interaction test: p = N.E.)					
< 2 Years	0 / 14	1 / 12 (8.3)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 2 Years	0 / 22	0 / 19	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Age at C3G diagnosis (Interaction test: p = N.E.)					
< 18 Years	0 / 14	0 / 5	N.E.	N.E.	N.E.

			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 18 Years	0 / 22	1 / 26 (3.8)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Hypertension at C3G diagnosis (Interaction test: p = N.E.)					
Yes	0 / 22	1 / 16 (6.3)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
No	0 / 14	0 / 15	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm one patient with 0.5 events was added to each treatment arm for estimation of the OR/RR.
In case of zero events in both treatment arms, no treatment comparison is performed.

Table 5-3.4.1: SF-36 MCS: Analysis of change from baseline - subgroup analysis (Full Analysis Set)

	Treatment groups						
	Iptacopan (N=38)		Placebo (N=36)		Comparison		
Subgroup Level	N[a]	LS Mean (SE)	N[a]	LS Mean (SE)	Overall treatment effect	[95% CI]	p-value
Age groups (Interaction test: p = 0.452)							
< Median	19	-1.5 (1.3)	8	1.7 (1.9)	-3.1	[-7.64; 1.35]	0.168
>= Median	17	-0.4 (1.4)	23	0.6 (1.2)	-1.0	[-4.63; 2.63]	0.585
Sex (Interaction test: p = 0.850)							
Male	25	-0.6 (1.1)	18	1.6 (1.3)	-2.2	[-5.59; 1.21]	0.202
Female	11	-1.9 (1.7)	13	-0.2 (1.5)	-1.7	[-6.04; 2.68]	0.445
Race (Interaction test: p = 0.689)							
White	26	-1.4 (1.1)	21	0.7 (1.2)	-2.1	[-5.38; 1.13]	0.198
Other	10	0.2 (1.7)	10	1.2 (1.7)	-1.0	[-5.77; 3.78]	0.679
Region (Interaction test: p = 0.111)							
North America	7	0.3 (1.9)	7	2.6 (1.9)	-2.3	[-7.65; 3.09]	0.399
Europe	21	-2.6 (1.1)	17	0.9 (1.3)	-3.5	[-7.02; -0.03]	0.048
Other	8	2.1 (1.8)	7	-1.1 (1.9)	3.2	[-2.17; 8.58]	0.238
Corticosteroid and/or mycophenolic acid treatment at randomization (Interaction test: p = 0.139)							
Yes	16	-2.9 (1.3)	12	1.1 (1.5)	-4.1	[-8.06; -0.07]	0.046
No	20	0.8 (1.2)	19	1.0 (1.2)	-0.2	[-3.66; 3.19]	0.892
Baseline UPCR 24h (Interaction test: p = 0.071)							
< 3 g/g	15	-2.8 (1.4)	21	1.4 (1.2)	-4.2	[-7.73; -0.57]	0.024
>= 3 g/g	21	0.3 (1.2)	10	-0.3 (1.6)	0.6	[-3.45; 4.55]	0.785
Baseline total urinary protein 24h (Interaction test: p = 0.010)							
< 3 g/day	10	-4.4 (1.7)	12	2.2 (1.5)	-6.6	[-10.91; -2.27]	0.003
>= 3 g/day	26	0.3 (1.1)	19	0.0 (1.2)	0.3	[-2.79; 3.42]	0.839
Baseline eGFR category (Interaction test: p = 0.708)							
< 60 mL/min/1.73m2	10	-0.3 (1.7)	2	0.2 (3.7)	-0.5	[-8.63; 7.55]	0.895
>= 60 mL/min/1.73m2	26	-1.2	29	0.9	-2.1	[-5.15; 0.87]	0.161

		(1.1)		(1.0)			
Baseline eGFR category (Interaction test: p = 0.823)							
< 90 mL/min/1.73m2	18	-0.0 (1.3)	9	1.8 (1.8)	-1.8	[-6.11; 2.53]	0.412
>= 90 mL/min/1.73m2	18	-1.9 (1.3)	22	0.5 (1.2)	-2.4	[-5.84; 1.06]	0.172
Baseline C3 (Interaction test: p = 0.496)							
< 45 mg/dL	26	-1.1 (1.1)	22	1.3 (1.2)	-2.4	[-5.60; 0.80]	0.140
>= 45 mg/dL	10	-0.7 (1.8)	9	-0.2 (1.8)	-0.4	[-5.40; 4.53]	0.862
Years since first C3G diagnosis (Interaction test: p = 0.393)							
< 2 Years	14	-1.8 (1.5)	12	1.5 (1.6)	-3.3	[-7.57; 1.04]	0.135
>= 2 Years	22	-0.5 (1.2)	19	0.5 (1.3)	-1.0	[-4.41; 2.43]	0.564
Age at C3G diagnosis (Interaction test: p = 0.939)							
< 18 Years	14	-1.9 (1.4)	5	-0.2 (2.3)	-1.7	[-7.14; 3.75]	0.536
>= 18 Years	22	-0.4 (1.2)	26	1.0 (1.1)	-1.5	[-4.66; 1.74]	0.366
Hypertension at C3G diagnosis (Interaction test: p = 0.749)							
Yes	22	-1.9 (1.2)	16	0.1 (1.3)	-2.0	[-5.55; 1.48]	0.252
No	14	0.5 (1.4)	15	1.7 (1.4)	-1.2	[-5.16; 2.72]	0.538

CI: Confidence Interval
MMRM: Mixed Model for Repeated Measures
LS Mean: Least Square Mean
SE: Standard Error
.....
[a] Number of patients included in the analysis
MMRM including treatment, time point, subgroup, corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as fixed effects, treatment*time point and treatment*subgroup as interaction terms and baseline values as covariate.
Patients with an evaluable baseline score and at least one evaluable post-baseline score were included in the analysis.

Table 5-3.4.2: MCS: Improvement of SF-36 Mental Component Score - increase of >= 9.6 points at 6 months - subgroup analysis (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup Level	Iptacopan (N=38) n / N* (%)	Placebo (N=36) n / N* (%)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Age groups (Interaction test: p = N.E.)					
< Median	3 / 19 (15.8)	1 / 8 (12.5)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
>= Median	0 / 17	3 / 23 (13.0)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Sex (Interaction test: p = N.E.)					
Male	1 / 25 (4.0)	3 / 18 (16.7)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Female	2 / 11 (18.2)	1 / 13 (7.7)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Race (Interaction test: p = N.E.)					
White	1 / 26 (3.8)	3 / 21 (14.3)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Other	2 / 10 (20.0)	1 / 10 (10.0)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Region (Interaction test: p = N.E.)					
North America	0 / 7	1 / 7 (14.3)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Europe	1 / 21 (4.8)	3 / 17 (17.6)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Other	2 / 8 (25.0)	0 / 7	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Corticosteroid and/or mycophenolic acid treatment at randomization (Interaction test: p = N.E.)					
Yes	1 / 16 (6.3)	2 / 12 (16.7)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
No	2 / 20 (10.0)	2 / 19 (10.5)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
C3G subtype at diagnosis (Interaction test: p = N.E.)					
C3GN	2 / 25 (8.0)	2 / 27 (7.4)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
DDD	1 / 8 (12.5)	1 / 1 (100.0)	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]

			N.E.	N.E.	N.E.
Mixed C3GN/DDD	0 / 2	1 / 2 (50.0)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Unknown	0 / 1	0 / 1	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline UPCR 24h (Interaction test: p = N.E.)					
< 3 g/g	1 / 15 (6.7)	3 / 21 (14.3)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 3 g/g	2 / 21 (9.5)	1 / 10 (10.0)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline total urinary protein 24h (Interaction test: p = N.E.)					
< 3 g/day	1 / 10 (10.0)	3 / 12 (25.0)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 3 g/day	2 / 26 (7.7)	1 / 19 (5.3)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline eGFR category (Interaction test: p = N.E.)					
< 60 mL/min/1.73m2	0 / 10	0 / 2	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 60 mL/min/1.73m2	3 / 26 (11.5)	4 / 29 (13.8)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline eGFR category (Interaction test: p = N.E.)					
< 90 mL/min/1.73m2	0 / 18	0 / 9	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 90 mL/min/1.73m2	3 / 18 (16.7)	4 / 22 (18.2)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline C3 (Interaction test: p = N.E.)					
< 45 mg/dL	3 / 26 (11.5)	4 / 22 (18.2)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 45 mg/dL	0 / 10	0 / 9	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Years since first C3G diagnosis (Interaction test: p = N.E.)					
< 2 Years	2 / 14 (14.3)	1 / 12 (8.3)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 2 Years	1 / 22 (4.5)	3 / 19 (15.8)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Age at C3G diagnosis (Interaction test: p = N.E.)					
< 18 Years	1 / 14 (7.1)	0 / 5	N.E.	N.E.	N.E.

			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 18 Years	2 / 22 (9.1)	4 / 26 (15.4)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Hypertension at C3G diagnosis (Interaction test: p = N.E.)					
Yes	1 / 22 (4.5)	3 / 16 (18.8)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
No	2 / 14 (14.3)	1 / 15 (6.7)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm one patient with 0.5 events was added to each treatment arm for estimation of the OR/RR.
In case of zero events in both treatment arms, no treatment comparison is performed.

Table 5-3.4.3: MCS: Worsening of SF-36 Mental Component Score - decrease of >= 9.6 points at 6 months - subgroup analysis (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup Level	Iptacopan (N=38) n / N* (%)	Placebo (N=36) n / N* (%)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Age groups (Interaction test: p = N.E.)					
< Median	2 / 19 (10.5)	0 / 8	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
>= Median	2 / 17 (11.8)	3 / 23 (13.0)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Sex (Interaction test: p = N.E.)					
Male	2 / 25 (8.0)	2 / 18 (11.1)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Female	2 / 11 (18.2)	1 / 13 (7.7)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Race (Interaction test: p = N.E.)					
White	3 / 26 (11.5)	2 / 21 (9.5)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Other	1 / 10 (10.0)	1 / 10 (10.0)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Region (Interaction test: p = N.E.)					
North America	0 / 7	0 / 7	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Europe	4 / 21 (19.0)	2 / 17 (11.8)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Other	0 / 8	1 / 7 (14.3)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Corticosteroid and/or mycophenolic acid treatment at randomization (Interaction test: p = N.E.)					
Yes	3 / 16 (18.8)	2 / 12 (16.7)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
No	1 / 20 (5.0)	1 / 19 (5.3)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
C3G subtype at diagnosis (Interaction test: p = N.E.)					
C3GN	3 / 25 (12.0)	3 / 27 (11.1)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
DDD	1 / 8 (12.5)	0 / 1	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]

			N.E.	N.E.	N.E.
Mixed C3GN/DDD	0 / 2	0 / 2	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Unknown	0 / 1	0 / 1	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline UPCR 24h (Interaction test: p = N.E.)					
< 3 g/g	3 / 15 (20.0)	2 / 21 (9.5)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 3 g/g	1 / 21 (4.8)	1 / 10 (10.0)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline total urinary protein 24h (Interaction test: p = N.E.)					
< 3 g/day	3 / 10 (30.0)	0 / 12	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 3 g/day	1 / 26 (3.8)	3 / 19 (15.8)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline eGFR category (Interaction test: p = N.E.)					
< 60 mL/min/1.73m2	0 / 10	0 / 2	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 60 mL/min/1.73m2	4 / 26 (15.4)	3 / 29 (10.3)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline eGFR category (Interaction test: p = N.E.)					
< 90 mL/min/1.73m2	1 / 18 (5.6)	0 / 9	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 90 mL/min/1.73m2	3 / 18 (16.7)	3 / 22 (13.6)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline C3 (Interaction test: p = N.E.)					
< 45 mg/dL	3 / 26 (11.5)	2 / 22 (9.1)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 45 mg/dL	1 / 10 (10.0)	1 / 9 (11.1)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Years since first C3G diagnosis (Interaction test: p = N.E.)					
< 2 Years	1 / 14 (7.1)	0 / 12	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 2 Years	3 / 22 (13.6)	3 / 19 (15.8)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Age at C3G diagnosis (Interaction test: p = N.E.)					
< 18 Years	2 / 14 (14.3)	0 / 5	N.E.	N.E.	N.E.

			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 18 Years	2 / 22 (9.1)	3 / 26 (11.5)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Hypertension at C3G diagnosis (Interaction test: p = N.E.)					
Yes	2 / 22 (9.1)	2 / 16 (12.5)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
No	2 / 14 (14.3)	1 / 15 (6.7)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm one patient with 0.5 events was added to each treatment arm for estimation of the OR/RR.
In case of zero events in both treatment arms, no treatment comparison is performed.

Table 5-3.5.1: PGIS: Analysis of change from baseline - subgroup analysis (Full Analysis Set)

	Treatment groups						
	Iptacopan (N=38)		Placebo (N=36)		Comparison		
Subgroup Level	N[a]	LS Mean (SE)	N[a]	LS Mean (SE)	Overall treatment effect	[95% CI]	p-value
Age groups (Interaction test: p = 0.927)							
< Median	19	0.1 (0.1)	8	-0.1 (0.2)	0.2	[-0.22; 0.60]	0.359
>= Median	17	-0.0 (0.1)	23	-0.2 (0.1)	0.2	[-0.15; 0.48]	0.303
Sex (Interaction test: p = 0.041)							
Male	25	-0.1 (0.1)	18	-0.1 (0.1)	0.0	[-0.26; 0.33]	0.822
Female	11	0.4 (0.1)	13	-0.2 (0.1)	0.5	[0.16; 0.91]	0.006
Race (Interaction test: p = 0.999)							
White	26	0.1 (0.1)	21	-0.1 (0.1)	0.2	[-0.09; 0.49]	0.164
Other	10	0.0 (0.2)	10	-0.2 (0.2)	0.2	[-0.23; 0.64]	0.356
Region (Interaction test: p = 0.849)							
North America	7	0.1 (0.2)	7	-0.1 (0.2)	0.3	[-0.26; 0.79]	0.316
Europe	21	0.1 (0.1)	17	-0.1 (0.1)	0.2	[-0.10; 0.56]	0.169
Other	8	-0.1 (0.2)	7	-0.1 (0.2)	0.1	[-0.44; 0.59]	0.769
Corticosteroid and/or mycophenolic acid treatment at randomization (Interaction test: p = 0.964)							
Yes	16	0.1 (0.1)	12	-0.1 (0.1)	0.2	[-0.16; 0.58]	0.256
No	20	0.0 (0.1)	19	-0.2 (0.1)	0.2	[-0.13; 0.53]	0.225
Baseline UPCR 24h (Interaction test: p = 0.930)							
< 3 g/g	15	0.1 (0.1)	21	-0.1 (0.1)	0.2	[-0.09; 0.56]	0.154
>= 3 g/g	21	0.0 (0.1)	10	-0.3 (0.2)	0.3	[-0.12; 0.64]	0.177
Baseline total urinary protein 24h (Interaction test: p = 0.108)							
< 3 g/day	10	0.2 (0.2)	12	-0.3 (0.1)	0.5	[0.07; 0.90]	0.022
>= 3 g/day	26	-0.0 (0.1)	19	-0.1 (0.1)	0.1	[-0.21; 0.36]	0.601
Baseline eGFR category (Interaction test: p = 0.436)							
< 60 mL/min/1.73m2	10	0.0 (0.2)	2	0.1 (0.4)	-0.1	[-0.83; 0.68]	0.841
>= 60 mL/min/1.73m2	26	0.1	29	-0.2	0.2	[-0.02; 0.50]	0.074

		(0.1)		(0.1)			
Baseline eGFR category (Interaction test: p = 0.862)							
< 90 mL/min/1.73m2	18	0.0 (0.1)	9	-0.1 (0.2)	0.2	[-0.22; 0.58]	0.362
>= 90 mL/min/1.73m2	18	0.1 (0.1)	22	-0.1 (0.1)	0.2	[-0.08; 0.54]	0.146
Baseline C3 (Interaction test: p = 0.288)							
< 45 mg/dL	26	0.1 (0.1)	22	-0.2 (0.1)	0.3	[0.01; 0.57]	0.045
>= 45 mg/dL	10	-0.0 (0.2)	9	-0.0 (0.2)	-0.0	[-0.46; 0.45]	0.994
Years since first C3G diagnosis (Interaction test: p = 0.554)							
< 2 Years	14	-0.0 (0.1)	12	-0.3 (0.1)	0.3	[-0.08; 0.70]	0.120
>= 2 Years	22	0.1 (0.1)	19	-0.0 (0.1)	0.2	[-0.13; 0.46]	0.278
Age at C3G diagnosis (Interaction test: p = 0.221)							
< 18 Years	14	0.1 (0.1)	5	0.2 (0.2)	-0.1	[-0.60; 0.39]	0.667
>= 18 Years	22	0.0 (0.1)	26	-0.2 (0.1)	0.2	[-0.03; 0.52]	0.078
Hypertension at C3G diagnosis (Interaction test: p = 0.409)							
Yes	22	0.1 (0.1)	16	-0.0 (0.1)	0.1	[-0.21; 0.42]	0.512
No	14	0.0 (0.1)	15	-0.3 (0.1)	0.3	[-0.05; 0.67]	0.094

CI: Confidence Interval
MMRM: Mixed Model for Repeated Measures
LS Mean: Least Square Mean
SE: Standard Error
.....
[a] Number of patients included in the analysis
MMRM including treatment, time point, subgroup, corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as fixed effects, treatment*time point and treatment*subgroup as interaction terms and baseline values as covariate.
Patients with an evaluable baseline score and at least one evaluable post-baseline score were included in the analysis.

Table 5-3.5.2: PGIS: Worsening of PGIS - increase of >= 1 point at 6 months - subgroup analysis (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup Level	Iptacopan (N=38) n / N* (%)	Placebo (N=36) n / N* (%)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Age groups (Interaction test: p = N.E.)					
< Median	3 / 19 (15.8)	1 / 8 (12.5)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
>= Median	2 / 17 (11.8)	3 / 23 (13.0)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Sex (Interaction test: p = N.E.)					
Male	1 / 25 (4.0)	2 / 18 (11.1)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Female	4 / 11 (36.4)	2 / 13 (15.4)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Race (Interaction test: p = N.E.)					
White	4 / 26 (15.4)	2 / 21 (9.5)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Other	1 / 10 (10.0)	2 / 10 (20.0)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Region (Interaction test: p = N.E.)					
North America	0 / 7	0 / 7	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Europe	5 / 21 (23.8)	2 / 17 (11.8)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Other	0 / 8	2 / 7 (28.6)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Corticosteroid and/or mycophenolic acid treatment at randomization (Interaction test: p = N.E.)					
Yes	3 / 16 (18.8)	1 / 12 (8.3)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
No	2 / 20 (10.0)	3 / 19 (15.8)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
C3G subtype at diagnosis (Interaction test: p = N.E.)					
C3GN	4 / 25 (16.0)	4 / 27 (14.8)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
DDD	1 / 8 (12.5)	0 / 1	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]	N.E. [N.E.; N.E.]

			N.E.	N.E.	N.E.
Mixed C3GN/DDD	0 / 2	0 / 2	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Unknown	0 / 1	0 / 1	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline UPCR 24h (Interaction test: p = N.E.)					
< 3 g/g	1 / 15 (6.7)	4 / 21 (19.0)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 3 g/g	4 / 21 (19.0)	0 / 10	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline total urinary protein 24h (Interaction test: p = N.E.)					
< 3 g/day	3 / 10 (30.0)	1 / 12 (8.3)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 3 g/day	2 / 26 (7.7)	3 / 19 (15.8)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline eGFR category (Interaction test: p = N.E.)					
< 60 mL/min/1.73m2	1 / 10 (10.0)	1 / 2 (50.0)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 60 mL/min/1.73m2	4 / 26 (15.4)	3 / 29 (10.3)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline eGFR category (Interaction test: p = N.E.)					
< 90 mL/min/1.73m2	2 / 18 (11.1)	2 / 9 (22.2)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 90 mL/min/1.73m2	3 / 18 (16.7)	2 / 22 (9.1)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline C3 (Interaction test: p = N.E.)					
< 45 mg/dL	4 / 26 (15.4)	3 / 22 (13.6)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 45 mg/dL	1 / 10 (10.0)	1 / 9 (11.1)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Years since first C3G diagnosis (Interaction test: p = N.E.)					
< 2 Years	1 / 14 (7.1)	1 / 12 (8.3)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 2 Years	4 / 22 (18.2)	3 / 19 (15.8)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Age at C3G diagnosis (Interaction test: p = N.E.)					
< 18 Years	3 / 14 (21.4)	1 / 5 (20.0)	N.E.	N.E.	N.E.

			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 18 Years	2 / 22 (9.1)	3 / 26 (11.5)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Hypertension at C3G diagnosis (Interaction test: p = N.E.)					
Yes	4 / 22 (18.2)	3 / 16 (18.8)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
No	1 / 14 (7.1)	1 / 15 (6.7)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm one patient with 0.5 events was added to each treatment arm for estimation of the OR/RR.
In case of zero events in both treatment arms, no treatment comparison is performed.

Table 5-3.5.3: PGIS: No worsening of PGIS - increase of < 1 point at 6 months - subgroup analysis (Full Analysis Set)

	Treatment groups		Comparison		
Subgroup Level	Iptacopan (N=38) n / N* (%)	Placebo (N=36) n / N* (%)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value
Age groups (Interaction test: p = 0.866)					
< Median	16 / 19 (84.2)	7 / 8 (87.5)	0.91 [0.11; 7.51] 0.933	0.98 [0.67; 1.44] 0.916	-0.04 [-0.34; 0.26] 0.816
>= Median	15 / 17 (88.2)	20 / 23 (87.0)	1.17 [0.17; 7.97] 0.875	1.01 [0.80; 1.28] 0.902	0.01 [-0.19; 0.22] 0.902
Sex (Interaction test: p = 0.142)					
Male	24 / 25 (96.0)	16 / 18 (88.9)	2.69 [0.32; 22.80] 0.363	1.09 [0.88; 1.35] 0.427	0.07 [-0.10; 0.24] 0.434
Female	7 / 11 (63.6)	11 / 13 (84.6)	0.34 [0.05; 2.10] 0.245	0.74 [0.42; 1.32] 0.314	-0.22 [-0.61; 0.17] 0.268
Race (Interaction test: p = 0.450)					
White	22 / 26 (84.6)	19 / 21 (90.5)	0.65 [0.12; 3.42] 0.608	0.94 [0.75; 1.17] 0.591	-0.06 [-0.25; 0.12] 0.518
Other	9 / 10 (90.0)	8 / 10 (80.0)	1.86 [0.20; 17.27] 0.584	1.12 [0.75; 1.67] 0.585	0.10 [-0.21; 0.41] 0.527
Region (Interaction test: p = 0.308)					
North America	7 / 7 (100.0)	7 / 7 (100.0)	0.97 [0.05; 18.49] 0.985	0.99 [0.71; 1.39] 0.969	N.E. [N.E.; N.E.] N.E.
Europe	16 / 21 (76.2)	15 / 17 (88.2)	0.50 [0.10; 2.60] 0.407	0.88 [0.65; 1.18] 0.379	-0.12 [-0.36; 0.12] 0.319
Other	8 / 8 (100.0)	5 / 7 (71.4)	4.58 [0.38; 55.35] 0.232	1.35 [0.81; 2.25] 0.244	0.29 [-0.05; 0.62] 0.092
Corticosteroid and/or mycophenolic acid treatment at randomization (Interaction test: p = 0.337)					
Yes	13 / 16 (81.3)	11 / 12 (91.7)	0.39 [0.04; 4.35] 0.447	0.89 [0.66; 1.19] 0.416	-0.10 [-0.35; 0.14] 0.409
No	18 / 20 (90.0)	16 / 19 (84.2)	1.69 [0.25; 11.42] 0.592	1.07 [0.84; 1.36] 0.592	0.06 [-0.15; 0.27] 0.589
C3G subtype at diagnosis (Interaction test: p = 0.637)					
C3GN	21 / 25 (84.0)	23 / 27 (85.2)	0.91 [0.20; 4.12] 0.906	0.99 [0.78; 1.25] 0.908	-0.01 [-0.21; 0.19] 0.908
DDD	7 / 8 (87.5)	1 / 1 (100.0)	2.01 [0.12; 34.99]	1.20 [0.49; 2.91]	-0.20 [-0.55; 0.15]

			0.633	0.692	0.264
Mixed C3GN/DDD	2 / 2 (100.0)	2 / 2 (100.0)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Unknown	1 / 1 (100.0)	1 / 1 (100.0)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline UPCR 24h (Interaction test: p = 0.157)					
< 3 g/g	14 / 15 (93.3)	17 / 21 (81.0)	2.50	1.13	0.12
			[0.35; 18.06]	[0.87; 1.46]	[-0.09; 0.33]
			0.365	0.349	0.261
>= 3 g/g	17 / 21 (81.0)	10 / 10 (100.0)	0.33	0.86	-0.19
			[0.03; 3.19]	[0.65; 1.13]	[-0.35; -0.02]
			0.337	0.274	0.031
Baseline total urinary protein 24h (Interaction test: p = 0.158)					
< 3 g/day	7 / 10 (70.0)	11 / 12 (91.7)	0.33	0.78	-0.22
			[0.05; 2.28]	[0.50; 1.21]	[-0.55; 0.12]
			0.263	0.258	0.199
>= 3 g/day	24 / 26 (92.3)	16 / 19 (84.2)	2.08	1.10	0.08
			[0.36; 11.88]	[0.86; 1.41]	[-0.12; 0.28]
			0.410	0.432	0.444
Baseline eGFR category (Interaction test: p = 0.168)					
< 60 mL/min/1.73m2	9 / 10 (90.0)	1 / 2 (50.0)	6.48	1.73	0.36
			[0.37; 112.55]	[0.54; 5.49]	[-0.38; 1.00]
			0.200	0.355	0.344
>= 60 mL/min/1.73m2	22 / 26 (84.6)	26 / 29 (89.7)	0.65	0.95	-0.05
			[0.13; 3.26]	[0.78; 1.16]	[-0.22; 0.13]
			0.604	0.609	0.614
Baseline eGFR category (Interaction test: p = 0.295)					
< 90 mL/min/1.73m2	16 / 18 (88.9)	7 / 9 (77.8)	2.23	1.15	0.09
			[0.31; 15.80]	[0.77; 1.70]	[-0.21; 0.39]
			0.422	0.494	0.563
>= 90 mL/min/1.73m2	15 / 18 (83.3)	20 / 22 (90.9)	0.55	0.93	-0.06
			[0.09; 3.18]	[0.72; 1.18]	[-0.27; 0.14]
			0.503	0.541	0.560
Baseline C3 (Interaction test: p = 0.884)					
< 45 mg/dL	22 / 26 (84.6)	19 / 22 (86.4)	0.89	0.97	-0.02
			[0.17; 4.53]	[0.77; 1.23]	[-0.22; 0.18]
			0.887	0.832	0.832
>= 45 mg/dL	9 / 10 (90.0)	8 / 9 (88.9)	1.09	1.00	-0.01
			[0.13; 9.47]	[0.65; 1.53]	[-0.33; 0.32]
			0.939	0.986	0.970
Years since first C3G diagnosis (Interaction test: p = 0.787)					
< 2 Years	13 / 14 (92.9)	11 / 12 (91.7)	1.21	1.04	0.02
			[0.14; 10.15]	[0.79; 1.36]	[-0.17; 0.22]
			0.861	0.796	0.821
>= 2 Years	18 / 22 (81.8)	16 / 19 (84.2)	0.83	0.97	-0.02
			[0.16; 4.32]	[0.73; 1.29]	[-0.26; 0.21]
			0.829	0.844	0.843
Age at C3G diagnosis (Interaction test: p = 0.872)					
< 18 Years	11 / 14 (78.6)	4 / 5 (80.0)	1.05	1.00	-0.02

			[0.11; 9.67]	[0.53; 1.91]	[-0.48; 0.45]
			0.965	0.993	0.938
>= 18 Years	20 / 22 (90.9)	23 / 26 (88.5)	1.34	1.03	0.02
			[0.20; 8.88]	[0.85; 1.25]	[-0.15; 0.20]
			0.765	0.776	0.776
Hypertension at C3G diagnosis (Interaction test: p = 0.936)					
Yes	18 / 22 (81.8)	13 / 16 (81.3)	1.06	1.01	0.01
			[0.20; 5.56]	[0.75; 1.37]	[-0.24; 0.26]
			0.950	0.936	0.936
No	13 / 14 (92.9)	14 / 15 (93.3)	0.94	0.99	-0.01
			[0.09; 10.16]	[0.79; 1.25]	[-0.19; 0.17]
			0.957	0.949	0.937

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm one patient with 0.5 events was added to each treatment arm for estimation of the OR/RR.
In case of zero events in both treatment arms, no treatment comparison is performed.

Table 5-3.5.4: PGIS: Improvement of PGIS - decrease of >= 1 point at 6 months - subgroup analysis (Full Analysis Set)

Subgroup Level	Treatment groups: Iptacopan (N=38) n / N* (%)	Treatment groups: Placebo (N=36) n / N* (%)	Comparison: OR [95% CI] p-value	Comparison: RR [95% CI] p-value	Comparison: RD [95% CI] p-value
Age groups (Interaction test: p = 0.714)					
< Median	2 / 19 (10.5)	2 / 8 (25.0)	0.35 [0.04; 3.06] 0.341	0.43 [0.07; 2.52] 0.348	-0.14 [-0.47; 0.19] 0.398
>= Median	2 / 17 (11.8)	10 / 23 (43.5)	0.21 [0.04; 1.01] 0.051	0.31 [0.08; 1.20] 0.090	-0.31 [-0.58; -0.05] 0.021
Sex (Interaction test: p = N.E.)					
Male	3 / 25 (12.0)	6 / 18 (33.3)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Female	1 / 11 (9.1)	6 / 13 (46.2)	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.	N.E. [N.E.; N.E.] N.E.
Race (Interaction test: p = 0.629)					
White	3 / 26 (11.5)	9 / 21 (42.9)	0.18 [0.04; 0.78] 0.022	0.27 [0.07; 0.96] 0.043	-0.30 [-0.56; -0.05] 0.019
Other	1 / 10 (10.0)	3 / 10 (30.0)	0.34 [0.04; 2.87] 0.320	0.43 [0.08; 2.35] 0.329	-0.20 [-0.53; 0.13] 0.232
Region (Interaction test: p = 0.873)					
North America	0 / 7	1 / 7 (14.3)	0.43 [0.03; 5.85] 0.526	0.50 [0.06; 4.26] 0.524	-0.16 [-0.44; 0.11] 0.245
Europe	3 / 21 (14.3)	8 / 17 (47.1)	0.19 [0.04; 0.90] 0.037	0.30 [0.08; 1.11] 0.071	-0.31 [-0.60; -0.02] 0.036
Other	1 / 8 (12.5)	3 / 7 (42.9)	0.26 [0.03; 2.45] 0.239	0.36 [0.07; 1.81] 0.214	-0.33 [-0.72; 0.07] 0.103
Corticosteroid and/or mycophenolic acid treatment at randomization (Interaction test: p = 0.071)					
Yes	3 / 16 (18.8)	3 / 12 (25.0)	0.69 [0.11; 4.24] 0.691	0.75 [0.18; 3.09] 0.690	-0.06 [-0.37; 0.25] 0.693
No	1 / 20 (5.0)	9 / 19 (47.4)	0.06 [0.01; 0.53] 0.012	0.11 [0.01; 0.76] 0.025	-0.42 [-0.67; -0.18] <.001
C3G subtype at diagnosis (Interaction test: p = 0.897)					
C3GN	2 / 25 (8.0)	10 / 27 (37.0)	0.14 [0.03; 0.75] 0.022	0.22 [0.05; 0.89] 0.035	-0.29 [-0.50; -0.08] 0.007
DDD	1 / 8 (12.5)	1 / 1 (100.0)	0.12 [0.01; 2.08]	0.31 [0.07; 1.32]	-0.80 [-1.00; -0.45]

			0.144	0.112	<.001
Mixed C3GN/DDD	1 / 2 (50.0)	1 / 2 (50.0)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Unknown	0 / 1	0 / 1	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline UPCR 24h (Interaction test: p = N.E.)					
< 3 g/g	2 / 15 (13.3)	7 / 21 (33.3)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 3 g/g	2 / 21 (9.5)	5 / 10 (50.0)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline total urinary protein 24h (Interaction test: p = N.E.)					
< 3 g/day	1 / 10 (10.0)	6 / 12 (50.0)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 3 g/day	3 / 26 (11.5)	6 / 19 (31.6)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Baseline eGFR category (Interaction test: p = 0.444)					
< 60 mL/min/1.73m2	1 / 10 (10.0)	0 / 2	0.61	0.57	0.00
			[0.04; 9.27]	[0.08; 4.21]	[N.E.; N.E.]
			0.719	0.583	N.E.
>= 60 mL/min/1.73m2	3 / 26 (11.5)	12 / 29 (41.4)	0.19	0.28	-0.29
			[0.05; 0.77]	[0.08; 0.94]	[-0.51; -0.07]
			0.020	0.039	0.010
Baseline eGFR category (Interaction test: p = 0.746)					
< 90 mL/min/1.73m2	1 / 18 (5.6)	3 / 9 (33.3)	0.20	0.25	-0.28
			[0.03; 1.33]	[0.05; 1.39]	[-0.61; 0.06]
			0.096	0.113	0.104
>= 90 mL/min/1.73m2	3 / 18 (16.7)	9 / 22 (40.9)	0.29	0.41	-0.23
			[0.07; 1.33]	[0.12; 1.36]	[-0.51; 0.04]
			0.111	0.145	0.090
Baseline C3 (Interaction test: p = 0.968)					
< 45 mg/dL	4 / 26 (15.4)	10 / 22 (45.5)	0.22	0.33	-0.30
			[0.06; 0.87]	[0.11; 0.98]	[-0.55; -0.04]
			0.031	0.046	0.022
>= 45 mg/dL	0 / 10	2 / 9 (22.2)	0.24	0.31	-0.25
			[0.02; 2.73]	[0.04; 2.35]	[-0.53; 0.03]
			0.248	0.258	0.085
Years since first C3G diagnosis (Interaction test: p = N.E.)					
< 2 Years	3 / 14 (21.4)	6 / 12 (50.0)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
>= 2 Years	1 / 22 (4.5)	6 / 19 (31.6)	N.E.	N.E.	N.E.
			[N.E.; N.E.]	[N.E.; N.E.]	[N.E.; N.E.]
			N.E.	N.E.	N.E.
Age at C3G diagnosis (Interaction test: p = 0.356)					
< 18 Years	2 / 14 (14.3)	1 / 5 (20.0)	0.60	0.67	-0.07

			[0.06; 5.98]	[0.12; 3.59]	[-0.49; 0.34]
			0.660	0.637	0.729
>= 18 Years	2 / 22 (9.1)	11 / 26 (42.3)	0.16	0.24	-0.33
			[0.04; 0.76]	[0.06; 0.92]	[-0.56; -0.11]
			0.020	0.038	0.004
Hypertension at C3G diagnosis (Interaction test: p = 0.296)					
Yes	4 / 22 (18.2)	6 / 16 (37.5)	0.37	0.48	-0.19
			[0.08; 1.65]	[0.15; 1.59]	[-0.49; 0.11]
			0.194	0.230	0.215
No	0 / 14	6 / 15 (40.0)	0.10	0.15	-0.40
			[0.01; 0.90]	[0.02; 1.10]	[-0.65; -0.15]
			0.040	0.062	0.002

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
The RR, RD and the respective 95% CIs were estimated using the Cochran-Mantel-Haenszel (CMH) method with treatment and corticosteroid or mycophenolic acid treatment at randomization (yes vs. no) as factors.
In case of zero events in only one treatment arm one patient with 0.5 events was added to each treatment arm for estimation of the OR/RR.
In case of zero events in both treatment arms, no treatment comparison is performed.

Table 5-4.1: Adverse events: Binary analysis - subgroup analysis (Safety Set)

Subgroup Level	Treatment groups Iptacopan (N=38) n / N* (%)	 Placebo (N=36) n / N* (%)	Comparison OR [95% CI] p-value	 RR [95% CI] p-value	 RD [95% CI] p-value
Any adverse events					
Age groups (Interaction test: p = 0.025)					
< Median	17 / 21 (81.0)	3 / 9 (33.3)	8.50 [1.46; 49.54] 0.017	2.43 [0.94; 6.26] 0.066	0.48 [0.13; 0.83] 0.008
>= Median	12 / 17 (70.6)	21 / 27 (77.8)	0.69 [0.17; 2.73] 0.593	0.91 [0.63; 1.31] 0.605	-0.07 [-0.34; 0.20] 0.598
Sex (Interaction test: p = 0.102)					
Male	20 / 27 (74.1)	16 / 20 (80.0)	0.71 [0.18; 2.88] 0.636	0.93 [0.68; 1.27] 0.630	-0.06 [-0.30; 0.18] 0.630
Female	9 / 11 (81.8)	8 / 16 (50.0)	4.50 [0.73; 27.74] 0.105	1.64 [0.93; 2.88] 0.087	0.32 [-0.02; 0.65] 0.062
Race (Interaction test: p = 0.223)					
White	22 / 27 (81.5)	20 / 24 (83.3)	0.88 [0.21; 3.74] 0.863	0.98 [0.76; 1.26] 0.862	-0.02 [-0.23; 0.19] 0.862
Other	7 / 11 (63.6)	4 / 12 (33.3)	3.50 [0.63; 19.50] 0.153	1.91 [0.76; 4.77] 0.167	0.30 [-0.09; 0.69] 0.128
Region (Interaction test: p = 0.070)					
North America	5 / 7 (71.4)	2 / 8 (25.0)	7.50 [0.76; 74.16] 0.085	2.86 [0.79; 10.36] 0.110	0.46 [0.01; 0.91] 0.043
Europe	18 / 22 (81.8)	18 / 19 (94.7)	0.25 [0.03; 2.46] 0.235	0.86 [0.69; 1.08] 0.199	-0.13 [-0.32; 0.06] 0.182
Other	6 / 9 (66.7)	4 / 9 (44.4)	2.50 [0.37; 16.89] 0.347	1.50 [0.63; 3.56] 0.358	0.22 [-0.23; 0.67] 0.330
Corticosteroid and/or mycophenolic acid treatment at randomization (Interaction test: p = 0.091)					
Yes	14 / 16 (87.5)	10 / 17 (58.8)	4.90 [0.84; 28.73] 0.078	1.49 [0.96; 2.31] 0.076	0.29 [0.00; 0.57] 0.048
No	15 / 22 (68.2)	14 / 19 (73.7)	0.77 [0.20; 2.98] 0.700	0.93 [0.63; 1.37] 0.698	-0.06 [-0.33; 0.22] 0.698
C3G subtype at diagnosis (Interaction test: p = 0.762)					
C3GN	20 / 26 (76.9)	21 / 32 (65.6)	1.75 [0.54; 5.62] 0.350	1.17 [0.84; 1.63] 0.342	0.11 [-0.12; 0.34] 0.338
DDD	7 / 9 (77.8)	1 / 1 (100.0)	1.00 [0.03; 33.32]	1.00 [0.42; 2.40]	-0.22 [-0.49; 0.05]

			1.000	1.000	0.109
Mixed C3GN/DDD	1 / 2 (50.0)	1 / 2 (50.0)	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Unknown	1 / 1 (100.0)	1 / 1 (100.0)	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Baseline UPCR 24h (Interaction test: p = 0.881)					
< 3 g/g	12 / 17 (70.6)	16 / 25 (64.0)	1.35	1.10	0.07
			[0.36; 5.08]	[0.72; 1.69]	[-0.22; 0.35]
			0.657	0.651	0.653
>= 3 g/g	17 / 21 (81.0)	8 / 11 (72.7)	1.59	1.11	0.08
			[0.29; 8.87]	[0.73; 1.69]	[-0.23; 0.39]
			0.595	0.615	0.606
Baseline total urinary protein 24h (Interaction test: p = 0.235)					
< 3 g/day	8 / 11 (72.7)	7 / 15 (46.7)	3.05	1.56	0.26
			[0.57; 16.19]	[0.81; 2.99]	[-0.10; 0.63]
			0.191	0.182	0.161
>= 3 g/day	21 / 27 (77.8)	17 / 21 (81.0)	0.82	0.96	-0.03
			[0.20; 3.40]	[0.72; 1.28]	[-0.26; 0.20]
			0.788	0.786	0.787
Baseline eGFR category (Interaction test: p = 0.169)					
< 60 mL/min/1.73m2	9 / 10 (90.0)	2 / 4 (50.0)	9.00	1.80	0.40
			[0.52; 155.24]	[0.66; 4.90]	[-0.12; 0.92]
			0.130	0.250	0.135
>= 60 mL/min/1.73m2	20 / 28 (71.4)	22 / 32 (68.8)	1.14	1.04	0.03
			[0.37; 3.45]	[0.75; 1.45]	[-0.21; 0.26]
			0.821	0.821	0.821
Baseline eGFR category (Interaction test: p = 0.788)					
< 90 mL/min/1.73m2	15 / 19 (78.9)	9 / 12 (75.0)	1.25	1.05	0.04
			[0.23; 6.91]	[0.71; 1.57]	[-0.27; 0.35]
			0.798	0.802	0.800
>= 90 mL/min/1.73m2	14 / 19 (73.7)	15 / 24 (62.5)	1.68	1.18	0.11
			[0.45; 6.25]	[0.78; 1.78]	[-0.17; 0.39]
			0.439	0.432	0.429
Baseline C3 (Interaction test: p = 0.950)					
< 45 mg/dL	21 / 28 (75.0)	17 / 26 (65.4)	1.59	1.15	0.10
			[0.49; 5.15]	[0.81; 1.63]	[-0.15; 0.34]
			0.441	0.445	0.438
>= 45 mg/dL	8 / 10 (80.0)	7 / 10 (70.0)	1.71	1.14	0.10
			[0.22; 13.41]	[0.69; 1.90]	[-0.28; 0.48]
			0.608	0.608	0.603
Years since first C3G diagnosis (Interaction test: p = 0.748)					
< 2 Years	12 / 15 (80.0)	10 / 15 (66.7)	2.00	1.20	0.13
			[0.38; 10.51]	[0.77; 1.86]	[-0.18; 0.45]
			0.413	0.415	0.404
>= 2 Years	17 / 23 (73.9)	14 / 21 (66.7)	1.42	1.11	0.07
			[0.39; 5.20]	[0.75; 1.63]	[-0.20; 0.34]
			0.599	0.602	0.599
Age at C3G diagnosis (Interaction test: p = 0.782)					
< 18 Years	12 / 15 (80.0)	4 / 6 (66.7)	2.00	1.20	0.13

			[0.24; 16.61]	[0.65; 2.23]	[-0.29; 0.56]
			0.521	0.564	0.542
>= 18 Years	17 / 23 (73.9)	20 / 30 (66.7)	1.42	1.11	0.07
			[0.43; 4.71]	[0.78; 1.57]	[-0.17; 0.32]
			0.570	0.564	0.564
Hypertension at C3G diagnosis (Interaction test: p = 0.883)					
Yes	17 / 23 (73.9)	11 / 18 (61.1)	1.80	1.21	0.13
			[0.48; 6.81]	[0.78; 1.88]	[-0.16; 0.42]
			0.384	0.398	0.384
No	12 / 15 (80.0)	13 / 18 (72.2)	1.54	1.11	0.08
			[0.30; 7.87]	[0.76; 1.62]	[-0.21; 0.37]
			0.605	0.600	0.598
Serious adverse events					
Age groups (Interaction test: p = -)					
< Median	0 / 21	0 / 9	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
>= Median	3 / 17 (17.6)	1 / 27 (3.7)	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Sex (Interaction test: p = -)					
Male	1 / 27 (3.7)	0 / 20	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Female	2 / 11 (18.2)	1 / 16 (6.3)	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Race (Interaction test: p = -)					
White	2 / 27 (7.4)	1 / 24 (4.2)	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Other	1 / 11 (9.1)	0 / 12	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Region (Interaction test: p = -)					
North America	1 / 7 (14.3)	0 / 8	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Europe	2 / 22 (9.1)	0 / 19	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Other	0 / 9	1 / 9 (11.1)	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Corticosteroid and/or mycophenolic acid treatment at randomization (Interaction test: p = -)					
Yes	2 / 16 (12.5)	1 / 17 (5.9)	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
No	1 / 22 (4.5)	0 / 19	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-

C3G subtype at diagnosis (Interaction test: p = -)					
C3GN	3 / 26 (11.5)	1 / 32 (3.1)	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
DDD	0 / 9	0 / 1	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Mixed C3GN/DDD	0 / 2	0 / 2	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Unknown	0 / 1	0 / 1	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Baseline UPCR 24h (Interaction test: p = -)					
< 3 g/g	1 / 17 (5.9)	0 / 25	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
>= 3 g/g	2 / 21 (9.5)	1 / 11 (9.1)	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Baseline total urinary protein 24h (Interaction test: p = -)					
< 3 g/day	1 / 11 (9.1)	0 / 15	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
>= 3 g/day	2 / 27 (7.4)	1 / 21 (4.8)	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Baseline eGFR category (Interaction test: p = -)					
< 60 mL/min/1.73m2	1 / 10 (10.0)	1 / 4 (25.0)	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
>= 60 mL/min/1.73m2	2 / 28 (7.1)	0 / 32	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Baseline eGFR category (Interaction test: p = -)					
< 90 mL/min/1.73m2	1 / 19 (5.3)	1 / 12 (8.3)	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
>= 90 mL/min/1.73m2	2 / 19 (10.5)	0 / 24	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Baseline C3 (Interaction test: p = -)					
< 45 mg/dL	2 / 28 (7.1)	1 / 26 (3.8)	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
>= 45 mg/dL	1 / 10 (10.0)	0 / 10	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Years since first C3G diagnosis (Interaction test: p = -)					
< 2 Years	2 / 15 (13.3)	0 / 15	-	-	-
			[-; -]	[-; -]	[-; -]

			-	-	-
>= 2 Years	1 / 23 (4.3)	1 / 21 (4.8)	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Age at C3G diagnosis (Interaction test: p = -)					
< 18 Years	1 / 15 (6.7)	1 / 6 (16.7)	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
>= 18 Years	2 / 23 (8.7)	0 / 30	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Hypertension at C3G diagnosis (Interaction test: p = -)					
Yes	2 / 23 (8.7)	1 / 18 (5.6)	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
No	1 / 15 (6.7)	0 / 18	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Grade >= 3 adverse events					
Age groups (Interaction test: p = -)					
< Median	0 / 21	0 / 9	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
>= Median	2 / 17 (11.8)	1 / 27 (3.7)	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Sex (Interaction test: p = -)					
Male	1 / 27 (3.7)	0 / 20	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Female	1 / 11 (9.1)	1 / 16 (6.3)	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Race (Interaction test: p = -)					
White	1 / 27 (3.7)	1 / 24 (4.2)	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Other	1 / 11 (9.1)	0 / 12	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Region (Interaction test: p = -)					
North America	1 / 7 (14.3)	0 / 8	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Europe	1 / 22 (4.5)	0 / 19	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Other	0 / 9	1 / 9 (11.1)	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Corticosteroid and/or mycophenolic acid treatment at randomization (Interaction test: p = -)					

Yes	2 / 16 (12.5)	1 / 17 (5.9)	- [-; -] -	- [-; -] -	- [-; -] -
No	0 / 22	0 / 19	- [-; -] -	- [-; -] -	- [-; -] -
C3G subtype at diagnosis (Interaction test: p = -)					
C3GN	2 / 26 (7.7)	1 / 32 (3.1)	- [-; -] -	- [-; -] -	- [-; -] -
DDD	0 / 9	0 / 1	- [-; -] -	- [-; -] -	- [-; -] -
Mixed C3GN/DDD	0 / 2	0 / 2	- [-; -] -	- [-; -] -	- [-; -] -
Unknown	0 / 1	0 / 1	- [-; -] -	- [-; -] -	- [-; -] -
Baseline UPCR 24h (Interaction test: p = -)					
< 3 g/g	1 / 17 (5.9)	0 / 25	- [-; -] -	- [-; -] -	- [-; -] -
>= 3 g/g	1 / 21 (4.8)	1 / 11 (9.1)	- [-; -] -	- [-; -] -	- [-; -] -
Baseline total urinary protein 24h (Interaction test: p = -)					
< 3 g/day	1 / 11 (9.1)	0 / 15	- [-; -] -	- [-; -] -	- [-; -] -
>= 3 g/day	1 / 27 (3.7)	1 / 21 (4.8)	- [-; -] -	- [-; -] -	- [-; -] -
Baseline eGFR category (Interaction test: p = -)					
< 60 mL/min/1.73m2	1 / 10 (10.0)	1 / 4 (25.0)	- [-; -] -	- [-; -] -	- [-; -] -
>= 60 mL/min/1.73m2	1 / 28 (3.6)	0 / 32	- [-; -] -	- [-; -] -	- [-; -] -
Baseline eGFR category (Interaction test: p = -)					
< 90 mL/min/1.73m2	1 / 19 (5.3)	1 / 12 (8.3)	- [-; -] -	- [-; -] -	- [-; -] -
>= 90 mL/min/1.73m2	1 / 19 (5.3)	0 / 24	- [-; -] -	- [-; -] -	- [-; -] -
Baseline C3 (Interaction test: p = -)					
< 45 mg/dL	2 / 28 (7.1)	1 / 26 (3.8)	- [-; -] -	- [-; -] -	- [-; -] -

>= 45 mg/dL	0 / 10	0 / 10	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Years since first C3G diagnosis (Interaction test: p = -)					
< 2 Years	1 / 15 (6.7)	0 / 15	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
>= 2 Years	1 / 23 (4.3)	1 / 21 (4.8)	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Age at C3G diagnosis (Interaction test: p = -)					
< 18 Years	1 / 15 (6.7)	1 / 6 (16.7)	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
>= 18 Years	1 / 23 (4.3)	0 / 30	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Hypertension at C3G diagnosis (Interaction test: p = -)					
Yes	2 / 23 (8.7)	1 / 18 (5.6)	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
No	0 / 15	0 / 18	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment as factor.
The RR and RD (with Wald CIs and p-values) were calculated from a 2x2 table.
In case of zero events in only one treatment arm one patient with 0.5 events was added to each treatment arm for estimation of the OR/RR.
In case of zero events in both treatment arms, no treatment comparison is performed.

Table 5-4.2: Any adverse events by SOC and PT: Binary analysis - subgroup analysis (Safety Set)

	Treatment groups		Comparison		
System Organ Class **Preferred Term** **Subgroup** **Level**	**Iptacopan (N=38)** **n / N* (%)**	**Placebo (N=36)** **n / N* (%)**	**OR** **[95% CI]** **p-value**	**RR** **[95% CI]** **p-value**	**RD** **[95% CI]** **p-value**
Selection criteria not fullfilled.					

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
SOC: System organ class
PT: Preferred term
.....
MedDRA version: 26.1
The OR and the respective 95% CI was estimated using a logistic regression model with treatment as factor.
The RR and RD (with Wald CIs and p-values) were calculated from a 2x2 table.
In case of zero events in only one treatment arm one patient with 0.5 events was added to each treatment arm for estimation of the OR/RR.
In case of zero events in both treatment arms, no treatment comparison is performed.

Table 5-4.3: Serious adverse events by SOC and PT: Binary analysis - subgroup analysis (Safety Set)

	Treatment groups		Comparison		
System Organ Class Preferred Term Subgroup Level	**Iptacopan (N=38) n / N* (%)**	**Placebo (N=36) n / N* (%)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Selection criteria not fullfilled.					

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
SOC: System organ class
PT: Preferred term
.....
MedDRA version: 26.1
The OR and the respective 95% CI was estimated using a logistic regression model with treatment as factor.
The RR and RD (with Wald CIs and p-values) were calculated from a 2x2 table.
In case of zero events in only one treatment arm one patient with 0.5 events was added to each treatment arm for estimation of the OR/RR.
In case of zero events in both treatment arms, no treatment comparison is performed.

Table 5-4.4: Grade >= 3 adverse events by SOC and PT: Binary analysis - subgroup analysis (Safety Set)

	Treatment groups		Comparison		
System Organ Class Preferred Term Subgroup Level	**Iptacopan (N=38) n / N* (%)**	**Placebo (N=36) n / N* (%)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Selection criteria not fullfilled.					

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
SOC: System organ class
PT: Preferred term
.....
MedDRA version: 26.1
The OR and the respective 95% CI was estimated using a logistic regression model with treatment as factor.
The RR and RD (with Wald CIs and p-values) were calculated from a 2x2 table.
In case of zero events in only one treatment arm one patient with 0.5 events was added to each treatment arm for estimation of the OR/RR.
In case of zero events in both treatment arms, no treatment comparison is performed.

Table 5-4.5: Adverse events leading to treatment discontinuation by SOC and PT: number and percentage of patients with event - subgroup analysis (Safety Set)

	Treatment groups		Comparison		
System Organ Class Preferred Term Subgroup Level	**Iptacopan (N=38) n / N* (%)**	**Placebo (N=36) n / N* (%)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Selection criteria not fullfilled.					

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
SOC: System organ class
PT: Preferred term
.....
MedDRA version: 26.1
The OR and the respective 95% CI was estimated using a logistic regression model with treatment as factor.
The RR and RD (with Wald CIs and p-values) were calculated from a 2x2 table.
In case of zero events in only one treatment arm one patient with 0.5 events was added to each treatment arm for estimation of the OR/RR.
In case of zero events in both treatment arms, no treatment comparison is performed.

Table 5-4.6: Adverse events of special interest: Binary analysis - subgroup analysis (Safety Set)

Subgroup Level	Treatment groups: Iptacopan (N=) n / N* (%)	Treatment groups: Placebo (N=) n / N* (%)	Comparison: OR [95% CI] p-value	Comparison: RR [95% CI] p-value	Comparison: RD [95% CI] p-value
Treatment Emergent Adverse Events of Special Interest					
Infections caused by encapsulated bacteria					
Age groups (Interaction test: p = -)					
< Median	1 / 21 (4.8)	0 / 9	- [-; -] -	- [-; -] -	- [-; -] -
>= Median	1 / 17 (5.9)	1 / 27 (3.7)	- [-; -] -	- [-; -] -	- [-; -] -
Sex (Interaction test: p = -)					
Male	2 / 27 (7.4)	1 / 20 (5.0)	- [-; -] -	- [-; -] -	- [-; -] -
Female	0 / 11	0 / 16	- [-; -] -	- [-; -] -	- [-; -] -
Race (Interaction test: p = -)					
White	2 / 27 (7.4)	1 / 24 (4.2)	- [-; -] -	- [-; -] -	- [-; -] -
Other	0 / 11	0 / 12	- [-; -] -	- [-; -] -	- [-; -] -
Region (Interaction test: p = -)					
North America	0 / 7	0 / 8	- [-; -] -	- [-; -] -	- [-; -] -
Europe	2 / 22 (9.1)	1 / 19 (5.3)	- [-; -] -	- [-; -] -	- [-; -] -
Other	0 / 9	0 / 9	- [-; -] -	- [-; -] -	- [-; -] -
Corticosteroid and/or mycophenolic acid treatment at randomization (Interaction test: p = -)					
Yes	1 / 16 (6.3)	0 / 17	- [-; -] -	- [-; -] -	- [-; -] -
No	1 / 22 (4.5)	1 / 19 (5.3)	- [-; -] -	- [-; -] -	- [-; -] -
C3G subtype at diagnosis (Interaction test: p = -)					
C3GN	1 / 26 (3.8)	1 / 32 (3.1)	- [-; -] -	- [-; -] -	- [-; -] -

DDD	1 / 9 (11.1)	0 / 1	- [-; -] -	- [-; -] -	- [-; -] -
Mixed C3GN/DDD	0 / 2	0 / 2	- [-; -] -	- [-; -] -	- [-; -] -
Unknown	0 / 1	0 / 1	- [-; -] -	- [-; -] -	- [-; -] -
Baseline UPCR 24h (Interaction test: p = -)					
< 3 g/g	1 / 17 (5.9)	1 / 25 (4.0)	- [-; -] -	- [-; -] -	- [-; -] -
>= 3 g/g	1 / 21 (4.8)	0 / 11	- [-; -] -	- [-; -] -	- [-; -] -
Baseline total urinary protein 24h (Interaction test: p = -)					
< 3 g/day	0 / 11	0 / 15	- [-; -] -	- [-; -] -	- [-; -] -
>= 3 g/day	2 / 27 (7.4)	1 / 21 (4.8)	- [-; -] -	- [-; -] -	- [-; -] -
Baseline eGFR category (Interaction test: p = -)					
< 60 mL/min/1.73m2	0 / 10	0 / 4	- [-; -] -	- [-; -] -	- [-; -] -
>= 60 mL/min/1.73m2	2 / 28 (7.1)	1 / 32 (3.1)	- [-; -] -	- [-; -] -	- [-; -] -
Baseline eGFR category (Interaction test: p = -)					
< 90 mL/min/1.73m2	2 / 19 (10.5)	0 / 12	- [-; -] -	- [-; -] -	- [-; -] -
>= 90 mL/min/1.73m2	0 / 19	1 / 24 (4.2)	- [-; -] -	- [-; -] -	- [-; -] -
Baseline C3 (Interaction test: p = -)					
< 45 mg/dL	1 / 28 (3.6)	1 / 26 (3.8)	- [-; -] -	- [-; -] -	- [-; -] -
>= 45 mg/dL	1 / 10 (10.0)	0 / 10	- [-; -] -	- [-; -] -	- [-; -] -
Years since first C3G diagnosis (Interaction test: p = -)					
< 2 Years	1 / 15 (6.7)	1 / 15 (6.7)	- [-; -] -	- [-; -] -	- [-; -] -
>= 2 Years	1 / 23 (4.3)	0 / 21	- [-; -] -	- [-; -] -	- [-; -] -

Age at C3G diagnosis (Interaction test: p = -)					
< 18 Years	1 / 15 (6.7)	0 / 6	- [-; -] -	- [-; -] -	- [-; -] -
>= 18 Years	1 / 23 (4.3)	1 / 30 (3.3)	- [-; -] -	- [-; -] -	- [-; -] -
Hypertension at C3G diagnosis (Interaction test: p = -)					
Yes	1 / 23 (4.3)	1 / 18 (5.6)	- [-; -] -	- [-; -] -	- [-; -] -
No	1 / 15 (6.7)	0 / 18	- [-; -] -	- [-; -] -	- [-; -] -
Treatment Emergent Adverse Events of Special Interest					
Serious or severe infections					
Age groups (Interaction test: p = -)					
< Median	0 / 21	0 / 9	- [-; -] -	- [-; -] -	- [-; -] -
>= Median	2 / 17 (11.8)	0 / 27	- [-; -] -	- [-; -] -	- [-; -] -
Sex (Interaction test: p = -)					
Male	1 / 27 (3.7)	0 / 20	- [-; -] -	- [-; -] -	- [-; -] -
Female	1 / 11 (9.1)	0 / 16	- [-; -] -	- [-; -] -	- [-; -] -
Race (Interaction test: p = -)					
White	2 / 27 (7.4)	0 / 24	- [-; -] -	- [-; -] -	- [-; -] -
Other	0 / 11	0 / 12	- [-; -] -	- [-; -] -	- [-; -] -
Region (Interaction test: p = -)					
North America	1 / 7 (14.3)	0 / 8	- [-; -] -	- [-; -] -	- [-; -] -
Europe	1 / 22 (4.5)	0 / 19	- [-; -] -	- [-; -] -	- [-; -] -
Other	0 / 9	0 / 9	- [-; -] -	- [-; -] -	- [-; -] -
Corticosteroid and/or mycophenolic acid treatment at randomization (Interaction test: p = -)					
Yes	1 / 16 (6.3)	0 / 17	- [-; -] -	- [-; -] -	- [-; -] -

No	1 / 22 (4.5)	0 / 19	- [-; -] -	- [-; -] -	- [-; -] -
C3G subtype at diagnosis (Interaction test: p = -)					
C3GN	2 / 26 (7.7)	0 / 32	- [-; -] -	- [-; -] -	- [-; -] -
DDD	0 / 9	0 / 1	- [-; -] -	- [-; -] -	- [-; -] -
Mixed C3GN/DDD	0 / 2	0 / 2	- [-; -] -	- [-; -] -	- [-; -] -
Unknown	0 / 1	0 / 1	- [-; -] -	- [-; -] -	- [-; -] -
Baseline UPCR 24h (Interaction test: p = -)					
< 3 g/g	0 / 17	0 / 25	- [-; -] -	- [-; -] -	- [-; -] -
>= 3 g/g	2 / 21 (9.5)	0 / 11	- [-; -] -	- [-; -] -	- [-; -] -
Baseline total urinary protein 24h (Interaction test: p = -)					
< 3 g/day	0 / 11	0 / 15	- [-; -] -	- [-; -] -	- [-; -] -
>= 3 g/day	2 / 27 (7.4)	0 / 21	- [-; -] -	- [-; -] -	- [-; -] -
Baseline eGFR category (Interaction test: p = -)					
< 60 mL/min/1.73m2	1 / 10 (10.0)	0 / 4	- [-; -] -	- [-; -] -	- [-; -] -
>= 60 mL/min/1.73m2	1 / 28 (3.6)	0 / 32	- [-; -] -	- [-; -] -	- [-; -] -
Baseline eGFR category (Interaction test: p = -)					
< 90 mL/min/1.73m2	1 / 19 (5.3)	0 / 12	- [-; -] -	- [-; -] -	- [-; -] -
>= 90 mL/min/1.73m2	1 / 19 (5.3)	0 / 24	- [-; -] -	- [-; -] -	- [-; -] -
Baseline C3 (Interaction test: p = -)					
< 45 mg/dL	1 / 28 (3.6)	0 / 26	- [-; -] -	- [-; -] -	- [-; -] -
>= 45 mg/dL	1 / 10 (10.0)	0 / 10	- [-; -] -	- [-; -] -	- [-; -] -

Years since first C3G diagnosis (Interaction test: p = -)					
< 2 Years	2 / 15 (13.3)	0 / 15	- [-; -] -	- [-; -] -	- [-; -] -
>= 2 Years	0 / 23	0 / 21	- [-; -] -	- [-; -] -	- [-; -] -
Age at C3G diagnosis (Interaction test: p = -)					
< 18 Years	0 / 15	0 / 6	- [-; -] -	- [-; -] -	- [-; -] -
>= 18 Years	2 / 23 (8.7)	0 / 30	- [-; -] -	- [-; -] -	- [-; -] -
Hypertension at C3G diagnosis (Interaction test: p = -)					
Yes	1 / 23 (4.3)	0 / 18	- [-; -] -	- [-; -] -	- [-; -] -
No	1 / 15 (6.7)	0 / 18	- [-; -] -	- [-; -] -	- [-; -] -
Treatment Emergent Adverse Events of Special Interest					
Thyroid changes					
Age groups (Interaction test: p = -)					
< Median	0 / 21	0 / 9	- [-; -] -	- [-; -] -	- [-; -] -
>= Median	0 / 17	1 / 27 (3.7)	- [-; -] -	- [-; -] -	- [-; -] -
Sex (Interaction test: p = -)					
Male	0 / 27	1 / 20 (5.0)	- [-; -] -	- [-; -] -	- [-; -] -
Female	0 / 11	0 / 16	- [-; -] -	- [-; -] -	- [-; -] -
Race (Interaction test: p = -)					
White	0 / 27	1 / 24 (4.2)	- [-; -] -	- [-; -] -	- [-; -] -
Other	0 / 11	0 / 12	- [-; -] -	- [-; -] -	- [-; -] -
Region (Interaction test: p = -)					
North America	0 / 7	0 / 8	- [-; -] -	- [-; -] -	- [-; -] -
Europe	0 / 22	1 / 19 (5.3)	- [-; -] -	- [-; -] -	- [-; -] -

Other	0 / 9	0 / 9	- [-; -] -	- [-; -] -	- [-; -] -
Corticosteroid and/or mycophenolic acid treatment at randomization (Interaction test: p = -)					
Yes	0 / 16	1 / 17 (5.9)	- [-; -] -	- [-; -] -	- [-; -] -
No	0 / 22	0 / 19	- [-; -] -	- [-; -] -	- [-; -] -
C3G subtype at diagnosis (Interaction test: p = -)					
C3GN	0 / 26	0 / 32	- [-; -] -	- [-; -] -	- [-; -] -
DDD	0 / 9	1 / 1 (100.0)	- [-; -] -	- [-; -] -	- [-; -] -
Mixed C3GN/DDD	0 / 2	0 / 2	- [-; -] -	- [-; -] -	- [-; -] -
Unknown	0 / 1	0 / 1	- [-; -] -	- [-; -] -	- [-; -] -
Baseline UPCR 24h (Interaction test: p = -)					
< 3 g/g	0 / 17	1 / 25 (4.0)	- [-; -] -	- [-; -] -	- [-; -] -
>= 3 g/g	0 / 21	0 / 11	- [-; -] -	- [-; -] -	- [-; -] -
Baseline total urinary protein 24h (Interaction test: p = -)					
< 3 g/day	0 / 11	1 / 15 (6.7)	- [-; -] -	- [-; -] -	- [-; -] -
>= 3 g/day	0 / 27	0 / 21	- [-; -] -	- [-; -] -	- [-; -] -
Baseline eGFR category (Interaction test: p = -)					
< 60 mL/min/1.73m2	0 / 10	0 / 4	- [-; -] -	- [-; -] -	- [-; -] -
>= 60 mL/min/1.73m2	0 / 28	1 / 32 (3.1)	- [-; -] -	- [-; -] -	- [-; -] -
Baseline eGFR category (Interaction test: p = -)					
< 90 mL/min/1.73m2	0 / 19	0 / 12	- [-; -] -	- [-; -] -	- [-; -] -
>= 90 mL/min/1.73m2	0 / 19	1 / 24 (4.2)	- [-; -] -	- [-; -] -	- [-; -] -

Baseline C3 (Interaction test: p = -)					
< 45 mg/dL	0 / 28	1 / 26 (3.8)	- [-; -] -	- [-; -] -	- [-; -] -
>= 45 mg/dL	0 / 10	0 / 10	- [-; -] -	- [-; -] -	- [-; -] -
Years since first C3G diagnosis (Interaction test: p = -)					
< 2 Years	0 / 15	0 / 15	- [-; -] -	- [-; -] -	- [-; -] -
>= 2 Years	0 / 23	1 / 21 (4.8)	- [-; -] -	- [-; -] -	- [-; -] -
Age at C3G diagnosis (Interaction test: p = -)					
< 18 Years	0 / 15	0 / 6	- [-; -] -	- [-; -] -	- [-; -] -
>= 18 Years	0 / 23	1 / 30 (3.3)	- [-; -] -	- [-; -] -	- [-; -] -
Hypertension at C3G diagnosis (Interaction test: p = -)					
Yes	0 / 23	0 / 18	- [-; -] -	- [-; -] -	- [-; -] -
No	0 / 15	1 / 18 (5.6)	- [-; -] -	- [-; -] -	- [-; -] -
Serious Treatment Emergent Adverse Events of Special Interest					
Serious or severe infections					
Age groups (Interaction test: p = -)					
< Median	0 / 21	0 / 9	- [-; -] -	- [-; -] -	- [-; -] -
>= Median	2 / 17 (11.8)	0 / 27	- [-; -] -	- [-; -] -	- [-; -] -
Sex (Interaction test: p = -)					
Male	1 / 27 (3.7)	0 / 20	- [-; -] -	- [-; -] -	- [-; -] -
Female	1 / 11 (9.1)	0 / 16	- [-; -] -	- [-; -] -	- [-; -] -
Race (Interaction test: p = -)					
White	2 / 27 (7.4)	0 / 24	- [-; -] -	- [-; -] -	- [-; -] -
Other	0 / 11	0 / 12	- [-; -] -	- [-; -] -	- [-; -] -

Region (Interaction test: p = -)					
North America	1 / 7 (14.3)	0 / 8	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Europe	1 / 22 (4.5)	0 / 19	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Other	0 / 9	0 / 9	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Corticosteroid and/or mycophenolic acid treatment at randomization (Interaction test: p = -)					
Yes	1 / 16 (6.3)	0 / 17	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
No	1 / 22 (4.5)	0 / 19	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
C3G subtype at diagnosis (Interaction test: p = -)					
C3GN	2 / 26 (7.7)	0 / 32	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
DDD	0 / 9	0 / 1	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Mixed C3GN/DDD	0 / 2	0 / 2	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Unknown	0 / 1	0 / 1	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Baseline UPCR 24h (Interaction test: p = -)					
< 3 g/g	0 / 17	0 / 25	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
>= 3 g/g	2 / 21 (9.5)	0 / 11	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Baseline total urinary protein 24h (Interaction test: p = -)					
< 3 g/day	0 / 11	0 / 15	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
>= 3 g/day	2 / 27 (7.4)	0 / 21	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Baseline eGFR category (Interaction test: p = -)					
< 60 mL/min/1.73m2	1 / 10 (10.0)	0 / 4	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
>= 60 mL/min/1.73m2	1 / 28 (3.6)	0 / 32	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-

Baseline eGFR category (Interaction test: p = -)					
< 90 mL/min/1.73m2	1 / 19 (5.3)	0 / 12	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
>= 90 mL/min/1.73m2	1 / 19 (5.3)	0 / 24	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Baseline C3 (Interaction test: p = -)					
< 45 mg/dL	1 / 28 (3.6)	0 / 26	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
>= 45 mg/dL	1 / 10 (10.0)	0 / 10	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Years since first C3G diagnosis (Interaction test: p = -)					
< 2 Years	2 / 15 (13.3)	0 / 15	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
>= 2 Years	0 / 23	0 / 21	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Age at C3G diagnosis (Interaction test: p = -)					
< 18 Years	0 / 15	0 / 6	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
>= 18 Years	2 / 23 (8.7)	0 / 30	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Hypertension at C3G diagnosis (Interaction test: p = -)					
Yes	1 / 23 (4.3)	0 / 18	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
No	1 / 15 (6.7)	0 / 18	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Severe Treatment Emergent Adverse Events of Special Interest (grade >=3)					
Serious or severe infections					
Age groups (Interaction test: p = -)					
< Median	0 / 21	0 / 9	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
>= Median	1 / 17 (5.9)	0 / 27	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Sex (Interaction test: p = -)					
Male	1 / 27 (3.7)	0 / 20	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Female	0 / 11	0 / 16	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-

Race (Interaction test: p = -)					
White	1 / 27 (3.7)	0 / 24	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Other	0 / 11	0 / 12	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Region (Interaction test: p = -)					
North America	1 / 7 (14.3)	0 / 8	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Europe	0 / 22	0 / 19	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Other	0 / 9	0 / 9	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Corticosteroid and/or mycophenolic acid treatment at randomization (Interaction test: p = -)					
Yes	1 / 16 (6.3)	0 / 17	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
No	0 / 22	0 / 19	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
C3G subtype at diagnosis (Interaction test: p = -)					
C3GN	1 / 26 (3.8)	0 / 32	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
DDD	0 / 9	0 / 1	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Mixed C3GN/DDD	0 / 2	0 / 2	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Unknown	0 / 1	0 / 1	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Baseline UPCR 24h (Interaction test: p = -)					
< 3 g/g	0 / 17	0 / 25	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
>= 3 g/g	1 / 21 (4.8)	0 / 11	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Baseline total urinary protein 24h (Interaction test: p = -)					
< 3 g/day	0 / 11	0 / 15	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
>= 3 g/day	1 / 27 (3.7)	0 / 21	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-

Baseline eGFR category (Interaction test: p = -)					
< 60 mL/min/1.73m2	1 / 10 (10.0)	0 / 4	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
>= 60 mL/min/1.73m2	0 / 28	0 / 32	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Baseline eGFR category (Interaction test: p = -)					
< 90 mL/min/1.73m2	1 / 19 (5.3)	0 / 12	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
>= 90 mL/min/1.73m2	0 / 19	0 / 24	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Baseline C3 (Interaction test: p = -)					
< 45 mg/dL	1 / 28 (3.6)	0 / 26	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
>= 45 mg/dL	0 / 10	0 / 10	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Years since first C3G diagnosis (Interaction test: p = -)					
< 2 Years	1 / 15 (6.7)	0 / 15	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
>= 2 Years	0 / 23	0 / 21	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Age at C3G diagnosis (Interaction test: p = -)					
< 18 Years	0 / 15	0 / 6	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
>= 18 Years	1 / 23 (4.3)	0 / 30	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
Hypertension at C3G diagnosis (Interaction test: p = -)					
Yes	1 / 23 (4.3)	0 / 18	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-
No	0 / 15	0 / 18	-	-	-
			[-; -]	[-; -]	[-; -]
			-	-	-

N*: Number of patients included in the analysis
n: number of patients with event
N.E.: Not estimable
CI: Confidence Interval
OR: Odds Ratio
RR: Risk Ratio
RD: Risk difference
.....
The OR and the respective 95% CI was estimated using a logistic regression model with treatment as factor.
The RR and RD (with Wald CIs and p-values) were calculated from a 2x2 table.
In case of zero events in only one treatment arm one patient with 0.5 events was added to each treatment arm for estimation of the OR/RR.
In case of zero events in both treatment arms, no treatment comparison is performed.